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Abstract 
Background: The epithelial cells in Ductal Carcinoma in-situ (DCIS) are as 
genetically advanced as those in invasive disease therefore attention has 
focused on the tumour microenvironment (ME). A key component of the ME 
in DCIS is the myoepithelial cell (MEC) lying at the interface of the epithelial 
and stromal compartments. MEC are altered in DCIS with loss of Galectin-7 
and upregulation of avb6. Galectin-7 is proposed to play a role in control of 
apoptosis and adhesion. The hypothesis of this study is that changes in MEC 
phenotype in DCIS leads to an altered ME that promotes tumour progression. 
Methods: Galectin-7 expression was assessed using immunohistochemistry 
in a series of pure DCIS samples (low risk model) and DCIS with co-existent 
invasion (high risk model).  
An in-vitro model of normal primary myoepithelial cells was used to investigate 
the functional impact of loss of Galectin-7. The effect of Galectin-7 loss on 
MEC apoptosis, adhesion and migration was investigated. The global impact 
of loss of MEC Galectin-7 was explored using RNA sequencing. 
Results: There was greater loss of Galectin-7 in DCIS with co-existent 
invasion compared to the pure DCIS cohort, whilst the inverse was shown for 
avb6. Functional assays demonstrated knockdown of Galectin-7 sensitised 
MECs to apoptosis. They were less adhesive and more migratory to laminin 
and more adhesive and less migratory to Collagen I. 
RNA sequencing shows that silencing Galectin-7 increased LOX expression - 
a key regulator of the collagen matrix of the microenvironment. 
Conclusion: This study shows that loss of MEC Galectin-7 is associated with 
DCIS progression. Loss predisposes MEC to apoptosis and switches 
adhesion from basement membrane to interstitial matrix, all of which 
destabilizes this key interface in DCIS. Galectin-7 has the potential to be used 
in a risk stratification tool for DCIS. 
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1 Introduction  
1.1 Breast anatomy 
 
The physiological function of the female breast is lactation. The human breast 
comprises a branching network of ducts and lobules embedded in a 
surrounding stroma, which is encased in a variable amount of adipose tissue. 
The ducts converge towards the nipple (figure 1.1) The ducts are comprised 
of two types of epithelial cells; inner luminal epithelial cells and outer 
myoepithelial cells, surrounded by a protein-rich basement membrane (figure 
1.2) 
 
 
 
Figure 1-1 Breast anatomy 
The diagram shows a branching network of ducts, lobules and surrounding stroma. 
(From the National Cancer Institute © 2011 Terese Winslow LLC) 
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Figure 1-2  Structure of a normal breast duct. 
Normal breast duct A) schematic where arrows indicate; a) basement membrane, b) 
myoepithelial cell, c) luminal epithelial cell and d) stroma. B) Haematoxylin and eosin 
stained duct. 
a 
b 
c 
d 
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1.2 Breast cancer risk factors 
 
There are numerous risk factors which can increase the likelihood of 
developing breast cancer. Some risk factors are genetic and others 
environmental. Early diagnosis of breast cancer can lead to good prognosis 
and increased survival rates, and the breast screening program is instrumental 
in early detection. A key area of current research is breast cancer prevention 
in modifying risk factors (Figure 1-6) (Kamińska, Ciszewski, Łopacka-Szatan, 
Miotła, & Starosławska, 2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 Breast cancer risk factors. 
An outline of modifiable and non-modifiable breast cancer risk factors.  
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1.2.1 Age 
 
Ageing is one of the most important risk factors for breast cancer, with the 
incidence increasing with advancing age as shown in Figure 1-4. In 2016, 
approximately 99.3% and 71.2% of all breast cancer-associated deaths in 
America were reported in women over the age of 40 and 60, respectively 
(Siegel, Miller, & Jemal, 2017).  
 
 
Figure 1-4 Age-specific breast cancer incidence. 
Breast cancer average number of new cases per year and age-specific incidence 
rates per 100,000 population, females, UK, 2013-2015 
("http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-
by-cancer-type/breast-cancer/incidence-in-situ,")  
 
1.2.2 Family history 
 
Women who have a family history of breast cancer have an increased risk of 
developing breast cancer. A UK cohort study involving 113,000 women, 
demonstrated women with one first-degree relative and those with two or more 
first degree relatives have a 1.75 fold risk and 2.5 fold or higher risk, 
respectively, of developing breast cancer than those women without any 
affected relatives (Brewer, Jones, Schoemaker, Ashworth, & Swerdlow, 2017). 
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1.2.3 Obesity 
 
Obesity is an established risk factor for postmenopausal breast cancer, at 
least in part due to oestrogen production by adipose tissue. The Genesis 
Centre in Manchester has been a leader in breast cancer risk prevention, 
leading studies into the benefits of lifestyle modification.  In 2005, Harvie et al. 
collaborated with investigators running the Iowa Women’s Health Study in the 
United States to assess the effect of weight loss on breast cancer risk. This 
showed that women losing 5% body weight and maintaining this reduced their 
risk of breast cancer by approximately 25%-40% compared with women who 
continued to gain weight (Harvie et al., 2005).  
 
1.2.4 Mammographic density 
 
Mammographic density is defined as the proportion of the mammogram image 
which is occupied by dense fibroglandular tissue. This is defined as a 
percentage; a higher percentage conferring an increased density.  Women 
with mammographic density in the highest quartile have a risk of developing 
breast cancer 4-6 times higher than those with mammographic density in the 
lowest quartile (Boyd et al., 2005). High breast density in the general 
population is common, therefore the attributable risk is substantial, and it is 
estimated that approximately one third of breast cancers could be explained 
by density in more than 50% of the breast (Boyd et al., 2005). The impact of 
high mammographic density is two-fold – biological and technical. There is a 
decrease in mammographic sensitivity with increasing tissue density: in two 
separate reports of film-screen mammography, mammographic sensitivity 
decreased from a level of 85.7%–88.8% in patients with almost entirely fatty 
tissue to 62.2%–68.1% in patients with extremely dense breast tissue (Carney 
et al., 2007). Keely et al. used a mouse model of high density which showed 
increased tumour formation associated with increased collagen density (P. P. 
Provenzano et al., 2008). The alignment of collagen fibres is also an important 
factor. Weaver et al. used a LOX-overexpressing mouse model to 
demonstrate that increased lysyl oxidase (LOX), which functions to crosslink 
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collagen, results in a stiffer mammary fat pad (Levental et al., 2009) and 
enhanced tumour formation. Collagen crosslinking accompanies tissue 
fibrosis  (van der Slot et al., 2005) and fibrosis increases risk to malignancy 
(Colpaert et al., 2003). Moreover, LOX is proposed to have a key role in 
facilitating tumour metastasis (Erler et al., 2006). 
Breast density is modifiable to a degree and there are therapeutic options to 
reduce breast density.  
1.2.5 Hormonal factors 
 
Reproductive factors such as early menarche, late menopause, late age at 
first pregnancy and low parity can increase breast cancer risk (Sun et al., 
2017). Each 1-year delay in menopause increases the risk of breast cancer by 
3%. Each 1-year delay in menarche or each additional birth decreases the risk 
of breast cancer by 5% or 10%, respectively (Dall & Britt, 2017). 
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1.3 Breast cancer incidence 
 
The incidence of breast cancer increases with age. Cancer Research UK have 
monitored cancer incidence using figures from the Office of National Statistics. 
Advancements in diagnostics and the screening program have contributed 
towards earlier detection. In 2003, 2-view mammography was introduced 
contributing towards an increase in breast cancer incidence in the 65-69 age 
group, with small breast cancers that were not detected on single view 
mammography being detected with the introduction of 2-view mammography 
(Figure 1-5). 
 
 
  
Figure 1-5 Invasive breast cancer age-standardised incidence rates, by age, UK, 
1993-2015. 
Breast cancer incidence rates have increased overall in all broad adult age groups in 
females in the UK since the early 1990s. Rates in 25-49s have increased by 17%, in 
50-64s have increased by 14%, in 65-69s have increased by 69%, in 70-79s have 
increased by 32%, and in 80+s have increased by 23%. 
("http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-
by-cancer-type/breast-cancer/incidence-in-situ,") 
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1.4 Ductal carcinoma in situ (DCIS) incidence  
 
The introduction of breast screening led to a significant increase in DCIS 
incidence. DCIS is often asymptomatic and is detected through breast 
screening or at symptomatic clinics as an incidental finding. DCIS can less 
commonly present as a mass or bloody nipple discharge. Age standardised 
incidence rates are shown in Figure 1-6. 
 
 
 
 
 
 
 
 
 
Figure 1-6 In situ breast cancer age-standardised incidence rates, By Age, UK, 1993-
2015. 
Breast carcinoma in situ incidence rates have increased overall in all broad adult age 
groups in females in the UK since the early 1990s.[1-4] Rates in 25-49s have 
increased by 172%, in 50-64s have increased by 112%, in 65-69s have increased by 
600%, in 70-79s have increased by 450%, and in 80+s have increased by 
424%.("http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/breast-cancer/incidence-in-situ,") 
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The Office of National Statistics have published DCIS rates across different 
regions (Figure 1-7), the variation over time may be multifactorial. Regions will 
have switched to digital mammography at different times, which may be a 
contributing factor to this variation.  
Figure 1-7 In situ breast cancer cases in females between 2002 and 2014 across 
screening regions. 
The variation in DCIS across different screening region is evident. 
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1.5 Breast cancer histological classification 
 
Breast cancer is a heterogeneous disease. The progression to invasion is 
defined as when the malignant epithelial cells have breached the basement 
membrane and invaded the surrounding stroma. The two most common 
histological types of invasive breast cancer are ductal and lobular carcinomas, 
accounting for approximately 75 and 15% of all cases in the US, respectively 
(C. I. Li, Anderson, Daling, & Moe, 2003). The histological subtype of cancer 
is clinically relevant as this can alter the diagnostic work up of the patient and 
subsequent treatment, however the grade of the tumour is a more relevant 
prognostic feature. Invasive lobular carcinomas (ILC) are more often multifocal 
and bilateral and can be mammographically occult when compared to invasive 
ductal carcinoma (IDC), therefore a bilateral breast MRI is often performed 
prior to the commencement of treatment. The special type tumours often have 
a more favourable prognosis and include tubular carcinoma, cribriform 
carcinoma, mucinous carcinoma, medullary carcinoma, papillary carcinoma 
and adenoid cystic carcinoma (Berg & Hutter, 1995).  
 
In addition to the classical histological subtypes, Perou described four 
molecular subtypes: Luminal A, Luminal B, HER-2 overexpressing and basal-
like (Perou et al., 2000). These molecular subtypes were defined on gene 
expression analysis but they can be defined using immunohistochemistry and 
fluorescent in situ hybridisation. Sorlie et al., showed these subgroups had 
differing prognosis and treatment options as summarised in Table 1-1. 
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Tumour 
subtype 
Receptor 
expression 
Tumour 
characteristics 
Proportion 
of breast 
cancer 
10 year 
survival 
Targeted 
therapies 
Luminal 
A 
ER + 
PR +/- 
HER-2 - 
Low grade 71% 79-84% Hormonal 
Luminal 
B 
ER + 
PR +/- 
HER-2 + 
Low grade 
 
6% 60-87% Hormonal 
Trastuzumab 
HER-2 ER - 
PR - 
HER-2 + 
High grade 
aggressive 
6% 52-55% Trastuzumab 
Basal ER - 
PR - 
HER-2 - 
High grade 
aggressive 
10-25% 62-75% None 
 
 
The basal subtype of breast cancer is often referred to as Triple Negative 
breast cancer, since they lack oestrogen and progesterone receptors and 
Her2. These are often regarded as equivalent to the basal subtype however, 
not all triple negative tumours express basal cytokeratins (CKs). Basal-like 
tumours are more accurately defined using gene expression and this is an 
important prognostic indicator (Carey et al., 2006), (Rakha et al., 2007).  
  
Table 1-1 Breast cancer molecular subtypes. 
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1.6 Ductal Carcinoma in situ (DCIS) 
1.6.1 DCIS pathological classification 
 
The pathological classification of DCIS is complex and for many years there 
have been discrepancies in the way in which this is classified, one challenge 
includes the heterogeneity of DCIS such that the type of DCIS is often mixed. 
DCIS has generally been categorised on architectural pattern using five main 
groups: comedo (layer of neoplastic cells surrounding a central area of 
necrosis), cribriform (radially oriented neoplastic cells forming glandular 
lumina), papillary (large papillations with fibrovascular stalks), solid (ductal 
filling with neoplastic cells), and micropapillary (finger-like papillary projections 
into dilated ductal spaces) (Leonard & Swain, 2004). An important diagnostic 
factor and predictor of prognosis is the presence of comedo necrosis 
(Burstein, Polyak, Wong, Lester, & Kaelin, 2004).  The presence of comedo 
necrosis is included in the Van Nuys score as a poor prognostic feature.  
 
In current clinical practice in the UK, DCIS is classified as low, intermediate 
and high grade, with high thought to be the most aggressive. However, a 
challenge of risk stratifying DCIS is that often pathologists do not agree on the 
grade. The classification is the assessment of the size of the nuclei compared 
with adjacent normal cells, typically either normal epithelial or red blood cells. 
High grade DCIS is composed of large, pleomorphic cells with prominent 
nuclei, with a high mitotic count. The nuclei of high grade DCIS are typically 
more than 2.5 the size of red blood cells in diameter (Lester et al., 2009). Low 
grade DCIS is formed of regular cells with monotonous nuclei (Pinder, 2010), 
with a low mitotic count. Intermediate grade DCIS is used to classify DCIS 
when the nuclei show pleomorphism, but not to the degree that is seen in high 
grade DCIS and lack the regularity of cells seen in low grade DCIS. Within the 
UK National Health Service (NHS) Breast Screening Programme, the poorest 
agreement amongst clinicians is the categorisation of intermediate grade 
DCIS (Ellis et al., 2006). There is a shift in practice with some clinicians using 
high grade versus non-high grade and the thought is this should increase the 
reproducibility of the reports. 
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Comedo Cribriform Solid 
Micropapillary Papillary Mixed 
Figure 1-8 Architectural patterns of DCIS. 
Comedo (A), cribriform (B), solid (C), micropapillary (D), and papillary (E) subtypes. 
However, a large proportion of DCIS shows complex mixtures of growth patterns 
(F), which adds to the complexitiy of catogrising DCIS (Allred, 2010). 
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1.7 Breast screening program 
 
The NHS has a population-based breast screening program, currently offered 
to all women aged 50-70. There is currently an age extension trial that includes 
women in the 47-49 and 71-73 age range in order to assess if the screening 
age range should be expanded. Healthy individuals are screened to identify 
those whom have developed a breast lesion which may potentially be 
malignant. With regards to breast screening, women undergo a 2-view 
mammogram, these are then dual reported by radiologists. Any woman whose 
mammogram detects an abnormality is offered further investigations. There 
can be problems with false positives and false negatives. As a result of breast 
screening, breast carcinomas are more likely to be detected at the pre-
invasive or early stage, increasing the chances of curing the patient. However, 
concerns regarding over-diagnosis and subsequent over-treatment have been 
raised. 
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1.7.1 Breast screening invitations 
 
For screening to be effective it is important to screen the majority of the women 
invited for screening. The minimum standard is that 70% of those invited for 
screening should attend. It is only in London that the screening attendance 
falls below 70%. The breakdown shows that central London has the poorest 
screening attendance. This is likely to be due to the social demographic mix 
of these regions. It is important to make screening acceptable to women and 
this may increase uptake of screening. 
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Figure 1-9 Breast screening invitation uptake. 
A) Breast screening coverage among women aged 53-70 by region reported in 
England, March 2018 (Watson & screening and immunisation team, 2019) All regions 
apart from London reported coverage above the minimum standard of 70%. B) This 
illustrates the breakdown of screening coverage in London (Watson & screening and 
immunisation team, 2019).  
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Figure 4*: Breast screening coverage among women aged 53-70, by LA 
England, 31 March 2016  
 
NB: The definition of coverage changed in 2013 to include short term recalls. See Appendix C 
for more information.           
*Due to data being grouped using unrounded figures, the figures represented in Figure 4 may 
not match exactly those derived from aggregating the relevant column in Table 11 in the Data 
Tables. 
Source: KC63, NHS Digital – see also Table 11 in the Data Tables. 
 
2.1.5 Coverage in Other UK Countries 
Breast screening coverage figures are also available for Wales for 
women aged 53-70 years through the following link: 
http://www.breasttestwales.wales.nhs.uk/reports-1 
 
Coverage figures are not currently available for Scotland and Northern 
Ireland.  
75% and over 
70% to less than 75% 
Less than 70% 
A B 
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1.7.2 DCIS progression 
 
For several decades it has been accepted that DCIS constitutes a non-obligate 
precursor of IDC. In 1973, Wellings and Jensen proposed that DCIS lesions 
are precursors of invasive breast cancer (IBC) based on the evidence of 
gradual histological continuity observed in normal and abnormal breast tissues 
(Wellings & Jensen, 1973). Longitudinal studies of patients with DCIS 
managed with biopsy alone have revealed that only 20–50% of this population 
later developed IBC in the same quadrant of the same breast as the original 
DCIS (Page, Dupont, Rogers, & Landenberger, 1982) (Page, Dupont, Rogers, 
Jensen, & Schuyler, 1995),(Sanders, Schuyler, Dupont, & Page, 2005). 
Ozanne and colleagues created a simulation model to assess DCIS 
progression: this estimates that a lesion of a >1 cm, high grade DCIS in women 
under 45 years old would have a 60% rate of progression to IBC and those 
women more than 45 years of age with a <2.5cm, low or intermediate grade 
lesion to have a rate of progression to IBC of 10% (Ozanne et al., 2011). 
 
There is difficulty in establishing the rate of DCIS progression as most patients 
have definitive treatment at the time of diagnosis so halting the natural history. 
Leonard reviewed studies of patients with IBC who had previously had a 
benign biopsy.  On re-evaluation of these biopsies, evidence of DCIS was 
identified  in 14-73% of cases (Leonard & Swain, 2004). It is likely that the rate 
of recurrence is an overestimate, however, since the cases of invasive cancer 
were retrospectively reviewed. 
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Study Number 
of Cases 
Follow-
up 
(years) 
Histology Number 
(%) of 
cases that 
developed 
invasive 
carcinoma 
Kraus(KRAUS & 
NEUBECKER, 
1962) 
4 10-12 Papillary 2 (50%) 
Farrow(Farrow, 
1970) ( 
25 1-6 NR 5 (20%) 
Haagensen 
(Haagensen, 
Lane, & Lattes, 
1972) 
11 10 Papillary 8 (73%0 
Millis(Millis & 
Thynne, 1975) 
8 0-19 NR* 2 (25%) 
Page (Page et 
al., 1982) (Page 
et al., 1995) 
28 3-30 Noncomedo 9 (32%) 
Eusebi (Eusebi 
et al., 1994) 
80 5-28 Comedo 
Noncomedo 
11 (14%) 
 
 
*NR Non recorded 
 
A Dutch based population cohort study assessed all-cause mortality in 9799 
women treated for primary DCIS between 1989 and 2004. The standardised 
mortality rates for breast cancer decreased from 7.5 to 2.8 for women aged 
<50 and >50 years, respectively. DCIS patients >50 years at diagnosis, had 
lower all-cause mortality than the general female population. The lower 
mortality rates in women >50 years may reflect the demographic of women 
who attend breast screening or changes in lifestyle following DCIS diagnosis 
(Elshof et al., 2018). The higher risk in younger women may also reflect the 
greater time period available to develop recurrence. 
 
An Australian autopsy study of 207 women with a mean age of 60 years 
identified 27 women with carcinoma in situ, of which 21 were DCIS, 4 were 
mixed and 2 were LCIS. 37% of all carcinoma in situ identified was 
multicentric. This study identified 12% of women had occult DCIS (Bhathal, 
Brown, Lesueur, & Russell, 1985). A review of autopsy data in which women 
Table 1-2 DCIS with invasive recurrence.  
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thought not to have breast cancer at the time of death was performed by 
Gilbert and Welch in an attempt to establish how many women are dying with 
undiagnosed DCIS,. There are limitations to this review with pathological 
examination not being consistent between studies, with some studies 
examining 5 slides from the breast and one study examining 95 slides per 
breast. The median prevalence of DCIS was 8.9% within this review, but the 
rates varied widely (Welch & Black, 1997). In 2017, a further review of autopsy 
studies was performed which includes some data from the previous review 
with their estimate for the prevalence pool of incidental in situ breast cancer at 
~9% (E. T. Thomas et al., 2017). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-10 Schematic of DCIS progression. 
It is predicted that only a subset of DCIS will progress to invasive breast carcinoma 
with many (estimates vary between 10-80%) never developing into invasive cancer. 
Normal breast 
duct 
DCIS 
DCIS 
Invasion 
Time progression 
~50% 
~50% 
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1.7.3 Markers of DCIS progression 
 
Many studies have investigated markers that might predict or are associated 
with progression of DCIS, however to date the most important factors used 
clinically to predict progression is age, DCIS size, grade and margins. 
 
A DCIS scoring algorithm has been developed to risk stratify DCIS and is 
outlined in Table 1-4. The scoring system uses age, DCIS size, grade, 
necrosis and margin width, a score of 4-6 is low risk, 7-9 intermediate risk and 
10-12 high risk. This was initially developed to guide treatment decisions. 
 
Score 1 2 3 
Age >60 40-60 <40 
DCIS size 
(mm) 
<16 16-40 >40 
Histological 
grade 
1-2 
No 
necrosis 
1-2 
Necrosis 
3 
Necrosis 
Margin 
width (mm) 
³10 1-9 <1 
 
 
Silverstein and Lagios assessed recurrence in 949 patients treated with breast 
conservation, 345 with excision and radiation therapy, and 604 with excision 
alone and assessed recurrence at 12 years. There were 165 local recurrences 
of which 103 patients underwent excision only (37 invasive carcinoma and 66 
DCIS) and 62 patients were treated with excision plus post-operative radiation 
therapy (34 invasive carcinoma and 28 DCIS). The USC/Van Nuys prognostic 
index score was analysed to assess its predictive value (Silverstein, 2003).   
 
 
 
 
 
 
 
Table 1-3 Van Nuys prognostic index. 
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Score Number 
of 
patients 
Treatment Local 
recurrence 
at 12 
years 
4-6 320 Excision 
alone 
5.4% 
Excision 
with 
radiotherapy 
2.5% 
7 219 Excision 
alone 
30% 
Excision 
with 
radiotherapy 
13% 
10-12 98 Excision 
with 
radiotherapy 
>40% 
 
 
A higher incidence of recurrence is seen in the patients with a USC/Van Nuys score 
of 10-12 (Silverstein, 2003). 
 
The recurrence rates at 12 years are much higher with the 10-12 Van-Nuys 
score, an illustration the importance of grade and presence of necrosis. 
 
A range of biological markers has been investigated to assess their utility in 
predicting DCIS progression. ER negativity has been associated with an 
increased risk of DCIS recurrence (E. Provenzano et al., 2003). A study 
assessing 195 cases of low grade DCIS found 100% were ER positive and 
85.3% were PR positive (Koh et al., 2019). A study by Roka and colleagues of 
132 women diagnosed with DCIS treated with breast conserving surgery 
(BCS) with or without radiotherapy discovered a significantly lower rate of 
ipsilateral breast recurrence in patients with ER-positive DCIS compared to 
patients whose DCIS did not express ER (3.7% vs 12.2%, p<0.04).(Roka et 
al., 2004). HER-2 is a marker used in clinical practice to guide therapy for 
invasive breast cancer. Holmes and colleagues analysed 141 patients with 
DCIS who underwent breast conserving surgery, with confirmed disease-free  
surgical margins. There were 60 recurrences at a median time of 191 months. 
HER-2 positivity (3+) was found to be significantly associated with reduced 
Table 1-4 Analysis of recurrence using the USC/Van Nuys prognostic index. 
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time to tumour recurrence (Holmes et al., 2011). The immune response may 
have a role in DCIS progression. Immunotherapy is an evolving therapeutic 
option in many cancers, however to date success has been limited in the 
breast cancer field. In DCIS the tumour cells are separated from the immune 
system by the myoepithelial cell layer and an intact basement membrane, 
when there is progression to invasion the immune cells are intermingled with 
the tumour cells (Gil Del Alcazar et al., 2017). Polyak et al. investigated the 
immune infiltrate with particular focus on the T cells examining the difference 
between normal breast tissue, DCIS and IDC (Gil Del Alcazar et al., 2017). 
They showed that T cells in DCIS are enriched in activated effector CD8+ T 
cells characterised by the expression of Granzyme B (GZMB) and MKI67, 
while they were reduced in invasive disease. This was particularly evident in 
DCIS cases that recurred locally as IDC, implying that decreased immune 
activity may be necessary for invasive progression (Gil Del Alcazar et al., 
2017). 
 
Some theories propose the extracellular matrix (ECM) is a key driver in DCIS 
progression. Lyons et al., showed that mammary gland involution post 
pregnancy drives tumour progression by remodelling the ECM (Lyons et al., 
2011). They used post-partum murine models, demonstrating that involution 
resulted in large tumours with increased collagen deposition and over-
expression of cyclooxygenase-2 (COX-2) (Lyons et al., 2011). Hu et al. have 
shown in a xenograft model with up regulation of COX-2 an increase in VEGF 
and MMP14 expression, which may contribute to the larger tumour weight and 
invasive histology. A selective COX-2 inhibitor celecoxib was given and was 
found to decrease tumour weight and inhibit invasion (Hu et al., 2009). LOX 
elevation also causes modification of the ECM which in turn causes an 
increase in invasiveness and subsequent metastasis. Erler et al., assessed 
LOXL2 expression in patient samples using IHC, and xenograft models to 
investigate the function. They showed that LOXL2 promotes invasion by 
regulating the expression and activity of the extracellular proteins TIMP1 and 
MMP9 (Barker et al., 2011). 
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Theories of DCIS progression include linear and evolutionary progression. The 
linear multistep process initiates as flat epithelial atypia (FEA), progresses to 
atypical ductal hyperplasia (ADH), evolves into DCIS and progresses to IDC 
(Bombonati & Sgroi, 2011). Historically, it has been proposed there is a low-
grade and high-grade pathway of progression, hence low-grade DCIS 
develops into low-grade IDC and high-grade DCIS develops into high-grade 
IDC. The low-grade-like pathway is characterised by recurrent chromosomal 
loss of 16q, gains of 1q, a low-grade-like gene expression signature, with 
expression of oestrogen and progesterone receptors. The high-grade-like 
gene expression molecular pathway is characterised by recurrent gain of 
11q13, loss of 13q, expression of a high-grade-like gene expression signature, 
amplification of 17q12, and lack of oestrogen and progesterone receptors 
expression (Sgroi, 2010). Figure 1-6 illustrates hypothetical models of DCIS 
progression. In contradiction to this, more than one grade of DCIS is frequently 
present within a lesion (Chapman et al., 2007),  thus this theory is likely to be 
oversimplified. 
 
An alternative theory of DCIS progression is the evolutionary bottleneck model 
of progression. In this model a single cell in the duct gives rises to multiple 
clones, one of these clones passes through the bottleneck and subsequently 
escapes the basement membrane developing into invasive cancer, as shown 
in Figure 1-11. 
 
Tumour heterogeneity is one of the key challenges of DCIS management and 
contributes significantly towards the diagnostic and therapeutic dilemmas. The 
Navin lab have used a single cell DNA sequencing method, using laser capture 
microdissection to microdissect thousands of tumor cells from the in situ and 
invasive regions of a lesion for deep-exome sequencing: such an approach 
has emerged as a powerful tool for resolving intratumor heterogeneity (Navin 
et al., 2011), (Xu et al., 2012),(Zong, Lu, Chapman, & Xie, 2012). The results 
from this study support a multi-clonal invasion model, showing that multiple 
clones transform inside the duct and then one or more clones escape the ducts 
and migrate into the adjacent tissues to establish the invasive carcinoma. 
However, this recent study analysed only 10 patient samples of which 8/10 
 41 
cases were high-grade, so it is likely that as with previous studies there are 
also alternative models of DICS progression (Casasent et al., 2018). 
Consistent with Navin’s model, a study using flow-sorting and single cell copy 
number profiling in a single DCIS patient also reported evidence that multiple 
clones invaded the basement membrane (Martelotto et al., 2017).  
 
 
 
 
 
 
Figure 1-11 Schematic of hypothetical models of DCIS progression  
A) Progression from DCIS to invasive breast cancer as a convergent phenotype, 
where several combinations of somatic genetic and/or epigenetic aberrations result 
in the acquisition of the biological properties required for cancer cells to progress 
from in situ to invasive disease (i.e. the genetic/epigenetic aberrations selected for 
are distinct between patients but all result in the progression to invasive disease) 
B) Evolutionary bottleneck model when a single cell in the duct gives rise to multiple 
clones , a single clone and passes through the bottleneck (in the schematic the green 
cell) escapes the basement membrane to become invasive breast cancer  
Adapted from (Lopez-Garcia, Geyer, Lacroix-Triki, Marchió, & Reis-Filho, 2010) 
Progression as an evolutionary bottleneck 
Convergent 
A 
B 
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1.7.4 Artificial Intelligence in breast screening  
 
There is a recognised need to improve reliability and accuracy of breast 
screening. One factor in this improvement process is the accuracy of 
mammography interpretation.  One focus is the use of artificial intelligence (AI) 
in the analysis of mammograms. Tech company google have developed an 
interest in breast screening - they have an AI team who have assessed the 
mammograms of 7500 women. These mammograms are anonymised and 
stored in a database held by CRUK. The aim is to assess if there are 
machine learning algorithms that can alert radiologist more accurately than 
current available techniques ("https://deepmind.com/blog/applying-
machine-learning-mammography/," 2017). In addition to improved accuracy, 
these approaches have the potential to address workforce issues - at 
present there are challenges with NHS service provision with currently 13% 
of substantive consultant breast radiologist posts being vacant. Professor 
Anne Mackie, Director of Programmes for the UK National Screening 
Committee at Public Health England, commented: “Mammography is a key 
service for the NHS in the early detection of breast cancer. Exploring 
innovative new technologies such as machine learning has the potential to 
increase the efficiency of these services and make better use of the 
resources available to NHS screening 
programmes("https://deepmind.com/blog/applying-machine-learning-
mammography/," 2017).” 
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1.7.5 The effect of screening on breast cancer incidence 
 
Breast cancer remains the most commonly diagnosed cancer among women 
in the UK, accounting for a third of female cancer cases, and the second most 
common cause of female cancer related deaths 
("http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/breast-cancer/incidence-in-situ,"). The UK 
National Health Service screening program was implemented in 1988. Duffy 
and colleagues performed a case control study, assessing the impact of 
screening in London. Results showed that attendance at breast screening led 
to a decrease in breast cancer mortality of 35% (Massat et al., 2016). 
Incidence rates of DCIS increased by 40% between 1979-1981 and 1988-
1990, then by almost two-and-a-half times (142% increase) between 1988-
1990 and 1997-1999. Rates increased by 87% between 1997-1999 and 2011-
2013 ("http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/breast-cancer/incidence-in-situ,"). These 
trends in female in situ breast carcinoma incidence largely reflect the impact 
of the UK breast screening programme.  
 
1.7.6 Over-diagnosis and over-treatment 
 
The screening program has evolved over time leading to increased cancer 
detection rates. A surgical oncologist, who was key in establishing the breast 
screening program, has called for the program to be stopped, arguing it leads 
to healthy women being labelled 'cancer victims' and has not reduced the 
number of invasive tumours. The controversies associated with breast 
screening led to an independent review in 2012. 
 
This review found that for every 10000 UK women aged 50 who attended 
screening for 20 years, 43 deaths from breast cancer would be prevented and 
129 cases of invasive and non- invasive breast cancers would be over-
diagnosed. Over-diagnosis is defined as the detection of a cancer that would 
not have been clinically apparent in woman’s lifetime if they had not attended 
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screening. This is a key concern as this can lead to over-treatment which may 
subsequently mean that in certain cases the harm of breast screening 
outweighs the benefits.  The review found that one breast cancer death is 
prevented for about every three over-diagnosed cases identified and treated 
(Screening, 2012). It is also important to differentiate that the figures are 
different for women who are invited and those who actually attend screening, 
those women who actually attend are likely to be more engaging with health 
care. From the independent screening review the estimate was made for every 
235 women invited to screening one death from breast cancer would be 
prevented, however the absolute benefit would be higher for those women that 
actually attended screening: 180 women would need to be screened to 
prevent one breast cancer death (Screening, 2012). These figures have been 
interpreted from previously performed trials and there is some concern with 
regards to validity of these trials in modern breast screening. Table 1.5  is from 
the breast screening review and is used to illustrate that differing trials have 
shown large differences in how beneficial breast screening is. 
 
A further study estimated 52% over-diagnosis of breast cancer in a population 
offered organized mammographic screening (Torjesen, 2015). The NIH State 
of Science conference on DCIS, highlighted the need to understand more 
about the biological and molecular mechanisms underlying the progression of 
DCIS to invasive disease in order to achieve robust prognostic and therapeutic 
patient stratification (Allegra et al., 2010). An Independent UK panel on Breast 
Cancer Screening stated: ‘Further research is needed to improve the precision 
of screening to better distinguish between breast cancers that will or will not 
cause harm during a woman’s lifetime’ (Screening, 2012). 
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 Description Number of 
women 
Independent 
screening 
review(Screening, 
2012) 
Based on RR reduction of 20% for 
women aged 55-79 years in the UK 
235 women 
invited 
180 women 
screened 
Cochrane review 
(Gøtzsche & 
Jørgensen, 2013) 
Absolute risk reduction based on the 
13-year follow-up in the trials 
considered adequately randomised 
20000 women 
invited 
US task force 
(Nelson et al., 
2009) 
Based on 7 years of screening and 13 
years of follow-up 
1339 women 
invited aged 50-
59 years, and 377 
invited aged 60-
69 years 
Canadian Task 
Force(Tonelli et 
al., 2011) 
Women aged 50–69 years screened 
every 2–3 years for about 11 years 
720 women 
screened 
Duffy et al, 2010 
(Duffy et al., 2010) 
Based on 22-year follow-up of women 
aged 50–69 years in the Swedish Two-
County trial, assuming that the absolute 
risk reduction for the 7 years of 
screening can be multiplied up to reflect 
20 years in the UK screening 
programmes 
113 women 
screened 
Beral et al, 2011 
(Beral et al., 2011) 
Women aged 50–70 years regularly 
screened for 10 years, based on 
summary of published evidence 
400 women 
screened 
 
Due to the strength of opinion with regards to the value of breast screening 
prior to the 2012 screening review, there were divergent opinions in response 
to the screening review, stating the panel either underestimated or 
overestimated the problem of over-diagnosis. As a result of the strong 
response the panel reconvened to respond to these questions. Hanley and 
colleagues commented that the reduction in breast cancer mortality may be 
greater if a shorter follow up was used (Hanley, McGregor, Liu, Strumpf, & 
Dendukuri, 2013).  A Danish study of the effects of screening showed the 
burden of over-diagnosis was less when compared to the Marmot review, 
among 1,000 women invited to screening from age 50 and followed until 79, 
2–3 women would be prevented from dying from breast cancer for every 
woman over-diagnosed with invasive breast cancer or DCIS (Beau, Lynge, 
Njor, Vejborg, & Lophaven, 2017). Thus, there is an internationally recognized 
Table 1-5 Absolute risk reduction, expressed as number of women who need to be 
invited or screened to prevent one breast cancer death, in the trials of breast cancer 
screening.   
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need to better understand the biology of DCIS in order to more appropriately 
tailor therapy to individual patients. This means better biomarkers are needed 
for DCIS based on biological mechanisms that can help stratify patients into 
those that are at risk of disease progression and those who are not. 
 
1.7.7 DCIS clinical trials 
 
A number of clinical trials have been developed to evaluate the potential to 
treat non-high-grade DCIS by surveillance alone. There are currently trials 
open in the United Kingdom, Netherlands and United States. These trials aim 
to gain a better understanding of the natural course of certain types of DCIS. 
 
LORIS is a phase III clinical trial of surgery versus active monitoring for Low 
Risk Ductal Carcinoma in Situ recruiting in the UK. The trial started recruiting 
in July 2014 and recruitment is due to end March 2020, cases are required to 
be screen detected or incidental microcalcification, biopsy results confirmed 
as non-high-grade DCIS, which are then submitted for central review prior to 
recruitment to the trial. Memorial Sloan Kettering Cancer Centre reviewed their 
DCIS patients and only 16 percent of their patients with DCIS met the LORIS 
inclusion criteria, emphasizing that the results of this observation study will 
apply to only a minority of patients (Pilewskie et al., 2016). The original LORIS 
recruitment target was 932 this has been readjusted to 188, currently there are 
138 patients recruited to the trial. The LORIS Trial has many challenges with 
patient recruitment due to a combination of factors including the numbers of 
low-risk DCIS cases and entrenched ideology about how DCIS should be 
treated (https://www.dcisprecision.org/clinical-trials/loris/) 
 
The LORD (LOw Risk DCIS) trial opened to recruitment in January 2017 in the 
Netherlands, and there are currently 28 sites open with 33 patients recruited 
from a target of 1240. The trial compares standard local surgical treatment for 
DCIS vs active surveillance consisting of annual digital mammography for 10 
years. The primary outcome of the trial is Ipsilateral invasive breast cancer-
free rate at 10 years (https://www.dcisprecision.org/clinical-trials/lord/)  
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The Comparison of Operative to Monitoring and Endocrine Therapy (COMET) 
trial for low risk DCIS is currently recruiting in the United States. The primary 
outcome is to compare the number of patients that develop ipsilateral invasive 
cancer that received guidance-concordant care (standard treatment surgery 
+/- radiotherapy) to the number of ipsilateral invasive cancers in patients that 
were placed on active surveillance after 2 years of follow-up. The trial recruited 
the first patient in February 2017, 80 sites are open to recruitment and there 
are currently 253 patients recruited to the trial. The challenges for recruitment 
include low numbers of low risk DCIS and this has led to a change in eligibility 
criteria to accept comedo necrosis ("https://www.dcisprecision.org/clinical-
trials/comet/,"). 
 
The aim of the trials currently undergoing active recruitment is to gain an in 
depth understanding of DCIS. However, the clinical and scientific community 
are also striving to increase the biological understanding of DCIS progression 
to provide a more robust way of predicting DCIS progression. Table 1.6 shows 
a summary of current DCIS trials, patients recruited have been updated to 
reflect current status. 
 
 LORIS LORD COMET 
Phase III III III 
Study AS AS  AS+ET (choice) 
Screening MMG MMG MMG 
Nuclear grade 1 or 2 1 1 or 2 
Comedo 
necrosis 
No No Eligible 
ER N/S N/S Positive 
HER-2 N/S N/S Negative *** 
Size N/S Any size Any size 
Patients/Target 138/932 28/1240 253/1200 
 
 
Table 1-6 Summary of DCIS clinical trials 
AS: Active surveillance, ET: Endocrine therapy, N/S: Not stipulated in study protocol, 
* single arm confirmatory trial, ** breast US and MRI, *** if tested. 
 48 
The current DCIS trials have common issues with problems to recruit, this is a 
recurrent problem with surgical de-escalation trials. Along with recruitment 
difficulties only a small proportion of DCIS seen in the clinic is low risk DCIS 
and with low risk DCIS there is often a lack of agreement between pathologists 
as to the grade of DCIS and this had led to many cases being rejected at 
pathological central review. An international approach has now been applied 
with the PREvent ductal Carcinoma In situ Invasive Overtreatment Now 
(PRECISION) (van Seijen et al., 2019) initiative which is a multinational 
initiative to address current controversies in DCIS management. This will use 
data from patients recruited into LORIS, LORD and COMET. PRECISION has 
seven interlinked work packages (WP): 
 
1. WP1 -Retrospective DCIS data and tissue block collection. 
2. WP2- Comprehensive genomic characterization of DCIS. 
3. WP3- Characterisation of the role of the immune microenvironment as a 
determinant of DCIS clinical biology. 
4. WP4- The role of imaging in DCIS prognosis and outcome. 
5. WP5- Functional validation of DCIS drivers. 
6. WP6- Building and validation of DCIS risk stratification model. 
7. Using ctDNA and multi-OMICS in active surveillance of DCIS using LORIS, 
LORD and COMET trials. 
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1.8 Microenvironment 
1.8.1 DCIS Microenvironment 
It is now well recognised that the tumour microenvironment plays a central role 
in tumour progression. The DCIS microenvironment is complex, consisting of 
fibroblasts, immune cells and cells that support the blood vessels. It also 
includes many secreted proteins produced by all of the cells present in the 
tumour that support the growth of the cancer cells (Polyak, 2010). A unique 
component of the DCIS microenvironment is the myoepithelial population. It 
has been suggested that epigenetic alterations in the stroma may be involved 
in the progression from in situ to Invasive breast cancer (Hu et al., 2005). The 
components of the tumour microenvironment and their role in DCIS 
progression will be discussed in detail further on in this chapter. 
 
Angiogenesis is the formation of new blood vessels, which is required for 
tumour growth. Teo et al., assessed 355 DCIS cases of which 32 developed 
recurrence. A CD34 antibody was used to detect microvessel density (MVD). 
MVD was higher around foci of DCIS than around normal breast lobules 
(P=0.001) and was significantly higher in cases of DCIS that recurred 
(P<0.0001) (Teo et al., 2003). Two distinct vascular patterns have been 
described; an increase in stromal vascular density with angiogenic factors 
released by accessory cells and an increase in periductal vessels in which the 
angiogenic factors are secreted by intraductal tumour cells (Guidi et al., 1997), 
(Engels, Fox, Whitehouse, Gatter, & Harris, 1997), the latter pattern appears 
to be more associated with progression. 
 
Whilst there are certain common features in the microenvironment of DCIS 
and invasive breast cancers, some studies have shown differences. For 
example, upregulation of  MFAP2, MMP11, MMP2, COL1A2, 
VIM, and PLAU and downregulation of CDH1 and F2RL1 has been 
demonstrated in invasive disease compared to isolated DCIS (Abba et al., 
2015). Ma et al  compared gene expression changes in epithelial and stromal 
cells during DCIS progression (Ma, Dahiya, Richardson, Erlander, & Sgroi, 
2009). They demonstrated changes in epithelial and stromal cells in the 
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transition from normal to DCIS however there were no significant changes in 
epithelial cells in the transition of DCIS to invasion, though there were 
differences in the gene expression of the stromal cells. There were 76 
upregulated genes and 229 downregulated genes when comparing invasive 
cancer stroma to DCIS stroma (Ma et al., 2009). Genes increased in invasive 
cancer stroma included MMP11, MMP2 and MMP14, whilst there was 
decreased expression of genes involved in vasculature development 
(EMCN, FLT1. KDR,SEL,MTH11, EDNRB and PODXL). 
 
1.8.2 The role of normal myoepithelial cells 
 
The position of the myoepithelial cell (MEC) between the luminal cells and the 
stroma places them in the ideal anatomical position in which to influence both 
compartments and mediate environmental cross-talk. Myoepithelial cells are 
attached to luminal cells by desmosomes and to the basement membrane by 
hemidesmosomes (Adriance, Inman, Petersen, & Bissell, 2005). The 
myoepithelial cells contribute significantly to the formation of basement 
membrane, comprising collagen IV, fibronectin, laminin, nidogen, 
glycosaminoglycans, and proteoglycans. It forms a continuous layer 
separating myoepithelial cells from the stroma. Receptors for basement 
membrane components, especially integrins, present in MECs, are 
responsible for interactions with the matrix (Koukoulis et al., 1991).  
 
MECs have a prominent smooth muscle actin cytoskeleton which is 
responsible for their contractile phenotype (Murrell, 1995), (Bussolati, 
Cassoni, Ghisolfi, Negro, & Sapino, 1996), in keeping with their physiological 
function in the ejection of milk.  
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1.8.3 The role of myoepithelial cells in tumour suppression 
 
There is significant evidence for a regulatory role played by normal 
myoepithelial cells in the mammary gland, including control of epithelial cell 
polarity and anti-proliferative, anti-invasive and anti-angiogenic properties, 
thus providing a broad tumour-suppressor environment (Barsky & Karlin, 
2006). Myoepithelial cells, which surround ducts and acini of glandular organs, 
form a natural border separating proliferating epithelial cells from basement 
membrane and underlying stroma, thus physically preventing tumour cell 
invasion (Pandey, Saidou, & Watabe, 2010).  
 
Myoepithelial cells have been shown to down-regulate expression of matrix 
metalloproteinases (MMPs) in both tumour cells as well as fibroblasts, so 
promoting an anti-invasive phenotype (Jones, Shaw, Pringle, & Walker, 2003). 
Maspin is one of the most important tumour suppressor proteins that is 
secreted by normal myoepithelial cells which acts as an inhibitor of 
angiogenesis (Hopkins & Whisstock, 1994),(Pemberton et al., 1995). Thus, 
the myoepithelial cell could be considered as ‘guardian of the ductal 
microenvironment’ in the normal breast. 
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1.8.4 The role of myoepithelial cells in tumour progression 
 
Whilst acting as a tumour suppressor in the normal breast, myoepithelial cells 
in DCIS are different to normal MECs. They have been described as showing 
loss of hemidesmosome formation, thereby altering the key interaction with 
the basement membrane (Bergstraesser, Srinivasan, Jones, Stahl, & 
Weitzman, 1995). They also show up-regulation of pro-invasive ECM proteins 
such as Tenascin-C (Adams, Jones, Walker, Pringle, & Bell, 2002).  Allinen et 
al., showed that myoepithelial cells exhibit more dramatic changes than any 
other cell component between normal and DCIS tissues, suggesting extensive 
abnormal paracrine interactions in DCIS. Indeed, xenograft studies suggest 
that dedifferentiation of host myoepithelial cells leads to the transition of in situ 
to invasive disease (Allinen et al., 2004). Man et al (Man & Sang, 2004) 
hypothesised that myoepithelial cells are lost through cell death in the 
progression to invasive cancer: this theory is investigated further in chapter 3 
of this thesis.  
 
Work in our laboratory has shown that expression of avβ6 integrin is up-
regulated in myoepithelial cells in a subset of DCIS, leading to altered 
myoepithelial cell function and the establishment of a pro-tumorigenic 
environment. Myoepithelial cells expressing avβ6 integrin lead to enhanced 
tumour invasion through TGFβ -dependent up-regulation of MMP-9 (Allen, 
Marshall, & Jones, 2014). We also have shown that up-regulation of avβ6 
integrin on DCIS-associated myoepithelial cells is associated with an 
increased periductal immune infiltrate (unpublished data).  
 
An alternative theory to that proposed by Man et al is that myoepithelial cells 
become more migratory and less adhesive in the progression from DCIS to 
invasion. Structurally, myoepithelial cells form distinct desmosomes with both 
luminal cells and other myoepithelial cells, generate gap junctions and 
cadherin–cadherin interactions with other myoepithelial cells, and adhere to 
the basement membrane (BM) via integrins in focal adhesions and in 
hemidesmosomes(Ahmed, 1974), (Koukoulis et al., 1991), (Bergstraesser et 
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al., 1995), (Pitelka, Hamamoto, Duafala, & Nemanic, 2009). Runswick et al., 
found that inhibition of the myoepithelial-specific desmosomal cadherins, 
desmocollin 3 (Dsc 3) and desmoglein 3 (Dsg 3), prevented morphogenesis 
of the bilayered acinus structure and disrupted the basal positioning of 
myoepithelial cells (Bissell & Bilder, 2003), (Runswick, O'Hare, Jones, Streuli, 
& Garrod, 2001), demonstrating the importance of these interactions in 
maintaining normal duct structure.  
 
Whilst MECs exhibit altered characteristics in DCIS, loss of the myoepithelial 
cell population is pathognomonic of invasive breast disease.  The recognition 
of myoepithelial cells is crucial in the diagnosis of a number of pathological 
breast lesions (Joshi, Smith, Perusinghe, & Monoghan, 1986). A number of 
markers can be used in diagnostic pathology to identify the myoepithelial cells, 
of which a-Smooth Muscle Actin (aSMA) and the basal cytokeratin CK5/6 are 
the most commonly used.  
	
1.8.5 Fibroblasts 
 
Fibroblasts are embedded within the stroma surrounding the glandular unit. A 
key function of fibroblasts is to maintain the stability of the extracellular matrix 
(ECM) and they are the major source of collagen and fibronectin which provide 
mechanical and structural support for the epithelial tissue. Fibroblasts also 
produce proteases, such as MMPs, which degrade the ECM, resulting in 
stromal reorganization and release of growth factors (Inman, Robertson, Mott, 
& Bissell, 2015). Fibroblasts are important in collagen deposition and alteration 
of collagen fiber orientation which are potentially important in DCIS 
progression. Provenzano et al., demonstrated distinct patterns of collagen 
signatures at different stages of tumour progression (P.P. Provenzano et al., 
2006). Hu et al used a 3D co-culture model in which MDFDCIS cells were 
co-cultured with fibroblasts in recombinant basement membrane, the 
presence of fibroblasts led to increased invasive branching in the matrix, 
which was accompanied by increased levels of MMP-14 and MMP-9 in the 
co-cultures (Hu et al., 2009). A study assessing DCIS samples with micro 
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invasion showed myofibroblasts uPA, uPAR and MMP-13 which are linked 
to invasion (Nielsen, Rank, Illemann, Lund, & Danø, 2007). 
	
	
1.8.6 Immune cells 
The immune infiltrate of the stroma surrounding DCIS ducts is of increasing 
interest as a potential marker for DCIS progression and as a therapeutic target. 
Increased inflammation in DCIS is associated with high nuclear grade and 
HER2 positive lesions (A. H. Lee, Happerfield, Bobrow, & Millis, 1997a; 
Ramachandra, Machin, Ashley, Monaghan, & Gusterson, 1990). Esserman 
has also shown CD 68+ macrophages are also associated with high grade 
DCIS with comedo necrosis (Esserman et al., 2006). These are indications 
that an increased immune infiltrate within the stroma is likely to be a driver in 
tumour progression with the cross talk between the malignant epithelial cells 
and the progression with the cross talk between the malignant epithelial cells 
and the stroma. The tumour associated macrophages (TAMs) represent a 
major component of the immune infiltrate within the stroma of many tumours, 
M2 associated macrophages have pro-tumoral functions, including promotion 
of angiogenesis and matrix remodeling. There is an increase in periductal 
immune infiltrate associated with DCIS in particular showing increased 
numbers of T regulatory (Treg) cells, and this periductal immune infiltrate has 
been suggested to predict progression of DCIS to invasion (A. H. Lee, 
Happerfield, Bobrow, & Millis, 1997b). A functional role for inflammatory cells 
in the transition of DCIS to invasive disease has been hypothesised by Man 
and his group (Man, 2007), who suggest that factors released by the immune 
cells can damage myoepithelial cells, ultimately leading to their loss through 
apoptosis, so breaching the duct wall facilitating tumour invasion. Tumour 
necrosis factor related apoptosis-induced ligand (TRAIL) is a pro-apoptotic 
ligand, which is expressed by peripheral T lymphocytes (Salehi et al., 2007) 
including CD4+ve T cells (Sato et al., 2006). Therefore, an increase in the 
immune infiltrate in the DCIS microenvironment may lead to DCIS-associated 
myoepithelial cells being physiologically exposed to TRAIL. 
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The immune response of the tumour microenvironment is vitally important for 
both predicting progression and potential therapeutic targets. Tumour 
progression is likely to be compromised  by the infiltration of CD8/Th1 T cells, 
NK and M1 TAM whereas tumour progression may be aided by CD4+/Th2/T-
reg, MDSC and M2 TAM. A study of 27 cases of DCIS, 24 of which were pure 
DCIS, showed higher numbers of TILs were in ER- DCIS, and a higher 
CD8/Treg ratio in ER+ DCIS (Thompson et al., 2016). A comparison of high-
grade DCIS was found to have higher percentages of macrophages as 
identified by the macrophage marker CD68, compared with non-high-grade 
DCIS (Campbell et al., 2017).  
 
Cell Tumour suppressive Tumour promoting 
Myoepithelial cell TIMP-1 
Stefin A/B  
Maspin 
PAI-1 
MMP-8 
TSP-1 
CXCL12 
CXCL14 
TGFb 
aVb6 
Fibroblasts  IL-6 
CXCL1 
Cathespin B 
uPAR 
uPA 
MMP-13 
Myeloid cells  CCL2 
CXCR2- binding 
chemokines 
Lymphocytes CD8 
Th1 CD4 
Th2 CD4 
Treg 
 
 
1.8.7 The microenvironment in invasive breast cancer 
The tumour microenvironment plays a vital role in progression of breast 
cancer. In 1889 Paget discussed the importance of the microenvironment: 
metastasis is not due to chance events, but rather that some tumour cells (the 
“seed”) grow preferentially in the microenvironment of select organs (the “soil”) 
(Paget, 1989). The microenvironment is composed of fibroblasts, immune 
cells, endothelial cells, infiltrating inflammatory cells, adipocytes as well as 
signaling molecules and extracellular matrix (ECM), this is often collectively 
referred to as stroma (Hanahan & Coussens, 2012). The composition of the 
Table 1-7 Summary of stromal cells involved in tumour suppression and progression 
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stroma contributes towards breast density. The results of the International 
Breast Cancer Intervention Study (IBIS)-1 trial has suggested a link between 
the breast microenvironment and development of breast cancer. In those high-
risk women receiving prophylactic Tamoxifen, there was a 63% reduction in 
risk of breast cancer, but this risk reduction was only seen in those women 
who exhibited at least 10% decrease in breast density. In those women with 
no reduction in breast density there was no protective effect of Tamoxifen. 
This links the protective effect of Tamoxifen to a change in the breast 
microenvironment (Cuzick et al., 2011). Fibroblasts are the most abundant cell 
type within the breast stroma. Normal fibroblasts can have tumour suppressive 
functions, but these suppressive functions are lost in tumour progression 
(Alkasalias, Moyano-Galceran, Arsenian-Henriksson, & Lehti, 2018). The 
switch of normal fibroblasts to cancer associated fibroblasts (CAFs) is an 
important factor in tumour progression. Orimo et al., showed that fibroblasts 
derived from primary human invasive breast carcinomas significantly 
enhanced tumour growth in xenograft models compared to their normal 
counterparts (Orimo et al., 2005). The ECM becomes progressively stiffer and 
more collagen-rich during tumour progression (Paszek et al., 2005). Lysyl 
oxidase (LOX), primarily secreted by fibroblasts, increases cross-linkage in 
collagens and elastin, increasing the insoluble matrix and contributing to 
tensile strength (Kagan & Li, 2003). LOX has been shown to regulate invasion: 
high levels of LOX in primary breast tumours or systemic delivery of LOX in 
mouse models leads to osteolytic skeletal lesion formation that was abrogated 
when LOX was genetically silenced (Cox et al., 2015). The pleiotropic effects 
of the tumour microenvironment are summarised in figure 1-12. Changes to 
the normal microenvironment promote tumour invasion. Altered function of 
carcinoma-associated fibroblasts and induction of an inflammatory infiltrate 
lead to release of pro-angiogenic factors. Development of a desmoplastic 
stroma, partly in response to hypoxia, leads to tumour-specific interactions 
with tumour cell-surface receptors that enhance invasion (M. Allen & Louise 
Jones, 2011; Paszek et al., 2005). As in DCIS, the immune microenvironment 
also has been implicated in invasive breast cancer. Finak et al identified three 
gene clusters from the stroma around invasive breast cancer and showed that 
the good-outcome cluster overexpress a distinct set of immune-related genes, 
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including T cell and NK cell markers indicative of a TH1–type immune 
response (GZMA, CD52, CD247, CD8A) (Finak et al., 2008). Recently, an in-
silico analysis across nine datasets identified three distinct immune clusters 
dependent on both the abundance and composition of the infiltrate (Tekpli et 
al., 2019).  Immune clusters were characterised as Cluster A (immune cold), 
Cluster B (immune intermediate) and Cluster C (immune hot), where Cluster 
B was associated with significantly poorer relapse-free and overall survival 
across all invasive cancer subtypes. Cluster B was associated with an 
epithelial–mesenchymal transition (EMT) or proliferative phenotype. Whether 
similar clusters exist in the DCIS microenvironment remains to be 
established(Tekpli et al., 2019). 
 
 
 
 
 
  
Figure 1-12 Tumour microenvironment schematic 
Changes to the normal microenvironment promote tumour invasion. Altered function 
of carcinoma-associated fibroblasts and induction of an inflammatory infiltrate lead to 
release of pro-angiogenic factors. Development of a desmoplastic stroma, partly in 
response to hypoxia, leads to tumour-specific interactions with tumour cell-surface 
receptors that enhance invasion.(M. Allen & Louise Jones, 2011; Paszek et al., 2005) 
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1.9 Cell Adhesion 
 
Cell adhesion is the process by which cells interact and attach to neighbouring 
cells and the extracellular matrix. These interactions are regulated by 
specialised cell surface molecules and are vitally important for the stability of 
the normal breast duct. Breakdown in these interactions may contribute to loss 
of cellular organisation and potentially subsequent progression to invasive 
disease.  
 
Adherens junctions and tight junctions are present at cell-cell contacts. The 
adherens junctions’ mediate cell-cell adhesion via the actions of nectins and 
cadherins. The tight junctions regulate passage of ions and small molecules 
between cells and establish cell polarity (Campbell, Maiers, & DeMali, 2017). 
 
Hemidesmosomes (HDs) are highly specialized integrin-mediated epithelial 
attachment structures (Walko, Castañón, & Wiche, 2015). They are important 
in maintaining structural stability of epithelial cells by anchoring them to the 
basement membrane (Alberts et al.). a6b4 is the key integrin component of 
hemidesmosomes and shows strong, basal expression in normal 
myoepithelial cells (Bergstraesser et al., 1995). 
 
Desmosomes are intercellular junctions that tether intermediate filaments to 
the plasma membrane. Desmogleins and desmocollins, members of the 
cadherin superfamily, mediate adhesion at desmosomes (Delva, Tucker, & 
Kowalczyk, 2009). The various adhesion structures in breast epithelial cell 
populations are summarised in figure 1-13. 
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A summary of cell-cell junction and cell-matrix junction structures illustrating the 
interplay between cells and the extracelllar matrix.  
Figure 1-13 Schematic of cell adhesion 
Hemidesmosome ("6 β4) 
Integrin (β1, β3, β6) 
Basement Membrane 
Myoepithelial Cell 
Desmosome 
Tight junction 
Luminal Cell 
Extracellular Matrix 
Adherens junction 
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1.10 Integrin avb6  
 
As a member of the integrin family, integrin αvβ6 is a heterodimer made up of 
two subunits, αv and β6, and both are necessary for complete functioning (Niu 
& Li, 2017).  Integrin αvβ6 is not expressed in healthy adult epithelia but is 
upregulated during wound healing and in cancer. αvβ6 has been shown to 
modulate invasion, inhibit apoptosis, regulate the expression of matrix 
metalloproteases (MMPs) and activate TGF-β1(Bandyopadhyay & Raghavan, 
2009). Integrin αvβ6 appears to promote cell invasion and migration, both of 
which are involved in metastasis. The expression of αvβ6 is often associated 
with a poor prognosis (G. J. Thomas, Nyström, & Marshall, 2006). 
Allen et al have shown upregulation of integrin αvβ6 by myoepithelial cells in 
52% to 69% of non–high-grade and high-grade DCIS, respectively, but it is 
present in almost 100% of DCIS associated with invasive disease (M. D. Allen, 
Thomas, et al., 2014). To assess if αvβ6 may be used to predict recurrence, 
expression was assessed in a cohort of DCIS cases treated with local excision, 
confirmed margins free of disease and with long-term follow-up as part of the 
UK/ANZ DCIS trial (Cuzick et al., 2014). This showed a significant correlation 
between αvβ6 expression in myoepithelial cells and recurrence of breast 
cancer either as in situ or invasive disease, independent of patient age, 
disease grade, or extent. Those with αvβ6 positivity developed recurrence 
more quickly than those lacking αvβ6, with median time to recurrence of 2.3 
versus 11.4 years, respectively (M. D. Allen, Thomas, et al., 2014). 
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1.11 Galectins  
 
Galectins are a family of carbohydrate binding proteins, with a wide range of 
cellular functions. There are 15 different members which have been named in 
order of discovery. All Galectins contain a carbohydrate binding recognition 
domain (CRD). There are 3 groups which have differing structure; proteolytic 
galectins have one CRD (galectin 1,2,5,7,10,11,13,14,and 15), the tandem 
repeat galectins contain two homologous CRDs linked by a single polypeptide 
chain (galectin 4,6,8,9 and 12) and chimeric galectin which has a CRD 
connected to a non- lectin N terminal is galectin- 3. (R. Y. Yang, Rabinovich, 
& Liu, 2008)  
 
Galectins have a diverse physiological role with functions in; cell adhesion, cell 
migration, apoptosis, differentiation. They have both intracellular and 
extracellular roles and their function can be location dependent. Galectins 
have been shown to have roles in inflammation, angiogenesis, immune 
response and cancer(Klyosov & Traber, 2012)  
 
The dysregulation of galectin expression is frequently observed in cancer 
tissue (Vladoiu, Labrie, & St-Pierre, 2014), frequently in a tissue-specific 
manner. 
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1.12 Galectin-7 
1.12.1 The Role of Galectin-7 in DCIS 
 
Galectins are a family of evolutionary-conserved carbohydrate binding 
proteins. Essential functions include regulation of development, differentiation, 
cell-cell adhesion, cell-matrix interaction, growth and apoptosis. Galectins 
exhibit a wide range of subcellular localisations, and are found in both 
intracellular and extracellular compartments, however, Galectin-7 is reported 
to be predominantly intracellular (Grosset et al., 2014), and in normal breast it 
is strongly and exclusively expressed by the myoepithelial cells, located 
predominantly in the nucleus (Demers et al., 2010). Several functions have 
been described for Galectin-7. It has been shown to suppress TGFβ-mediated 
gene transcription by promoting nuclear export of SMAD2/3 (Gendronneau et 
al., 2008), so acting as an antagonist of TGFβ signalling. It has also been 
identified as a regulator of apoptosis with both pro- or anti-apoptotic effects 
being described (Demers et al., 2010). Thus, Galectin-7 has the potential to 
antagonise the pro-tumourigenic TGFβ-mediated signalling generated by 
myoepithelial-associated β6 integrin, and to modulate response to apoptotic 
signals generated in the periductal environment that might compromise the 
myoepithelial barrier. Therefore Galectin-7 may comprise part of the tumour-
suppressor armoury of normal myoepithelial cells. Thus, loss of Galectin-7 
from DCIS associated myoepithelial cells may be predicted to augment the 
effects of β6 integrin and destabilise the myoepithelial-basement membrane 
barrier so predisposing to progression to invasive disease. Establishing the 
functional relevance of Galectin-7, its interaction with β6 integrin and the 
myoepithelial response to pro-apoptotic stimuli in the periductal environment, 
would clarify the role of Galectin-7 and may identify loss of Galectin-7 as an 
important marker of disease progression.  
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1.12.2 The role of Galectin-7 in Breast Carcinoma 
 
There have been various studies regarding the role of Galectin-7 in breast 
carcinoma. In the normal breast duct, myoepithelial cells strongly express 
Galectin-7, while luminal cells are negative. Demers et al., used mouse 
models to demonstrate the effect of Galectin-7 in breast cancer. Breast cancer 
cells expressing high levels of Galectin-7 exhibit an increased ability to 
metastasise to lungs and bone. Examination of normal and malignant human 
breast tissue indicated that Galectin-7 is expressed in breast carcinoma with 
an aggressive phenotype (Demers et al., 2010).  High levels of Galectin-7 in 
breast cancer cells render them more resistant to apoptosis and they 
metastasise earlier.  The resistance of breast cancer cells to apoptosis is 
suggested to be dependent on the subcellular localisation of Galectin-7. To 
demonstrate this, the MCF-7 breast carcinoma cell line was transfected with a 
mutant form of Galectin-7 (R74S) with altered sub-cellular location (Grosset et 
al., 2014). Normally, intracellular Galectin-7 is found in the cytoplasm, nucleus 
and mitochondria. The mutation at position 74 affected the translocation of 
Galectin-7 to mitochondrial and nuclear compartments. Both mutant and wild 
type Galectin-7 were found to give equal resistance to drug induced cell death, 
indicating that the anti-apoptotic function of Galectin-7 is independent of 
subcellular localization (Grosset et al., 2014), however, this study is limited to 
one cancer cell line and therefore appropriate weighting should be applied. 
Other studies have shown the importance of subcellular localization of 
Galectin-7 and indicate that this may vary between different cancers or cell 
lines.  Lu et al., found Galectin-7 is overexpressed in chemically induced 
mammary carcinoma in rat models. Galectin-7 was restricted to the mammary 
carcinoma and not found in any normal tissue pointing to a role for Galectin-7 
in tumour progression (Lu, Pei, Kaeck, & Thompson, 1997). These studies 
indicate that the cellular context in which Galectin-7 is expressed may 
determine its function: thus, in myoepithelial cells Galectin-7 appears to favour 
tumour-suppression whilst in invasive cancer cells it associates with more 
aggressive behaviour. 
 
 64 
1.12.3 Role of Galectin-7 in other cancers 
1.12.3.1 Prostate Carcinoma 
Prostate and breast carcinoma have many biological similarities. St-Pierre’s 
group investigated the role of Galectin-7 in prostate carcinoma and found 
Galectin-7 was expressed in the basal cells of normal prostate tissue – the 
equivalent of breast myoepithelial cells -  and this was down regulated in 
prostate cancer (Labrie et al., 2015). The prostate cancer cell line DU-145 was 
transfected with Galectin-7 and demonstrated increased sensitivity to 
apoptosis following treatment with the pro-apoptotic drug cisplatin, using 
cleavage of PARP as a marker (Labrie et al., 2015). DU-145 cells transfected 
with wild -type or mutant Galectin-7 injected into adult male NOD/SCID mice 
showed a modest but significant reduction in tumour size with overexpression 
of Galectin-7wt. The mutant Galectin-7 transfectant resulted in a significant 
increase in tumour size compared with control and Galectin-7wt. The mutant 
form of Galectin-7 exhibited a change in the carbohydrate recognition domain 
(Labrie et al., 2015). This study illustrates the complex diverse role of Galectin-
7, acting as a tumour suppressor in-vitro and as a pro-tumorigenic protein in-
vivo. This suggests the role of galectins in cancer likely involves a delicate 
balance of pro and anti-tumoural interactions occurring within intra and 
extracellular compartments with the microenvironment playing an important 
role (Labrie et al., 2015).  
 
1.12.3.2 Gastric Carcinoma 
A study on tissue microarrays of gastric cancers showed low expression levels 
of Galectin-7 in malignant tissue compared with matched normal tissue (S. J. 
Kim, Hwang, Ro, Lee, & Chun, 2013).  Advanced TNM stage was associated 
with decreased expression of Galectin-7. In gastric carcinoma Galectin-7 is 
thought to act as a tumour suppressor, with expression of Galectin-7 
suppressing the proliferation, migration, and invasion of gastric cancer cells 
(S. J. Kim et al., 2013).  
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1.12.3.3  Colorectal Carcinoma 
The human colorectal cancer cell line DLD-1 was used in a study to assess 
the impact of Galectin-7. The ectopic expression of Galectin-7 in DLD-1 
rendered the cells more sensitive to apoptosis (Ueda, Kuwabara, & Liu, 2004). 
Reduced angiogenesis may also contribute to the tumour-suppressive effect 
of Galectin-7, histological analysis showed reduction in CD31 expression in 
Galectin-7 DLD-1 cells compared to control cells (Ueda et al., 2004). 
 
1.12.3.4 Oesophageal Carcinoma 
Proteomics analysis revealed that Galectin-7 was highly expressed in 
oesophageal squamous cell carcinoma tissues when compared to normal 
oesophageal tissue. The alteration in the expression of Galectin-7 was 
confirmed on a tissue microarray. These findings suggest that Galectin-7 could 
be used as a potential biomarker for oesophageal cell carcinoma (X. Zhu et 
al., 2010). As previously discussed the subcellular localisation may be of 
importance in the role Galectin-7 plays in cancer progression. In normal tissue 
Galectin-7 was localised in the nuclei, whereas it was distributed throughout 
the cytoplasm, nuclei and membranes of oesophageal squamous cell 
carcinoma cells. These results suggest that tumour progression of 
oesophageal cell carcinoma may be associated with a translocation of 
Galectin-7 from the nucleus to the cytoplasm(X. Zhu et al., 2010).  Zhu and 
colleagues also showed well differentiated oesophageal tumours had a 
stronger expression of Galectin-7 compared to poorly differentiated tumours 
and suggested up-regulation of Galectin-7 may be a mechanism of organ self-
protection, and this early up-regulation could be a potential marker for 
detection of early treatable oesophageal carcinoma (X. Zhu et al., 2010). 
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1.12.3.5  Ovarian Carcinoma 
In ovarian carcinoma a number of studies have demonstrated that increased 
levels of Galectin-7 is an indication of poor prognosis. Elevated Galectin-7 
expression was found to be positively correlated with histological grade of 
tumour, advanced age, high mortality rate and poor survival outcome (H. J. 
Kim et al., 2013; Labrie, Vladoiu, Grosset, Gaboury, & St-Pierre, 2014) 
Immunohistochemical analysis of Galectin-7 expression in tissue microarrays 
showed that while Galectin-7 was not detected in normal ovarian tissues, 
positive cytoplasmic staining for Galectin-7 was detected in tumour cells of all 
epithelial ovarian carcinoma histological subtypes, but was more frequent in 
high grade tumours and metastatic samples (Labrie et al., 2014). 
 
1.12.3.6  Cervical carcinoma 
In cervical squamous cell carcinoma Galectin-7 appears to have a protective 
effect. Expression of Galectin-7 in cervical carcinoma tissues was shown to be 
negatively associated with lymph nodes metastasis and expression of 
Galectin-7 was negatively correlated with MMP-9 expression in the clinical 
samples (H. Zhu et al., 2013).  Lack of Galectin-7 in cervical carcinoma 
samples identified a cohort of patients with a lower 5 year overall survival rate 
as compared to those tumours with positive staining, as indicated by Kaplan -
Meier survival analysis (H. Zhu et al., 2013). Elevated Galectin-7 expression 
had been associated with improved outcomes after radiation therapy (Tsai et 
al., 2013).  
 
1.12.3.7 Lymphoma 
Galectin-7 has a similar role in conferring resistance to apoptosis in both 
lymphoma and breast carcinoma (Demers et al., 2010). Demers and 
colleagues used a Galectin-7 vector to transfect low metastatic lymphoma 
cells this increased their metastatic behaviour through inducing MMP-9 in a 
mouse model (Demers, Magnaldo, & St-Pierre, 2005). In a further study 
Demers has shown using a mouse model inhibition of Galectin-7 in aggressive 
lymphoma cells correlated with a decreased invasion of tumour cells in target 
organs(Demers et al., 2007). Abnormal expression of Galectin-7 is thought to 
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favour dissemination of lymphoma cells. Galectin-7 was found in a significant 
proportion of mature human B cell lymphoid neoplasms, but not in normal B 
lymphocytes (Demers et al., 2007). 
 
1.12.3.8 Melanoma 
An analysis of whole transcriptome profiling of human melanoma tissues 
revealed that Galectin-7 mRNA was detected in in more than 90% of biopsies 
of patients with nevi, while its expression was rarely found in biopsies collected 
from patients with malignant melanoma (Biron-Pain, Grosset, Poirier, 
Gaboury, & St-Pierre, 2013). 
 
The expression patterns and relationship to behaviour in various tumour types 
is summarised in Table 1-7. 
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Type Galectin-7 +ve/ high Galectin-7 –
ve/low 
Role/ relevance Ref 
Skin Galectin-7 is positive 
throughout all layers of 
the skin with the 
strongest being in the 
basal layer.  
Expression 
rarely found in 
malignant 
melanoma 
A study showed 
overexpression of Galectin-7 
is insufficient to modulate the 
growth of primary tumors or 
the dissemination of B16 
melanoma cells to the lung. 
(Biron-
Pain et 
al., 2013) 
Breast Normal Myoepithelial 
Cells 
 
Expressed in Basal 
phenotype of Breast 
Cancer 
Normal 
Luminal Cells 
High levels of Galectin-7 in 
breast cancer cells render 
them more resistant to 
apoptosis and thus this 
aggressive subtype 
metastasise earlier. 
(Demers 
et al., 
2010) 
Cervical Squamous epithelial 
cells 
Negative 
staining in 
cervical 
carcinoma 
showed 
significantly 
lower 5 year 
Elevated Galectin-7 
expression is associated with 
improved outcomes after 
radiation therapy 
(H. Zhu 
et al., 
2013) 
(Tsai et 
al., 2013) 
Ovarian Galectin-7 was 
detected in epithelial 
cells in all epithelial 
ovarian carcinoma 
histological subtypes 
but was more frequent 
in high grade tumours 
and metastatic 
samples 
Normal 
Ovarian Tissue 
 
 
A number of studies 
demonstrate that increased 
levels of Galectin-7 are an 
indicator of poor prognosis. 
 
 
 
(H. J. 
Kim et 
al., 2013; 
Labrie et 
al., 2014) 
Oesophagus Galectin-7 was highly 
expressed in 
Oesophageal 
Squamous Cell 
Carcinoma 
Normal 
Oesophageal 
tissue 
Associated with well-
differentiated tumours 
(X. Zhu 
et al., 
2010) 
Gastric Normal Gastric tissue Associated 
with advanced 
Gastric 
Carcinoma 
In gastric carcinoma 
Galectin-7 acts as a tumour 
suppressor, with expression 
of Galectin-7 supressing the 
proliferation, migrations and 
invasion gastric cancer cells. 
(S. J. 
Kim et 
al., 2013) 
Prostate Galectin-7 was present 
in basal cells of normal 
prostate tissue 
 
 
Down 
regulated in 
prostate 
cancer 
This study illustrates a 
complex relationship 
between Galectin-7 and 
apoptosis, with Galectin-7 
acting as a tumour 
suppressor in-vitro and as a 
pro tumorigenic protein in-
vivo. This study suggests 
mutation in the CRD drives a 
phenotypic switch in the 
prostate carcinoma cells. 
(Labrie et 
al., 2015) 
Lymphoma Galectin-7 is present in 
normal B and T 
lymphocytes 
Abnormal 
expression of 
Galectin-7 is 
thought to 
favour 
dissemination 
of lymphoma 
cells 
Galectin-7 increases the 
metastatic behaviour of 
lymphoma cells and induces 
expression of MMP-9 
(Demers 
et al., 
2005) 
(Demers 
et al., 
2007) 
Table 1-7 Summary of Galectin-7 expression in cancer 
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1.13 Aims and hypothesis 
 
The hypothesis of this study is that loss of expression of Galectin-7 by 
myoepithelial cells in DCIS alters myoepithelial cell function and contributes to 
a transition in myoepithelial cell function from tumour suppressor to tumour 
promotor. Specifically, the hypothesis is that loss of Galectin-7 combined with 
gain of avb6 indicates a more advanced stage of DCIS. Furthermore, since 
galectins have a role in modulating adhesion and apoptosis, the hypothesis is 
that a loss of Galectin-7 may alter myoepithelial cell adhesion to the basement 
membrane and promote apoptosis, so leading to loss of integrity of the 
myoepithelial -basement membrane barrier. 
 
To investigate this further the aims are 
1. Establish the expression of Galecin-7 and avb6 in tissue samples of 
pure DCIS and DCIS with associated invasion using 
immunohistochemistry. 
 
2. Investigate the functional relevance of changes in the levels of 
myoepithelial cell Galectin-7 focusing on its role in apoptosis and 
adhesion. 
 
3. Undertake RNA sequencing to investigate the global effect of altered 
myoepithelial Galectin -7. 
 
Together, this work will further dissect the role of DCIS-altered myoepithelial 
cells in DCIS behaviour, and specifically elucidate the impact and potential 
clinical utility of Galectin-7. 
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Figure 1-14  Hypothetical progression of DCIS 
This schematic illustrates a normal breast duct with luminal cells organised and 
polarised with myoepithelial cells strongly positive for Galectin-7 and negative for 
avb6. There is then transition to DCIS with neoplastic proliferation of epithelial cells 
within the ductal-lobular structures of the breast that does not penetrate the 
myoepithelial basement membrane interface. The myoepithelial cells have an 
altered phenotype with loss of Galectin-7 and up-regulation of avb6.  In the DCIS 
ducts that progress to invasive disease there is loss of the myoepithelial basement 
membrane interface, possibly through TRAIL-induced apoptosis. 
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2 Myoepithelial cell expression of Galectin-7 has an 
inverse correlation with poor prognostic marker 
avb6  
 
2.1 Material and methods- Immunohistochemistry 
 
2.1.1 Sample selection 
Formalin Fixed Paraffin Embedded (FFPE) sections from a cohort of 45 
patients collected between 2000 and 2015 at Barts Health NHS Trust were 
used for immunohistochemical characterization. All patients had consented to 
the Barts Cancer Institute tissue bank for their tissue to be used in research 
(Ethical Approval Reference 10/H0308/49, Cambridgeshire Ethics Committee 
October 2010).  The cohort included 23 patients with pure DCIS (without any 
associated invasion) and 22 patients with DCIS with associated invasion, 
representing low-risk and high-risk models respectively (see introduction). 
	
Sections at 4µM were cut onto charged glass slides and heated for 18 hours 
at room temperature.  All antibodies used throughout were optimised with 
positive and negative controls prior to using on the DCIS tissue sections. Initial 
optimisation studies included varying the incubation time with the primary 
antibody, variable concentration of primary antibody and different 
concentrations of BSA for blocking non-specific staining in order to achieve 
optimal staining and minimal background. Optimal conditions are described in 
Table 2-1. 
	
Sections were heated at 60°C for 10 minutes, and incubated serially in xylene 
(Fisher Scientific, X5-1) for 2 x 5 minutes then in decreasing alcohol dilutions 
and dH2O after which endogenous peroxidase was blocked with a 10-minute 
incubation in 100% methanol/0.9% hydrogen peroxide. Antigen retrieval was 
performed using boiling citrate buffer at pH 6.0 for 8 minutes. Sections were 
blocked with appropriate serum (depending on the secondary antibody used) 
and BSA/PBS, as outlined in Table 2-1, for 15 minutes, then primary and 
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secondary antibodies were applied as outlined in Table 2-1. The incubation for 
all primary antibodies was 4oC overnight as this gave optimal results following 
the optimisation. 
Following incubation, sections were then washed with PBS in triplicate 
followed by incubation with the secondary antibody at room temperature for 
40 minutes. The sections were then washed again in triplicate followed by 
incubation with an avidin-biotin peroxidase complex (ABC) reagent 
(Vectastatin ABC Kit, Vecor Laboratories PK Rabbit 6101, Mouse 6102) for 30 
minutes at room temperature. Sections were washed again in triplicate with 
PBS before developing using a DAB kit (Vectastain, Vector Laboratories SK 
4100) and then counterstained with Haematoxylin for 2 minutes (Sigma, 
MHS16). The sections were washed with tap water and dehydrated through 
graded alcohols and xylene, and mounted with DPX (Sigma, 06522) and glass 
cover slips. 
 
 
Antibody Source/clone Species Dilution Antigen 
retrieval 
Positive 
control 
Galectin-7 Abcam/ 
Ab108623 
Rabbit 1:750 in 
5% BSA 
Citrate Skin 
Normal 
breast 
tissue 
b6 
 
Calbiochem 
/ 407317 
 
Mouse 1:800 in 
5% milk 
Pepsin b6 
Positive 
DCIS 
Oestrogen Abcam /  
Ab16660 
Rabbit 1:500 in 
1% BSA 
Citrate ER 
positive 
breast 
cancer 
Her 2 Abcam/   
Ab134182 
Rabbit 1:20 in 
1% BSA 
Citrate Her 2 
positive 
DCIS 
Progesterone Novocastra/  
NCL-PGR-312 
Mouse 1:100 in 
1% BSA 
Citrate Normal 
breast  
LOX Novus Bio/  
NB 1002327 
Rabbit 1:500 in 
1% BSA 
Citrate Colorectal 
cancer 
P-Cadherin BD 
Biosciences/ 
616228 
Mouse 1:25 in 
1% BSA 
Citrate Tonsil 
Table 2-1 Details of primary antibodies used in immunohistochemistry. 
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2.1.2 Scoring of Galectin-7 and avb6 staining 
 
Sequential sections were used for Galectin-7 and avb6 staining. All slides 
were scanned on the Panoramic 250 slide scanner (3D HISTECH). The 
computer program ‘panoramic viewer’ was used for analysis. Each DCIS duct 
was annotated as shown in Figure 2-1 and a score of either positive, 
heterogeneous or negative was assigned to each DCIS duct. DCIS ducts with 
myoepithelial cells homogenously positive for either Galectin-7 or avb6 were 
positive, as detailed in Figure 2-2. DCIS ducts with some positive myoepithelial 
cells were designated heterogeneous, whilst DCIS ducts where the 
myoepithelial cells were homogenously negative were defined as negative. 
 
 
 
 
  
Figure 2-1 Annotation of ducts using panoramic viewer program. 
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Individual ducts were assessed and scored. The staining of the myoepithelial cells 
was scored as negative (no staining), heterogeneous (some myoepithelial cells were 
stained) or positive where all myoepithelial cells in the duct were positive. Galectin-7 
and avb6 both were scored using this method. Galectin-7 staining is shown in this 
figure. 
 
Figure 2-2 Schematic of DCIS duct scoring.  
Negative 
Heterogeneous 
Positive 
Galectin-7 
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2.2  Results- Immunohistochemistry 
 
2.2.1 Patient Cohort 
 
The cohort of 45 patients included 23 cases of pure DCIS and 22 cases of 
DCIS with associated invasion, representing low-risk and high-risk models, 
respectively. Serial sections were used for staining for Galectin-7 and avb6. 
There is some disparity between the markers in the number of ducts scored 
as DCIS ducts were not always present in all sections. There was no 
significant difference in the age of the patients or in the type of surgical 
intervention between the two groups (p-0.854, Table 2.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Galectin-7 
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Pure DCIS DCIS with 
associated 
invasion 
P value 
Age (mean) 
 
55.0 55.6 0.587 
Size (mm)  31.3 (5-90) 22 (6-43)  
DCIS 
Grade 
(Number of 
patients) 
High 15 20  
Intermediate 6 0  
Low 2   
Unknown  2  
 
 
 
 
 
 
Type of 
DCIS 
Comedo 
Necrosis 
7 14  
Solid 6 3  
Cribriform 1 0  
Mixed 2 2  
Apocrine 1 0  
Micropapillary 4 0  
No special 
type 
0 1  
Unknown 2 2  
Surgery (%) Mastectomy 64.0 66.7 0.854 
Wide Local 
excision 
36.0 33.3 
Axillary 
Surgery (%) 
None 48.0 9.5 
 
0.0002 
SNS 44.0 38.1 
ANS 4.0 33.3 
ANC 4.0 19.0 
Table 2-2 Patient Cohort- summary of age distribution and operative management 
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2.2.2 Galectin-7 and avb6 Immunohistochemistry 
 
Each DCIS duct was initially scored for Galectin-7 and avb6 independently, 
being blinded to the status of the other marker. On completion of scoring, the 
ducts were identified and the score for each marker combined. 
 
2.2.3 Galectin-7 Immunohistochemistry 
A total of 1926 DCIS ducts were scored for Galectin-7 and significant 
differences were seen between pure DCIS cases and DCIS with associated 
invasion. Pure DCIS and DCIS with associated invasion had 338 and 144 
homogenously positive DCIS ducts, respectively (p=0.0014). Pure DCIS and 
DCIS with associated invasion had 286 and 413 heterogeneous DCIS ducts 
respectively (p=0.89), with 99 pure DCIS and 646 DCIS with associated 
invasion being homogenously negative for Galectin-7 (p=0.0002).  Thus, there 
are significantly more Galectin-7 negative DCIS ducts in the DCIS with 
associated invasion cohort and significantly more Galectin-7 positive ducts in 
the pure DCIS group as shown in Figure 2-3. 
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Comparison between pure DCIS and DCIS with associated invasion patient cohorts 
for Galectin-7 showing the number of DCIS ducts homogenously positive, 
heterogeneously positive and homogenously negative. 
Figure 2-3 Myoepithelial expression of Galectin-7 in DCIS 
*** ns *** 
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2.2.4 avb6 Immunohistochemistry 
 
A total of 1888 DCIS ducts were stained for avb6. Pure DCIS and DCIS with 
invasion had 102 and 207 homogeneously positive DCIS ducts, respectively 
(p=0.165). Pure DCIS and DCIS with invasion had 319 and 267 
heterogeneously positive ducts, respectively (p=0.716), whilst pure DCIS had 
770 negative ducts and DCIS with associated invasion had 223 negative ducts 
(p=0.02). This indicates that significantly more DCIS ducts are negative for 
avb6 in DCIS with associated invasion compared to the pure DCIS cohort, as 
shown in Figure 2-4. 
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Figure 2-4 Myoepithelial expression of b6 in DCIS 
Comparison between pure DCIS and DCIS with associated invasion cohorts for  b6 
showing the number of DCIS ducts homogenously positive, heterogeneously positive 
and homogenously negative. 
ns ns 
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2.2.5 Combined Galectin-7 and  avβ6 score 
 
Following the independent scoring of Galectin-7 and avb6, the ducts were 
identified, and the scores combined. For this analysis, only DCIS ducts that 
were present in both the Galectin-7 and the avb6 sections were included. Each 
DCIS duct was given a Galectin-7/avb6 score. This analysis provides more 
information for each DCIS duct than assessing the markers in isolation. The 
potential score combinations are: 
 
1. Galectin-7 positive/avb6 negative  
2. Galectin-7 positive/ avb6 heterogeneous 
3. Galectin-7 heterogeneous/avb6 negative  
4. Galectin-7 negative /avb6 positive 
5. Galectin-7 heterogeneous /avb6 positive  
6. Galectin-7 negative /avb6 heterogeneous 
 
Of these, scores, combinations 1-3 were identified in significantly higher 
number of DCIS ducts in the pure DCIS cohort compared to the DCIS with 
associated invasion cohort. Conversely, the score combinations 4-6 were 
identified in a significantly higher number of DCIS ducts in the DCIS with 
associated invasion cohort (Tables 2-3 & 2-4 and Figure 2-5).  
Pure DCIS  β6 Positive β6 
Heterogeneous 
β6 Negative Total 
 Number of DCIS ducts (% of total DCIS ducts) 
Galectin-7 Positive 38 (5.38) 79 (11.19) 224 (31.73) 341 (48.30) 
Galectin-7 
Heterogeneous 
10 (1.42) 58 (8.22) 205 (29.04) 273 (38.67) 
Galectin-7 
Negative 
5 (0.71) 18 (2.55) 69 (9.77) 92 (13.03) 
Total 53 (7.51) 155 (21.95) 498 (70.54) 706 (100.00) 
 
 
Table 2-3 Pure DCIS cohort combined Galectin-7/ avβ6 score 
The number (percentage) of DCIS ducts assigned to each Galectin-7/ avβ6 score 
category.	
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DCIS with 
associated 
invasion 
β6 Positive β6 
Heterogeneous 
β6 Negative Total 
 Number of DCIS ducts (% of total DCIS ducts) 
Galectin-7 Positive 52 (9.59) 16 (2.95) 48 (8.85) 116 (21.40) 
Galectin-7 
Heterogeneous 
54 (9.94) 59 (10.88) 88 (16.20) 201 (37.08) 
Galectin-7 
Negative 
57 (10.51) 68 (12.55) 100 (18.41) 225 (41.51) 
Total 163 (30.07) 143 (26.38) 236 (43.54) 542 (100.00) 
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Table 2-4 DCIS with associated invasion cohort combined Galectin-7/ avβ6 score 
The number (percentage) of DCIS ducts assigned to each Galectin-7/ avβ6 score 
category. 
A comparison between pure DCIS and DCIS with associated invasion cohorts 
assessing Galectin-7/avb6 combination scores. Error bars represent standard 
deviation. 
Figure 2-5 Analysis of Galectin-7/avb6 combination scores 
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Only homogeneously positive or homogenously negative Galectin-7 and  avb6 
ducts were included in a further analysis. This shows higher numbers of 
Galectin-7 positive, avb6 negative DCIS ducts in the pure DCIS cohort 
compared to the DCIS with associated invasion cohort and higher numbers of 
Galectin-7 negative, avb6 positive DCIS ducts in the DCIS with associated 
invasion cohort compared to the pure DCIS cohort (Figure 2-6). 
 
  
 
Figure 2-6 Analysis of Galectin-7/avb6 combination scores (homogenously positive 
and negative scores only) 
A comparison between pure DCIS and DCIS with associated invasion cohorts 
assessing Galectin-7 / avb6 combination scores assessing homogenously positive 
and negative scores only. Error bars represent standard deviation. 
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2.2.6 Chi-squared analysis 
 
Chi-squared is used to assess the relationship between the 2 markers 
Galectin-7 and  avb6 in the pure DCIS and DCIS with associated invasion 
cohort. We have shown both these markers to change in our high risk DCIS 
model. There is the possibility that these markers are independent of each or 
that change in one protein may influence a change in the other protein.  
A chi-squared calculation has been performed for the pure DCIS and DCIS 
with associated invasion cohorts. The analysis indicates a significant inverse 
relationship between Galectin-7 and avb6 in both the pure DCIS and DCIS 
with associated invasion cohorts (p=<0.001 for both cohorts; Tables 2-5 & 2-
6). In pure DCIS there is more frequent Galectin-7 positivity and negativity for 
avb6, whilst in DCIS with associated invasion, the reverse is seen. 
	
	
	
Pure DCIS 
b6 
Positive 
b6 
Heterogeneous 
b6 
Negative 
Galectin 7 Positive 38 (25.6) [6.01] 79 (74.87) [0.23] 224(240.54) [1.14] 
Galectin7 
Heterogeneous 
10 (20.49) [5.37] 58 (59.94) [0.06] 205(192.57) [ 0.8] 
Galectin-7 
Negative 
5(6.91) [0.53] 68 (59.36) [1.26] 69(64.90 [0.26] 
 
Chi square  14.63 
p value  0.005518 
 
 
 
 
 
 
Table 2-5 Chi squared calculations for the pure DCIS cohort 
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DCIS with 
associated 
invasion 
b6 
Positive 
b6 
Heterogeneous 
b6 
Negative 
Galectin 7 Positive 52 (34.89) [8.40] 16 (30.61) [6.97] 48 (50.51) [0.12] 
Galectin7 
Heterogeneous 
54 (60.45) [0.69] 59 (53.03) [0.67] 88 (87.52) [0.0] 
Galectin-7 
Negative 
57 (67.67) [1.68] 68 (59.36) [1.26] 100 (97.97) [0.04] 
 
Chi square  19.8326 
p value 0.000539 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2-6 Chi squared calculations for the DCIS with associated invasion 
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2.3 Galectin-7 analysis to assess variation between patients 
As an alternative method of analysis, each patient has been assessed 
individually, as grouping the ducts from the pure DCIS cohort and DCIS with 
associated invasion together may mean certain patients with higher numbers 
of ducts would skew the data. 
 
The cases have been analysed looking at the number of positive, 
heterogenous or negative ducts per case, percentage of positive, 
heterogenous or negative ducts per case and also a score has been assigned  
to each patient and the method for this is discussed later in the chapter. 
 
In the pure DCIS cohort the average number of ducts scored per patient was 
41 whilst the average number of ducts scored in the DCIS with associated 
invasion group was 52.  A T Test was performed, and this difference was 
shown to not be statistically significant with a p value of 0.19. 
Analysis of each patient individually in the pure DCIS cohort to assess the 
number Galectin-7 positive, heterogeneous and negative ducts. 
 
 
 
Figure 2-7 Pure DCIS cohort analysis of duct number per patients 
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Analysis of each patient individually in the pure DCIS cohort to assess the 
percentage of Galectin-7 positive, heterogeneous and negative ducts. 
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Figure 2-8 Pure DCIS cohort analysis using % of DCIS ducts 
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Analysis of each patient individually in the DCIS with associated invasion 
cohort to assess the number of Galectin-7 positive, heterogeneous and 
negative ducts. 
 
 
 
 
 
 
 
Figure 2-9 DCIS with associated invasion cohort analysis using number of DCIS ducts 
scored for Galectin-7  
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Analysis of each patient individually in the DCIS with associated invasion 
cohort to assess the percentage of Galectin-7 positive, heterogeneous and 
negative ducts. 
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2.4 Galectin-7 score per patient 
 
In order to make comparison between patients and between pure DCIS and 
DCIS with associated invasion cohort each patient was allocated a score. 
The score was calculated using a weighting for positive, heterogenous and 
negative, this was then multiplied by the percentage of ducts that were in 
each category. The weightings allocated were negative - 0, heterogenous-1 
and positive-2. 
The distribution of scores for each cohort is shown in Figures 2.11 and 2.12. 
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A mean score for each cohort was calculated and a comparison was made 
between pure DCIS and DCIS with associated invasion cohorts. The mean 
score in the pure DCIS group is 1.25 and in the DCIS with associated invasion 
group is 0.74,   A Student T Test shows difference is statistically significant 
(<0.001). 
 
 
 
The mean score in the pure DCIS group is 1.25 and in the DCIS with 
associated invasion group is 0.74.  Student T Test indicates this difference is 
statistically significant (<0.001; error bars are standard deviation) 
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2.5 avb6 Scores per patient 
A mean score for each cohort was calculated and a comparison was made 
between pure DCIS and DCIS with associated invasion cohorts. The mean 
score in the pure DCIS group is 0.27 and in the DCIS with associated invasion 
group is 0.82. Student T Test indicates this difference is statistically significant 
(<0.005). 
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Figure 2-15 DCIS with associated invasion avb6 score per patient 
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The mean score in the pure DCIS group is 0.27 and in the DCIS with 
associated invasion group is 0.82. Student T Test indicates this difference is 
statistically significant (<0.005). 
 
 
2.6 A comparison between Galectin-7 and avb6 scores 
 
A score for each patient was assigned as described above, a comparison 
between the Galectin-7 score and avb6 was made. The initial hypothesis 
being that Galectin-7 positivity is a good prognostic sign in DCIS and with this 
model a high score would be a good prognostic sign therefore higher scores 
would be expected in the pure DCIS cohort. The analysis supports this 
hypothesis with a mean score in the pure DCIS group of 1.25 and in the DCIS 
with associated invasion group of 0.74, which  was statistically significant. In 
support of the hypothesis that  avb6 positivity is a poor prognostic sign it would 
be expected that the DCIS with associated invasion would have a higher 
score. Again, the analysis supports this with the mean score in the pure DCIS 
group of 0.27 and in the DCIS with associated invasion group of 0.82 which 
was statistically significant. Then for further analysis, each patient’s scores for 
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Figure 2-16 Comparison of the average avb6 score between pure DCIS and DCIS 
with associated invasion cohorts.  
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Galectin-7 and avb6 were plotted together. In devising a risk score for DCIS 
this would involve a number of markers and different markers would be likely 
to have more weighting.  
 
 
 
 
 
2.7 Comparison of Galectin-7 vs avb6 score per patient for pure 
DCIS 
A comparison  of the scores for Galectin-7 and avb6 was made for each 
patient in the pure DCIS cohort. In all 23 patients the Galectin-7 score was 
higher than the avb6 score.  
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Figure 2-17 A comparison between Galectin-7 and avb6 score per patient for the pure 
DCIS cohort  
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2.8 Comparison of Galectin-7 vs avb6 score per patient for DCIS 
with associated invasion 
A comparison  of the scores for Galectin-7 and avb6 was made for each 
patient in the DCIS with associated invasion cohort. The avb6 score was 
higher than Galectin-7 in 10 out of 22 patients, the score was the same in 1 
patient and the Galectin-7 score was higher than the avb6 score in 11 out of 
22 patients. 
 
 
 
 
A wilcoxian paired test was performed to assess the score differences 
between Galectin-7 and avb6 in individual patients. A wilcoxian test was used 
as the data is paired but non-parametric. In the pure DCIS cohort the null 
hypothesis can be rejected as the test statistic is lower than the critical value, 
the critical value was 73 and test statistic 0, indicating statistical significance. 
In the DCIS with associated invasion the critical value was 65 and the test 
statistic was 129 therefore the null hypothesis cannot be rejected. These were 
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Figure 2-18 A comparison between Galectin-7 and avb6 score per patient for the 
DCIS with associated invasion cohort 
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both for 95% confidence intervals. This is likely to indicate a significant inverse 
relationship between Galectin-7 and avb6  in pure DCIS, though this is not 
confirmed in the DCIS with associated invasion. To further test this hypothesis 
an increased number of patients or different validation set is required however 
time did not permit this. 
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Sequential DCIS ducts Galectin-7 homogenously positive x5 magnification (A), b6 
homogenously negative x5 magnification (B) Galectin-7 homogenously positive x40 
magnification(C), avb6 homogenously negative x40 magnification (D). 
Figure 2-19 Immunohistochemistry images Galectin-7 homogenously positive/av b6 
homogenously negative 
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 Figure 2-20 Immunohistochemistry images Galectin-7 homogenously negative/avb6 
homogenously negative 
 
Sequential DCIS ducts Galectin-7 homogenously negative x5 magnification (A), av 
b6 homogenously negative x5 magnification (B) Galectin-7 homogenously negative 
x40 magnification(C), avb6 homogenously negative x40 magnification (D). 
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Sequential DCIS ducts Galectin-7 heterogeneous x5 magnification (A), avb6 
heterogeneous x5 magnification (B) Galectin-7 heterogeneous x40 
magnification(C), b6 heterogeneous x40 magnification (D). 
 
 
  
 
Figure 2-21 Immunohistochemistry images Galectin-7 heterogeneous /avb6 
heterogeneous 
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C                                                                   D 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2-22 Immunohistochemistry images Galectin-7 homogenously negative/av b6 
homogenously positive 
Sequential DCIS ducts Galectin-7 homogenously negative x5 magnification (A), avb6 
homogenously positive x5 magnification (B) Galectin-7 homogenously negative x40 
magnification(C), avb6 homogenously positive x40 magnification (D). 
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2.8.1 Oestrogen Immunohistochemistry 
 
Immunohistochemistry for oestrogen receptor (ER), Progesterone receptor 
(PR) and HER-2 are used routinely in breast diagnostics for invasive 
carcinoma, though not routinely for DCIS. 
For this study, receptor status in DCIS was evaluated. A comparison has been 
made between the pure DCIS and DCIS with associated invasion cohort on a 
duct-by-duct basis.  
For ER the largest difference between the pure DCIS and DCIS with 
associated invasion group is a greater number of negative ducts in the pure 
DCIS group compared to the DCIS with associated invasion group as shown 
in figure 2.11 C, when assessing the percentage of DCIS ducts the difference 
between the 2 cohorts is not present. Figure 2.11 A is a representative image 
of ER positive DCIS ducts and figure 2.11 B is a representative image of an 
ER negative duct. 
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Figure 2-23 ER immunohistochemistry analysis  
ER strongly positive DCIS duct (A), ER negative DCIS duct (B), The number of ER 
DCIS ducts (C) or percentage of ER DCIS ducts(D) in pure DCIS or DCIS with 
associated invasion cohort across the scoring categories of Positive 3 Positive 2, 
positive 1, heterogenous 3, heterogenous 2, heterogenous 1, negative. Error bars 
represent standard deviation. 
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2.8.2 Progesterone immunohistochemistry 
 
There are a greater number (figure 2.12 C) and percentage (figure 2.12 D) of 
strongly PR positive DCIS ducts in the DCIS with associated invasion cohort 
compared to pure DCIS, which contains a greater number and percentage of 
PR negative DCIS ducts. Figure 2.12 A is a representative image of a PR 
positive DCIS duct and figure 2.12 B is a representative image of PR negative 
DCIS duct. 
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Figure 2-24 PR immunohistochemistry analysis 
PR strongly positive DCIS duct (A), PR negative DCIS duct (B), The number of PR 
DCIS ducts (C) or percentage of PR DCIS ducts (D) in pure DCIS or DCIS with 
associated invasion cohort across the scoring categories of Positive 3 Positive 2, 
positive 1, heterogenous 3, heterogenous 2, heterogenous 1, negative. Error bars 
represent standard deviation.  
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2.8.3 HER-2 immunohistochemistry 
 
There are a greater number (figure 2.13 C) and percentage (figure 2.13 D) of 
strongly HER-2 positive DCIS ducts in the pure DCIS compared to DCIS with 
associated invasion cohort, which contains a greater number and percentage 
of HER-2 negative DCIS ducts. Figure 2.13 A shows representative images of 
a HER-2 positive DCIS duct and figure 2.13 B shows a representative image 
of HER-2 negative DCIS duct. 
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Figure 2-25 HER -2-immunohistochemistry analysis 
 
HER-2 strongly positive DCIS duct (A), HER-2 negative DCIS duct (B), The number 
of HER-2 DCIS ducts(C) or percentage of HER-2 DCIS ducts(D) in pure DCIS or 
DCIS with associated invasion cohort across the scoring categories of Positive 3 
Positive 2, positive 1, heterogenous 3, heterogenous 2, heterogenous 1, negative. 
Error bars represent standard deviation. 
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2.8.4 Molecular subtype of DCIS ducts 
 
The individual markers were collated to define DCIS subtypes comparable to 
those assigned to invasive breast cancers (Table 2-7 DCIS cohort subtype). 
Only positive and negative ducts (not heterogeneous) were used in this 
analysis and only those which could be given a score for all 3 markers were 
included. Luminal A was defined as ER +ve, PR +ve and Her2 –ve, luminal B 
was defined as either ER +ve, PR-ve and Her2 –ve or ER+ ve, PR +ve and 
Her2 +ve or ER +ve, PR-ve and Her2 +ve , Triple negative was defined as ER 
-ve, PR-ve and Her2 -ve or ER-ve, PR +ve and Her2 -ve and the HER-2 
subtype is ER -ve, PR -ve and Her2 +ve or ER -ve, PR +ve and Her2 +ve. The 
number of DCIS ducts in luminal A category was 36 and 128 for pure DCIS 
and DCIS with associated invasion respectively, in luminal B was 204 and 86 
for pure DCIS and DCIS with associated invasion respectively, and for triple 
negative was 93 for pure DCIS and 108 for DCIS with invasion.  Her-2 +ve 
ducts which are ER -ve were seen in 231 pure DCIS ducts and 181 DCIS ducts 
with associated invasion. These results demonstrate, somewhat 
paradoxically, that the more aggressive molecular phenotype of HER-2 
positive DCIS is less associated with invasion, as is the luminal B subtype with 
luminal A being most associated with invasion.  
Subtype Marker Number of DCIS ducts 
 ER PR HER-2 Pure Invasive 
Luminal A + + - 36 36 128 128 
Luminal B + - - 54  
204 
21 86 
+ + + 28 49 
+ - + 122 16 
Triple Negative - - - 93 93 68 108 
- + - 0 40 
Her-2 - - + 129 231 148 181 
- + + 102 33 
Table 2-7 DCIS cohort subtype:  
The total number of DCIS ducts in each subtype a comparison between pure DCIS 
and DCIS with associated invasion. 
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Figure 2-26 The Number of DCIS ducts categorised into DCIS subtypes 
This shows a comparison between the pure DCIS and DCIS with associated invasion 
cohort with a higher number of luminal A ducts in the invasive cohort and a higher 
number of luminal B ducts in the pure cohort. 
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Figure 2-27 The Percentage of DCIS ducts categorised into DCIS subtypes. 
This shows a comparison between the pure DCIS and DCIS with associated invasion 
cohort. With a higher percentage of luminal A ducts in the invasive cohort and a higher 
percentage of luminal B ducts in the pure cohort. 
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2.9 Discussion 
 
It is estimated that only half of DCIS cases will progress to invasion within a 
patient’s lifetime, and therefore concerns surround the overdiagnosis and 
overtreatment of DCIS (Sanders et al., 2005), and is a key criticism of the NHS 
screening program (Screening, 2012). 
 
In the management of breast cancer, prognostic tools are already available 
including the Nottingham Prognostic Index, adjuvant online and oncotype Dx. 
These tools have been developed with an aim to offer more personalised 
treatment plans. Currently there is no tool in routine clinical practice to aid the 
risk stratification of DCIS that changes current clinical management. The 
development of a robust risk stratification tool has the potential to change the 
management of DCIS and improve the breast screening program. Both 
conventional histopathological factors and specific biomarkers have been 
related to DCIS behaviour.  High grade DCIS is  thought to be more likely to 
progress than non-high grade DCIS, Ozanne and colleagues created a 
simulation model to assess DCIS progression: this estimates that a >1 cm, 
high grade DCIS lesion in women under 45 years old has a 60% rate of 
progression to IBC and those women more than 45 years of age with a 
<2.5cm, low or intermediate grade lesion to have a rate of progression to IBC 
of 10% (Ozanne et al., 2011) 
 
A range of biological markers have been investigated to assess their utility in 
predicting DCIS progression. ER negativity in DCIS has been associated with 
an increased risk of DCIS recurrence (E. Provenzano et al., 2003). A study 
assessing 195 cases of low grade DCIS found 100% were ER positive and 
85.3% were PR positive (Koh et al., 2019). A study by Roka and colleagues of 
132 women diagnosed with DCIS treated with breast conserving surgery 
(BCS) with or without radiotherapy discovered a significantly lower rate of 
ipsilateral breast recurrence in patients with ER-positive DCIS compared to 
patients whose DCIS did not express ER (3.7% vs 12.2%, p<0.04).(Roka et 
al., 2004). 
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The Oncotype Dx DCIS Score has been developed and validated to assess 
risk recurrence in DCIS. It is a 12 gene assay performed on an individual 
patient’s tumour. (Solin et al., 2013) The aim of the oncotype dx DCIS score 
is to improve the predictions of DCIS recurrence rather than just using 
standard tumour characteristics alone. Two decision impact studies 
demonstrated that inclusion of the DCIS score alongside age and tumour size 
changed treatment recommendations approximately 30% of the time 
(Manders et al., 2017), (Alvarado et al., 2015). 
 
It is important in the development of a DCIS risk stratification tool that there is 
an understanding of the biological processes driving DCIS progression. It is 
now well recognized that the tumour microenvironment plays a central role in 
tumour progression and this should be encompassed into a tool to predict 
progression. The myoepithelial cell is a key component of the DCIS 
microenvironment. 
 
In order to evaluate the association of markers with DCIS progression, two 
patient cohorts were selected: one with pure DCIS, the other DCIS with 
associated invasion. These cohorts were chosen as DCIS with associated 
invasion represents late-stage DCIS and therefore changes critical to DCIS 
progression should be present in these samples. The pure DCIS samples are 
likely at different stages of their evolution, but since no more than 50% are 
ever likely to progress, any change critical to progression should be  
significantly less frequent. 
 
This study has focused particularly on the myoepithelial cells. Tissue sections 
from a pure DCIS cohort (low risk model) and DCIS with associated invasion 
(high risk model) cohort were assessed and scored on a duct-by-duct basis 
for a number of biological markers. Galectin-7, known to be a myoepithelial 
marker (Demers et al., 2010), was compared between the 2 cohorts. This 
shows there are significantly more Galectin-7 negative DCIS ducts in the DCIS 
with associated invasion cohort and significantly more Galectin-7 positive 
ducts in the pure DCIS group. This suggests that loss of myoepithelial 
Galectin-7 is associated with more advanced disease and could be considered 
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a poor prognostic marker. Work in our lab has previously shown that avb6 
positivity is a poor prognostic factor in DCIS (M. D. Allen, Marshall, et al., 
2014), therefore sequential sections of the two DCIS cohorts were stained for 
avb6. This demonstrated that there were significantly more avb6-negative 
DCIS ducts in the pure DCIS cohort compared to the DCIS with associated 
invasion, supporting the previous finding that acquisition of avb6 by DCIS 
myoepithelial cells is associated with more advanced disease. Any DCIS risk 
score will be improved by the integration of multiple markers, thus each duct 
was assigned a avb6- Galectin-7 score.  These indicated that scores of 
Galectin-7 positive/ avb6 heterogeneous, Galectin-7 positive/avb6 negative, 
Galectin-7 heterogeneous/ avb6 negative were significantly more frequent in 
DCIS ducts in the pure DCIS cohort compared to the DCIS with associated 
invasion cohort. Conversely, the combinations of Galectin-7 heterogeneous 
/avb6 positive, Galectin-7 negative /avb6 positive and Galectin-7 negative 
/avb6 heterogeneous were seen in a significantly higher number of DCIS ducts 
in the DCIS with associated invasion cohort. These findings suggest an 
inverse relationship between Galectin-7 and avb6 integrin in DCIS-
myoepithelial cells, though it is not clear from immunohistochemistry alone 
whether the two molecules are functionally related. 
 
The hypothesis  is that Galectin-7 positivity is a good prognostic sign in DCIS 
and avb6 is a poor prognostic sign. The same score and weighting has been 
used for both markers. DCIS with associated invasion has a lower average 
score for Galectin-7 than the pure DCIS cohort, supporting this hypothesis. 
For avb6,  the DCIS with associated invasion had a higher average score than 
pure DCIS, which would support the hypothesis that avb6  positivity is a poor 
prognostic marker. 
 
 
The relationship between the expression of oestrogen, progesterone and 
HER2 receptors with associated invasion has been assessed. All 3 markers 
reached statistical significance demonstrating a difference between the 2 
groups, however the results are clearer for progesterone and HER2. A higher 
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percentage of ducts strongly positive for progesterone receptor was seen in 
the DCIS with invasion group compared to the pure DCIS group. In contrast, 
for Her2, a higher percentage of strongly positive ducts was identified in the 
pure DCIS group compared to DCIS with invasion. The findings with Her2 are 
concordant with previous studies by Park et al., and Clark et al., who 
recognised that there is a higher frequency of Her2-positive DCIS compared 
with Her2-positive invasive breast cancer though the biological explanation for 
this is not understood (Park, Han, Kim, Kim, & Shin, 2006), (Clark et al., 2011). 
In contrast, the higher frequency of ER and PR positive DCIS in DCIS with 
associated invasion is in contradiction to published studies. Provenzano et al 
found that PR negativity In DCIS was independently associated with risk of 
local-regional recurrence (E. Provenzano et al., 2003). These authors 
compared tissues from patients who subsequently developed ipsilateral 
recurrence (cases) with those from patients who did not develop a recurrence 
(controls). Patients who developed a local-regional recurrence were more 
likely than controls to have PR-negative disease (63% vs. 34%) (E. 
Provenzano et al., 2003). Furthermore, in the IBIS-I study, ER negative DCIS 
was associated with higher risk of invasive recurrence (Cuzick et al., 2014). 
However, interestingly in those cases scored as ER positive, any 
heterogeneity of staining, that is the presence of any ducts negative for ER, 
resulted in the same prognosis as those soring ER negative overall. This 
emphasizes the importance of heterogeneity in DCIS behaviour, and that this 
needs to be taken into account when considering biomarker expression. A 
supplementary analysis of the data in the current study confirms this.  
 
The scoring of oestrogen receptor is not wholly consistent across the UK. The 
method of scoring in this thesis was chosen to both represent how positive a 
case is and the intensity of the stain, which could be converted into a modified 
Allred-type scoring system out of 8 as shown in the table below. 
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 % of cells 
positive 
Staining 
intensity 
Score 
Positive 3 100 High 8 
Positive 2 100 Moderate 7 
Positive 1 100 weak 6 
Heterogeneous 3 25-99% High 5 
Heterogeneous 2  25-99% Moderate 4 
Heterogeneous 1 25-99% weak 3 
Negative 0 0 < 2 
 
 
 
A recognised method is to score the percentage of cells in the case that were 
positive. Current consensus (ASCO/CAP and Mitch Dowsett, personal 
communication) is that the recommended cut-off point for positivity versus 
negativity for ER status is greater than or equal to 1% of tumour cells 
(Fitzgibbons, Murphy, Hammond, Allred, & Valenstein, 2010; Hammond et al., 
2010). However, many laboratories continue to use the Allred score that is 
comparable to the scoring method th used in this thesis: this assesses the 
percentage of cells which are positive as well as the intensity.  The proportion 
score (0 to 5) was derived from the percentage of positive cells (0%= 0 ;<1% 
=1; 1 – 10% =2; 11-33%= 3; 34-66%=4; 67-100%=5).This was combined with 
visually assessed intensity score (0=negative; 1=weak; 2=moderate; 
3=strong) to get the final Allred score (0- 8)(Vijayashree, Aruthra, & Rao, 
2015).  
 
There is not a recognised scoring method for oestrogen receptor scoring in 
DCIS as outlined in the Royal College of Pathologists guidelines. Not all trusts 
assess hormone receptor status on DCIS samples. Barts Health does not 
currently routinely assess oestrogen receptor on DCIS specimens. Ductal 
carcinoma in situ oestrogen receptor status may be assessed in patients with 
ductal carcinoma in situ for whom endocrine treatment is being considered, 
but it is not mandatory for all patients. There is no consensus on cut-offs as, 
unlike for invasive carcinoma, there are no data relating clinical outcome on 
endocrine treatment to the level of oestrogen receptor expression. At the 
present time it is recommended that the same scoring method and cut point 
Table 2-8 Oestrogen and Progesterone staining method 
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for positivity used for invasive carcinoma be used for assessment of DCIS. 
Hormone receptor status should be recorded on the NHSBSP and dataset 
forms as positive or negative with the percentage staining as a minimum and 
the average intensity or the result of the Allred score or H score as for invasive 
disease (Ellis, 2016) 
 
 
There is significant evidence for the regulatory role of normal myoepithelial 
cells in the mammary gland, including control of epithelial cell polarity and anti-
proliferative, anti-invasive and anti-angiogenic properties, thus providing a 
broad tumour-suppressor environment (Barsky & Karlin, 2006). Myoepithelial 
cells have been shown to down-regulate expression of matrix 
metalloproteinases (MMPs) in both tumour cells as well as fibroblasts, so 
promoting an anti-invasive phenotype (Jones et al., 2003). Maspin is one of 
the most important tumour suppressor proteins that is secreted by normal 
myoepithelial cells which acts as an inhibitor of angiogenesis (Hopkins & 
Whisstock, 1994),(Pemberton et al., 1995). Thus, the myoepithelial cell could 
be considered as ‘guardian of the ductal microenvironment’ in the normal 
breast. 
 
Given the consistent change in Galectin-7 and its potential to influence many 
pathways, this project aims to focus on Galectin-7 and investigate the 
functional significance of this in myoepithelial cells in order to establish 
whether it could be causally related to the DCIS-invasive transition. 
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3 Functional analysis of Myoepithelial Galectin-7 
 
3.1 Materials and methods 
3.1.1 Generation of myoepithelial cell (MEC) lines 
 
A breast myoepithelial cell line N-1089, derived from human cosmetic 
reduction breast tissue was a gift from Prof M. O’ Hare.  This was immortalised 
with h-TERT/SV40 LgT as described by O’Hare et al (O'Hare et al., 2001) and 
designated ‘Myo 1089’ cell line. This cell line originally was a mixed population 
composed of MECs express differing levels of α6β4. These cells were sorted 
by their α6β4 expression using β4 antibody (Millipore, MAB 1964) coated 
magnetic beads (Dynal Invitrogen, 110.31). The cell line generated by this 
selection was called N- 1089 and fully characterised by Dr M Allen to 
demonstrate MEC features including expression of vimentin, SMA and p63.  
 
In order to investigate the functional significance of αvβ6 Dr M Allen 
engineered a β6 overexpressing Myo 1089 cell line.  To do this, AM12 
packaging cell line was transfected with either empty pBABE-puro vector, or 
vector containing β6 integrin insert (Addgene plasmid:1734). β4-1089 cells 
were cultured with the medium containing virus from control or β6 carrying 
AM12 cells and selected for puromycin (Sigma, P8833, 1µg/ml) resistance. 
Control and αvβ6 over-expressing cell lines were designated N-1089 (Myo-
puro) and β6-1089 (Myo-β6) respectively. These cell lines were shown to 
switch their phenotype over time in culture; most notably they show gradual 
down-regulation of α6β4 integrin. In order to maintain α6β4 expression, cells 
are enriched by positive selection on β4 antibody-coated anti-mouse magnetic 
beads every 10-13 weeks. Along with this enrichment β6-1089 cells are re-
sorted by positive selection on αvβ6 coated beads, whereas N- 1089 cells are 
negatively selected. These cells were cultured in the presence of 
hydrocortisone (1µg/ml), Epidermal Growth Factor (EGF, Sigma, 9644, 
10ng/ml), insulin (1µg/ml). 
The breast cancer cell line MDA-MB-231 was obtained from ATCC HTB-26 
and represent ER negative highly invasive breast cancer cells.  The 
 116 
immortalised fibroblast cell line MRC-5 was obtained from ATCC. The cell line 
culture conditions are summarised in Table 3-1. 
 
3.1.2 Isolation of primary myoepithelial cells 
Human breast tissue was obtained from samples donated to the Breast 
Cancer Now Breast (BCN)/ Barts Cancer Institute (BCI) tissue bank (Ethical 
Approval Reference 10/H0308/49, Cambridgeshire Ethics Committee October 
2010).  
Normal myoepithelial cells were isolated from reduction mammoplasty tissue. 
The cell isolation protocol was performed by Dr J Gomm.(Gomm et al., 1995). 
Reduction mammoplasty tissue was collected and used to prepare breast 
organoids. The tissue was chopped and then digested overnight at 37˚C with 
collagenase (1 mg/ml, Sigma, C2674) and hyaluronidase (Sigma, H3506) on 
a roller. After digestion, the fat layer was separated by decanting and 
organoids and single cells were washed three times with RPMI (PAA, E15-
840), followed by 3 sedimentation steps at room temperature (RT) to isolate 
the fibroblast-containing stromal compartment. Organoids were digested to a 
single-cell suspension through digestion with 0.05%/0.02% (w/v) 
trypsin/EDTA solution (Hyclone, SV30031.01) containing 0.4mg/mL DNase 
(10104159001, Roche Life Science) for 15 minutes at 37oC, digestion was 
halted with RPMI containing 10% FBS and the cell suspension was filtered 
through gauze (pore size: 56μm2, Henry Simon, Stockport). Cells were 
counted and incubated in a 1:1 ratio sequentially with magnetic beads coated 
with CD10 antibody (AbD serotech, MCA1556) to isolate MECs, followed by 
magnetic beads coated with EpCAM (Ber-EP4) antibody (Invitrogen, 161.02) 
to isolate LECs, at 4˚C for 15 minutes on a roller. Further incubations with 
magnetic beads were employed until depletion of each cell type was achieved 
(summarised in Figure 3-1).  
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Figure 3-1 Isolation of normal primary breast cells 
Diagram showing isolation of normal primary cells from reduction mammoplasty tissue. 
Adapted from Gomm et al (Gomm et al., 1995)  
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3.1.3 Cell culture conditions 
Cell Type Source Media Passage 
N-1089 Gift from M 
O’Hare 
HAM F-12 (Sigma N6658)  
10% FBS 
1μg/mL Hydrocortisone  
5μg/mL Insulin  
10ng/mL Epidermal 
Growth Factor  
Maintained in T75 flask 
Passaged 1:10 
37oC in 5% CO2  
 
β6-1089 Engineered 
by Dr M 
Allen 
HAM F-12 (Sigma N6658)  
10% FBS 
1μg/mL Hydrocortisone  
5μg/mL Insulin  
10ng/mL Epidermal 
Growth Factor  
Maintained in T75 flask 
Passaged 1:10 
37oC in 5% CO2  
 
MDA-MB-
231  
ATCC Dulbecco’s Modified 
Eagles’s Medium (DMEM, 
Sigma, D6429) with 10% 
FBS  
Maintained in T175 flask 
Passaged 1:10 
37oC in 5% CO2  
 
MRC-5 ATCC Dulbecco’s Modified 
Eagles’s Medium (DMEM, 
Sigma, D6429) with 10% 
FBS 
Maintained in T75 flask 
Passaged 1:10 
37oC in 5% CO2  
 
 
 
3.1.4 Passage of cells 
 
Cells were grown in 5% CO2 at 37
oC until ~80% confluent then media was 
aspirated and discarded. Cells were detached using 3ml-5ml of 10x 
Trypsin/Ethylenediaminetetraacetic acid (EDTA) solution (Sigma 594186) added 
to T75 and T175 flasks, respectively. The flask was placed at 37oc for 5-10 
minutes until cells started to detach. The time taken for cells to detach varied 
amongst the cell lines with the myoepithelial cell lines taking longer to detach. The 
trypsin was neutralised with appropriate media and the cells were centrifuged at 
1200 rpm for 3 minutes. The supernatant was discarded and cell pellet re-
suspended in the appropriate media as outlined in Table 3.1. Cells were then 
transferred to fresh flasks and plated at a ratio of 1 ml of cell suspension to 9ml 
of media. 
 
Table 3-1 Cell culture conditions and media 
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3.1.5 Primary myoepithelial cell culture conditions 
 
Following the isolation of primary myoepithelial cells as outlined in Figure 3-1 cells 
were frozen and stored at -80oC until needed.  Myoepithelial cells were defrosted 
by hand and re-suspended in myoepithelial cell media. The cells were mixed 1:1 
with trypan blue and counted with a glass haemocytometer. The trypan blue was 
used to ensure only viable cells were plated. 10 µl of cell suspension and 10 µl of 
trypan blue was mixed and then 11µl of this mixture was pipetted into the 
haemocytometer. The cells were viewed under inverted phase contrast 
microscopy. The number of viable cells in each 4x4 grid was counted. The cell 
count per ml was the average across the 4 grids multiplied by 2 (to account for 
trypan blue) multiplied by 10000. Myoepithelial cells were seeded at a density of 
4-5x105 on collagen-coated 6 well plates and incubated in 5% CO2 at 37
oC. 
Myoepithelial cells were cultured in HuMEC medium (Thermo Fisher Scientific) 
supplemented with 0.5 μg/ml hydrocortisone, 5 μg/ml insulin, 10 ng/ml EGF and 
50 μg/ml bovine pituitary extract (Thermo Fisher Scientific), 0.5 μg/ml fungizone 
(Invitrogen, 15290-026) and 10 μg/ml gentamicin (Sigma, G1397) which was 
changed every 48 hours. 
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3.1.6 Detection of Galectin-7 in Myoepithelial cells by Western blotting 
 
Cell lysis 
Cells were harvested for protein analysis. The culture medium was removed from 
plates and the cells washed with PBS.  Radioimmunoprecipitation assay (RIPA 
buffer) (50mM Tris-hydrochloride (TrisHCl, Sigma, T3253) pH 7.4, 150mM 
sodium chloride (NaCl, Fisher, 358-1), 1% IGEPAL CA-630 (Calbiochem, 
490216), 0.1% sodium deoxycholate (Na-DOC, Sigma, D6750), 1mM EDTA 
(Fisher, BP 118-500), supplemented with 1:100 protease inhibitor cocktail set 
(Calbiochem, 539131), was added to the plates. The plate was scraped and the 
suspension transferred to an eppendorf.  The eppendorf was centrifuged at 10000 
rpm at 4oC, to pellet the insoluble cell remnants and the supernatant was placed 
in a fresh eppendorf and stored at -20 oC. 
 
Protein quantification  
Protein concentrations were quantified using the Bio-Rad DC Protein Assay Kit 
(Bio-Rad Laboratories, Reagent A 500-0113, Reagent B -114, Reagent S -115), 
according to the manufacturer’s instructions. Protein was quantified to ensure 
equal quantities of samples were loaded onto the gel. BSA (bovine serum 
albumin, Sigma, A9418) standards were used to create a standard curve and this 
was used to estimate the sample protein concentration. Cell lysates and BSA 
standards (diluted in distilled water) were added at 5μl volumes to a 96 well plate 
in triplicate, before adding 25μl of solution A/S (1000μl reagent A and 20μl reagent 
S) per well followed by 200μl of reagent B per well. The plate reader was used to 
read the 96 well plate at 595nm. The protein concentration of the samples was 
determined using a BSA standard curve and calculated on Microsoft excel using 
a linear regression equation. 
 
SDS Gel 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate the 
proteins. The gel percentage was adjusted to resolve the relevant protein by 
altering volumes of dH2O and 30% acrylamide mix (National Diagnostics, EC 
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890). The gel was placed into either a 1mm or 1.5mm cassette, which varied 
according to volume of sample which required loading into the gel. The 8% 
resolving gel solution comprised of 4.6ml distilled water (dH2O), 2.7ml 30% 
acrylamide mix (National Diagnostics, EC 890), 2.5ml 1.5M Tris (pH 8.8), 100μl 
10% SDS (Fisher BioReagents 7732-18-5), 100μL 10% ammonium persulphate 
(APS, Acros organics 7727-54-0) and 6μl TEMED (Flowgen, H17459). Once the 
gel was placed in the cassette dH2O was pipetted on top of the gel. When the gel 
was set the overlaying dH2O was discarded. Stacking gel (2.7ml dH20, 670μl 
30% acrylamide, 500μl 1M Tris (pH6.8), 40μl 10% SDS, 40μl 10% APS and 4μl 
TEMED) was added to the cassette and a suitable comb was inserted.  Once the 
gel had set the tape was removed from the cassette and placed into the gel tank. 
Running buffer (100ml tris-glycine/SDS Severn Biotech 20-6400-50 in 900ml 
dH20) was added to the tank and then the comb was removed. 
 
Sample preparation 
30μg of protein was combined with 4X sample loading buffer (5% SDS, 20% 
buffer (0.5M tris, 0.2M NaH2PO4, pH 7.8), 5% β- mercaptoethanol (Sigma, 
M7522), 50% glycerol (Fisher, G/0600/17), 0.01% bromophenol blue (Sigma, 
B8026) and 20% dH20). Samples were boiled for 5 minutes at 100
oC, centrifuged 
at 10000rpm for 1 minute and the loaded onto the gel, 10μl of Pageruler (Thermo 
Scientific 26619) was also loaded onto the gel, this is a prestained protein ladder 
used as a standard for comparing size of proteins of interest.  
Running of the gel 
The gel was run at room temperature at 150v between 80 and 90 minutes 
depending on the protein of interest. On completion of the run, the cassette was 
opened and gel removed. PVDF membrane was briefly pre-soaked in 100 % 
methanol prior to being soaked in transfer buffer (100ml tris glycine Severn 
Biotech, 20-6400-10, 700ml dH20 and 200ml 100% methanol) together with the 
sponges. A sandwich was made using 2 pre-soaked sponges, 2 pieces of filter 
paper, gel, membrane, 2 pieces of filter paper and 2 sponges, taking care to 
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remove any air bubbles. This was placed in the gel tank and the central chamber 
topped with transfer buffer.  The outer chamber was filled with dH2O and the tank 
was placed on ice. The transfer was performed at 30v for 90 minutes. 
Following the transfer, the membrane was blocked for 30 minutes in 5% skimmed 
milk (Sigma, 70166)/ PBST (0.1% Tween 20 (Applichem, A4974) in PBS) with 
gentle rocking at room temperature. 
 
The membrane was then incubated overnight at 4oC with the primary antibody 
diluted with 5ml of 5% skimmed milk and Tween. Details of the primary antibodies 
are outlined in Table 3-2.  
 
Membranes were washed 3 x 5 minutes with PBST, prior to being incubated with 
secondary antibodies (anti-mouse HRP Dako, P0260 or anti-rabbit IgG HRP 
Dako, P0488,) 1/2000 dilution in 5% skimmed milk 0.1% Tween for 60 minutes at 
room temperature. It is important to ensure the appropriate membranes are used, 
the experiment for cleaved caspase-3 was repeated a number of times with 
different membranes, prior to achieving an interpretable result. 
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Antibody Dilution Manufacture Species Membrane 
Galectin-7 1/1000 Ab-cam 
(ab108623) 
Rabbit 0.2μm PVDF novex 
life technologies 
LC2002 
Total-PARP 1/1000 Cell Signalling 
(9542L) 
Rabbit 0.45μm nitrocellulose 
No.10600002 
Cleaved-
PARP 
1/1000 Cell Signalling 
(D214) 
Rabbit 0.45μm nitrocellulose  
Cleaved 
Caspase -3 
1/1000 Cell signalling 
(D175) 
Rabbit 0.2μm Nitrocellulose 
P-Cadherin 1/1000 BD Biosciences 
(610228) 
Mouse 0.45μm nitrocellulose  
HSC70 1/10000 Santa Cruz (sc-
7298)  
Mouse 
monoclonal 
0.45μm nitrocellulose  
 
 
3.1.7 Knockdown of Galectin-7 in primary myoepithelial cells 
 
Primary myoepithelial cells endogenously express high levels of Galectin-7. To 
achieve knockdown of Galectin-7, primary myoepithelial cells were transfected 
with Galectin-7 siRNA (siGENOME SMART pool LGALS7, Thermoscientific 
Dharmacon M-011719-01) and compared to a non-targeting control (siGENOME 
Dharmacon D-001206-14-20). 
 
Myoepithelial cells were seeded at a density of 4-5x105 in collagen-coated 6 well 
plates. siRNA transfection was performed when cells were at 60% confluency. 
 
The quantities were worked out per 1 well in a 6 well plate and scaled up as 
required.  200µl of cell media was transferred to an eppendorf and combined with 
1.1µl of siRNA.  4µl Interferin (polyplus 409-50) was added, vortexed and 
incubated for 10 minutes. 2ml of fresh media was added to each well and 200µl 
of the siRNA mixture was then added. The extent of knockdown achieved was 
Table 3-2 Antibodies used in Western blotting 
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evaluated by western blotting at different time-points and the time-point showing 
optimal knockdown was used for all future experiments. 
 
3.1.8 Overexpression of Galectin-7 in myoepithelial cells 
 
N-1089 and b6-1089 cell lines were seeded at 6 x 105 onto 10 cm plates and 
incubated in Hams-F12 media with 10% FBS, 2mM glutamine, Hydrocortisone 
(1µg/ml) EGF (10ng/ml) and Insulin (5µg/ml). At 24 hours cells were transfected 
with 1µg Galectin-7 pc DNA 3.1 (engineered by Dr M Allen) or empty vector pc 
DNA 3.1, or GFP to confirm transfection. Transfections were performed using 
standard Jetprime protocol (polyplus). Briefly, DNA was diluted in 200µl Jetprime 
buffer, votexed for 10 seconds and then 4 µl jetprime reagent added with further 
vortexing for 10 seconds followed by incubation at room temperature for 10 
minutes. The transfection mixture was then added to 2 ml of myoepithelial cell 
media and added to the cells. The media was changed at 24 hours. 
 
3.1.9 Treatment with TRAIL pro-apoptotic ligand 
 
Human TRAIL Apo II ligand (peprotech;310-04), was used as a pro-apoptotic 
ligand to stimulate the extrinsic apoptosis pathway. TRAIL may be produced 
physiologically by Treg cells in the inflammatory DCIS microenvironment, so was 
considered an appropriate stimulus. The optimal dose of TRAIL was established 
using the Alamar blue assay to assess cell viability. The dose of TRAIL used in 
both cell lines and primary myoepithelial cells was 250ng/ml and 500ng/ml, 
respectively.  The cells were treated with TRAIL at different time-points and the 
extent of apoptosis assessed by Western blot for the apoptotic markers cleaved 
PARP and Caspase-3. 
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3.1.10 LDH cytotoxicity assay  
 
The myoepithelial cell lines were plated on a 24 well plate seeded at a density of 
2.5 x 104 per well and incubated for 48 hours. The cell lines were transfected with 
Galectin-7 plasmid or control plasmid. The primary myoepithelial cells were 
transfected with Galectin-7 siRNA or non-targeting control siRNA. 48 hours post 
transfection the cells were treated with TRAIL. At 48 and 72 hours post-TRAIL 
treatment, cytotoxicity was analysed using CytoTox96® non-radioactive 
cytotoxicity assay (Promega, G1780). 
Lysed cells release LDH and the LDH in the conditioned media was used as 
marker of cell death. The colour change gives an indication of the extent of cell 
death.  
Conditioned media from each well was transferred into separate eppendorfs and 
stored on ice. For maximal lysis controls, 100 µl of lysis solution (9 % Triton X-
100) was added to each control well and left for 45 minutes. Conditioned media 
was transferred to eppendorfs. 
50µl of each conditioned media was transferred to a 96 well plate in quintuplicate 
and 50µl of reagent was added to each well. This was left to incubate in the dark 
for 10 minutes after which 50µl of stop solution was added per well. The plates 
were then analysed at 490nm on a plate reader. The absorbance values obtained 
in the remaining experimental wells were normalised as a percentage of the 
maximal lysis value as shown in the equation below.  
%	%&'('() = +Experimental	release	LDHMax	LDH < )100  
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3.1.11 Apoptosis proteome profile 
 
Sample preparation 
Assessment of expression of apoptosis related proteins in primary myoepithelial 
cells was performed using the Human Apoptosis Array Kit (R&D Systems 
ARY009) This assesses 35 human apoptosis related proteins from a single 
sample.  
 
Primary myoepithelial cells were seeded onto collagen-coated 6 well plates at a 
density of 4x104 cells per well. Galectin-7 siRNA knockdown in primary 
myoepithelial cells was performed as previously described 3.1.7. Four different 
conditions were set up:  
siRNA non-targeting control 
siRNA Galectin-7 
siRNA non-targeting control with TRAIL treatment 
siRNA Galectin-7 with TRAIL treatment.   
The cells were treated with 250ng/ml of TRAIL and harvested at 4 hours post 
treatment. 
 
Cell Lysis 
The plates were placed on ice and cells were lysed using lysis buffer 17 (R&D 
Systems ARY009) with protease cocktail inhibitor. Protein was quantified using 
Bio-Rad assay. The Galectin-7 knockdown was confirmed using western blotting 
prior to protein being assessed on the human apoptosis array. Samples were 
stored at -80oC until required then thawed on ice. 
 
300µg of protein was used and the maximum volume of lysate was 250µl. 1.25 
ml of array buffer 1 was added to each sample. All samples were adjusted to the 
final volume of 1.5ml by adding lysis buffer 17 as required.  Array buffer 1 was 
aspirated from the dish and samples added to each well and incubated overnight 
at 4oC on a rocking platform.  
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Array procedure 
All reagents were brought to room temperature prior to use. 2ml of the blocking 
buffer Array buffer 1 was added to the 4 well multi dish and then each array was 
placed into the multi dish and was incubated with gentle rocking for 1 hour at room 
temperature. Following incubation of samples overnight on the nitrocellulose 
membranes, arrays were washed for 3 x 10 minutes to remove unbound protein 
with wash buffer. 
 
Detection 
Each array was then incubated with a 1.5ml cocktail of biotinylated detection 
antibodies. 15µl of reconstituted detection antibody cocktail was diluted with 1.5ml 
1x Array buffer 2/3 and incubated for 1 hour at room temperature on a rocking 
platform, Followed by 3 x 10 minute washes. Arrays were then incubated with 
2.0ml of diluted streptavidin-HRP reagent for 30 minutes on the rocking platform 
at room temperature followed by wash steps. Results were detected by adding 
1ml of chemi-reagent to each membrane. The chemi-doc system was used to 
read the protein intensity.  
 
Analysis 
The Image-J program was used to assess pixel density and comparison was 
made between conditions. For each protein there were duplicate spots. The 
average pixel density for each spot was used. Table 3.3 shows the coordinates 
and corresponding apoptotic protein for the array shows the coordinates and 
corresponding apoptotic protein.  
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Coordinate Target Coordinate Target Coordinate Target 
A1, A2, 
A23, A24 
Reference  C1, C2 TRAIL R1/ DR4 D1, D2 PON 2 
B1, B2 Bad C3, C4 TRAIL R2/DR5 D3, D4 p21/ 
CIP1/CDKN1A 
B3, B4 Bax C5, C6 FADD D5, D6 P27/ Kip1 
B5, B6 Bcl-2 C7, C8 Fas/ 
TNFRSF6/CD95 
D7, D8 Phospho-p53 
(s15) 
B7, B8 Bcl-x C9, C10 HIF-1a D9, D10 Phospho-p53 
(s46) 
B9, B10 Pro 
Caspase-3 
C11, C12 H0-
1/HM0X1/HSP32 
D11, D12 Phospho-p53 
(s392) 
B11, B12 Cleaved 
Caspase-3 
C13, C14 H0-2/HM0X2 D13, D14 Phospho-
Rad17 (s635) 
B13, B14 Catalase C15, C16 HSP27 D15, D16 SMAC, Diablo 
B15, B16 cIAP-1 C17, C18 HSP60 D17, D18 survivin 
B17, B18 cIAP-2 C19, C20 HSP70 D19, D20 TNF-
R1/TNFRSF1A 
B19, B20 Claspin C21, C22 HTRA2/0mi D21, D22 XIAP 
B21, B22 Clusterin C23, C24 Livin D23, D24 PBS (neg 
control) 
B23, B24 Cytochrome 
c 
  E1, E2 Reference 
 
 
  
Table 3-3 Apoptotic markers represented on the proteome profiler  
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3.1.12 Adhesion assay 
 
Plate preparation 
A non-tissue culture treated 96 well plate was coated with extracellular matrix 
proteins diluted in PBS. The follow conditions were assessed: 
Collagen I 0.5 μg/ml (Corning collagen type I 354236)  
Fibronectin 1μg/ml (sigma F1141)  
Laminin 10μg/ml (Sigma L6274)   
100 μl of ECM was added to each well and 1% BSA was used as base line control. 
This was incubated for 1 hour at 37oC and then washed with PBS twice to remove 
excess ECM. 
 
Primary cells 
Primary cells from patient 1989 were used to establish if altered Galectin-7 
expression influences adhesion to extracellular matrix proteins. Passage 2 
myoepithelial cells were used for the adhesion assays. The plating and 
knockdown was performed as previously described in 3.1.5. At 48 hours post-
siRNA treatment for Galectin-7 knockdown and non-targeting control, cells were 
trypsinised and counted and added to prepared plates.  
 
N-1089 and b6-1089 
N-1089 and b6-1089 cells were plated in 6 well plates at a density 5x104 cells per 
well. After 48 hours transfection with Galectin-7 or control vector was carried out 
as previously described 3.1.8. The cells were washed 3 times with EDTA (0.02%, 
pH 7.6), cells were then incubated for 10 minutes with 500ul EDTA and trypsin 
(5ml of EDTA and 100 ul of trypsin). The trypsin was neutralised and the cells 
spun down and re-suspended in serum free media F12 Hams media. Cells were 
counted and 2x104 cells in 50ul of media were pipetted into each well of the coated 
96 well plate. 
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Adhesion assay 
The plate was incubated at 37oC for 40 minutes. The plate was shaken manually 
once to remove unattached cells. Cells were fixed in 100% methanol for 10 
minutes, then the plate was shaken to remove methanol. The plate was then 
stained with 0.1% Crystal Violet in 30% methanol for 60 minutes at room 
temperature. The plate was shaken to remove excess crystal violet and then 
washed 3 times with dH2O. The cells were solubilised with 30% glacial acetic acid 
for 10 minutes whilst on the rocking platform. The plate was then read at a 
wavelength of 595nm. This assay was performed in biological triplicate for both 
primary cells and cell lines. 
 
Data analysis 
Microsoft Excel was used to analyse the data. The average read for adhesion to 
BSA was subtracted from adhesion to each extracellular matrix protein for the 
corresponding cells. The absorbance figures were then averaged and standard 
deviations calculated. The cells where the Galectin-7 levels had been 
manipulated were compared to the control cells to assess if the percentage 
adhesion to each extracellular matrix increased or decreased.  
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3.1.13 Immunofluorescence 
 
Glass coverslips (13mm) were placed in a 24 well plate. The coverslips were pre 
coated with 10μg/cm2 COL1 and seeded with 2 x 105 primary myoepithelial cells 
from 3 different patients. The cells were plated and when approximately 60% 
confluent incubated with siRNA to Galectin-7 or non-targeting control for 48 hours 
described in more detail in 3.1.7.  Media was aspirated prior to cells being fixed 
with formal saline for 10 minutes. Following three washes with filtered PBS cells 
were permeabilised with 0.1% Triton 100X (Alfa Aesar, A16046) for 5 minutes. 
Cells were blocked in 0.1% BSA/PBS for 10 minutes at room temperature. 
Primary antibody, as outlined in Table 3-4, was added at an appropriate 
concentration and incubated at 4oC overnight. Coverslips were washed three 
times with filtered PBS and incubated with the appropriate secondary antibody 
diluted in 0.1% BSA/PBS at 1:200, at room temperature for 1 hour in the dark. 
Coverslips were washed three times with filtered PBS and once with dH2O. 
Coverslips were removed from the 24 well plate and mounted onto glass slides 
using DAPI (Invitrogen P36391).  Slides were left overnight at room temperature 
then viewed on the Zeiss LSM 510 confocal microscope. 
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Antibody Source Clone  Species Dilution Secondary 
Galectin-7 Abcam Ab108623 Rabbit 1:750 in 
5% BSA 
1:200 goat anti-
rabbit (Alexa fluro 
488 Invitrogen 
A11008) 
P-Cadherin Novus 
biologicals 
104805 Mouse 1:50 in 
1%BSA 
1:200 goat anti 
mouse (Alexa fluro 
546 Invitrogen 
A11008) 
1:200 goat anti-
mouse  (Alexa fluro 
488 Invitrogen 
A11001) 
Desmoglein-3 Serotec AHP319 Rabbit 1:100 in 
1% BSA 
1:200 goat anti-
rabbit (Alexa fluro 
488 Invitrogen 
A11008) 
 
 
  
Table 3-4 Antibodies used for Immunofluorescence  
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3.1.14 Migration assay 
 
The underside of 8μm transwell inserts (Corning 3422) was coated with 100μl of 
different extracellular matrix proteins.  Four transwells were coated per ECM 
condition. Membranes were coated with either fibronectin (10μg/ml; Sigma sigma 
F1141), Collagen I 0.5 μg/ml (Corning collagen type I 354236), or 1% BSA as 
control (Sigma, A8022). These were left to incubate at room temperature for 1 
hour, following which any excess extracellular matrix was removed and the inserts 
rinsed with filtered PBS.  500μl of serum free F12 Hams media was added to each 
well prior to inserting the transwell.  
 
N-1089 cells transfected with either control or Galectin-7 vector, were counted 
and re-suspended in serum free media. 3 x104 cells in 200μl of media were added 
to the upper chamber of each transwell. These were incubated for 6 hours at 
37oC.  
 
The media was removed from both the upper and lower chambers. 500μl of 
trypsin was added to each chamber and incubated for 1 hour at 37oC. The trypsin 
solution was rinsed over the membrane from both upper and lower chambers prior 
to removal and then transferred to separate tubes of 9.5ml filtered isoton. The 
number of cells in each tube was counted using the Casy cell counter. The 
percentage of cells that had migrated to the lower chamber was calculated. This 
was performed in biological triplicate for the cell lines however this was performed 
only once with the primary cells. Passage 2 primary myoepithelial cells were used 
which are a finite resource and therefore it was not possible to perform all 
experiments in triplicate. 
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3.1.15 Scratch Assay  
 
Primary Passage 2 myoepithelial cells from patient 1989 were seeded at a density 
of 4x104 on collagen-coated 6 well plates. After 3 days cells were treated with 
Galectin-7 siRNA (siGENOME SMART pool LGALS7, Thermoscientific 
Dharmacon M-011719-01) or a non-targeting control. (Thermoscientific 
Dharmacon  siGENOME D-001206-14-20). 48 hours post siRNA treatment, 2 
scratches were made in each well with a 200µL pipette tip to make a central cross. 
Cells were washed three times with PBS to remove any unattached cells and 
primary fresh myoepithelial cell media was added to each well. This was 
performed in duplicate and the experiment was repeated three times. Images 
were taken at 0,10,12,14 and 16 hours. ImageJ was used to assess the area of 
the scratch and the rate of closure between Galectin-7 and non-targeting control 
siRNA treated cells was compared. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3-2 Scratch assay method and analysis 
100% Confluent Scratched cells 
100% open 
0 hours 
Scratched cells 
% Closure 
10,12,14,16 
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3.1.16 Invasion assay 
 
8μm transwell inserts were placed into a 24 well plate. Matrigel (BD biosciences, 
354 234) was diluted with ice-cold serum free media (SFM) at a 1:3 matrigel: SFM 
ratio. 70μl of matrigel:SFM mixture was pipetted into each transwell and 
incubated at 37oC for 40 mins. MDA MB 231 cells were counted and 3x104 cells 
in 200μl of SFM were added to each transwell. 500μl of conditioned media was 
placed in the lower chamber of the transwell. The plates were incubated at 37oC 
for 24 hours.  The media was removed from the lower transwell chamber, 500μl 
of trypsin was added to each well and incubated for 1hr at 37oC. The trypsin 
solution was rinsed over the bottom of the membrane removed and transferred to 
tubes of 9.5ml filtered isoton. The number of cells in each tube was counted using 
the Casy cell counter. The total number of cells that had invaded through the 
Matrigel was calculated. The cells that had invaded were calculated as a 
percentage of total cells. A comparison was made between conditioned media 
from non-targeting control primary myoepithelial cells and Galectin-7 knockdown 
myoepithelial cells. 
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3.1.17 Protease array sample preparation 
  
Primary myoepithelial cells were seeded onto collagen-coated 6 well plate at a 
density of 4x104   cells per well. Galectin-7 siRNA knockdown and non-targeting 
control siRNA in primary myoepithelial cells was performed as previously 
described. Conditioned media was harvested from 4 different patients, 
centrifuged at 1200 RPM for 3 minutes to remove any dead cells, this was then 
transferred to -20oC freezer. Prior to incubation on the proteome profiler (R&D 
Systems - ARY021B) the conditioned media was concentrated through spin 
columns (Millipore-Amicon Ultra UFC 800324) at x4000g for 25 minutes until a 
volume of 1ml of concentrated conditioned media remained. 500µL of 
conditioned media was mixed with 1ml of Array buffer 6 and 15µL of protease 
detection antibody cocktail, this was incubated at room temperature whilst the 
nitrocellulose membrane was blocking. 
 
Array procedure 
All reagents were brought to room temperature prior to use. 2ml of Array buffer 1 
was added to the 4 well multi dish and then each array was placed into the multi 
dish and was incubated with gentle rocking for 1 hour at room temperature. 
Following incubation of samples overnight on the nitrocellulose membranes, 
arrays were washed for 3x 10 minutes to remove unbound protein with wash 
buffer. 
 
Detection 
Each array was then incubated with a 1.5ml cocktail of biotinylated detection 
antibodies. 15µl of reconstituted detection antibody cocktail was diluted with 1.5ml 
1x Array buffer 2/3 and incubate for 1 hour at room temperature on a rocking 
platform. Washes were repeated as previously described. 
Arrays were then incubated with 2.0ml of diluted streptavidin-HRP reagent for 30 
minutes on the rocking platform at room temperature followed by washing. 
Results were detected by adding 1ml of chemi-reagent to each membrane. The 
chemi-doc system was used to read the protein intensity.  
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Analysis 
The Image-J program was used to assess pixel density and comparison was 
made between conditions. For each protein there were duplicate spots. The 
average pixel density for each spot was used. Table 3.5 shows the coordinates 
and corresponding protease protein. 
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Coordinate  Analyte/Control  Coordinate  Analyte/Control  
A1, A2  Reference Spots  C7, C8  Kallikrein 10  
A3, A4  ADAM8  C9, C10  Kallikrein 11  
A5, A6  ADAM9  C11, C12  Kallikrein 13  
A7, A8  ADAMTS1  C13, C14  MMP-1  
A9, A10  ADAMTS13  C15, C16  MMP-2  
A11, A12  Cathepsin A  C17, C18  MMP-3  
A13, A14  Cathepsin B  D3, D4  MMP-7  
A15, A16  Cathepsin C  D5, D6  MMP-8  
A17, A18  Cathepsin D  D7, D8  MMP-9  
A19, A20  Reference Spots  D9, D10  MMP-10  
B3, B4  Cathepsin E  D11, D12  MMP-12  
B5, B6  Cathepsin L  D13, D14  MMP-13  
B7, B8  Cathepsin S  D15, D16  Neprilysin/CD10  
B9, B10  Cathepsin V  D17, D18  Presenilin  
B11, B12  Cathepsin X/Z/P  E1, E2  Reference Spots  
B13, B14  DPPIV/CD26  E3, E4  Proprotein Convertase 9  
B15, B16  Kallikrein 3/PSA  E5, E6  Proteinase 3  
B17, B18  Kallikrein 5  E7, E8  uPA/Urokinase  
C3, C4  Kallikrein 6  E9, E10  Negative Control  
C5, C6  Kallikrein 7     
Table 3-5 Protease proteins 
Protease protein table and schematic to show how each spot corresponds to each 
protease marker 
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3.1.18 Organotypic cultures 
 
Organotypic gels were prepared on ice. The gel comprised of 4.9 ml of rat tail 
collagen type-I (Corning 354236), 2.1 ml of matrigel (Corning 354234), 1ml 10X 
DMEM (Sigma D2429) and 1 ml of fetal bovine serum (Sigma F9665). 200µl of 
1M NaOH was added slowly until the gel turned pink. 5 x 106 MRC-5 fibroblasts 
were re-suspended in 1ml of DMEM media (Sigma D6429) with 10% FBS and re-
suspended into the gel.  Eight gels were prepared by adding 1 ml of the mixture 
to each well of a 24 well plate.  The gels were incubated at 37oC for 1 hour. 1 ml 
of DMEM with 10% FBS media was then added to each well and incubated 
overnight at 37 oC.  N-1089 myoepithelial cell lines were transfected with control 
or Galectin-7 plasmid as described in 3.1.8.  1 X 106 myoepithelial cells were re-
suspended in 2 ml of Ham’s F12 and 500µl added to each gel each in 
quadruplicate.  After 4 hours at 37oC, 2.5 X 105 MDA MB 231 cells were was re-
suspended in 500µl DMEM media and added to the surface of each gel. The 
media was changed every 48 hours. After 8 days the gels were removed from the 
plate and fixed in 10% neutral buffered formalin (Cell Path BAF-0010-037) for 24 
hours prior to being transferred to 70% ethanol for 24 hours.  Gels were 
embedded in paraffin and sectioned. 
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3.2 Results 
 
3.2.1 Characterisation of MEC lines and primary MEC  
 
Primary myoepithelial cells and the myoepithelial cell lines were characterised 
using immunocytochemistry. Galectin-7 was strongly expressed in primary 
myoepithelial cells, however both N-1089 and b6-1089 myoepithelial cell lines 
lack Galectin-7, therefore the cell lines were transfected with Galectin-7 vector or 
control vector in order to investigate the impact of Galectin-7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunocytochemistry was used to characterise primary myoepithelial cells, N-
1089 and b6-1089. Markers assessed were Galectin-7, cytokeratin 8, cytokeratin 
14 and P- Cadherin. This was undertaken by Mary-Kate Hayward, PhD student 
in the lab. This demonstrated that the primary myoepithelial cells show strong 
expression of Galectin-7 and the myoepithelial-associated cytokeratin 14, 
retaining the basal P-Cadherin expression but with minimal expression of the 
luminal-associated cytokeratin 8. In contrast, the myoepithelial cell lines lack 
Galectin-7 and show mixed expression of cytokeratin 8 and cytokeratin 14, with 
minimal expression of P-Cadherin. 
Figure 3-3 Characterisation of MEC cell line and primary MEC 
Galectin-7 Cytokeratin 14 P-Cadherin Cytokeratin 8 
Primary  
MEC 
N-1089 
b6-1089 
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3.2.2 Expression of Galectin-7 in myoepithelial cells 
 
Baseline expression of Galectin-7 in primary myoepithelial cells and the 
myoepithelial cell lines N-1089 and b6-1089 was assessed by Western blotting. 
This demonstrated expression in primary myoepithelial cells but no Galectin-7 
protein was detected in N-1089 or b6-1089 cell lines. To generate appropriate 
models for further experiments, both N-1089 and b6-1089 cells were transfected 
with Galectin-7 vector or control vector. This achieved successful overexpression 
with the Galectin-7 vector (Figure 3-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
N-1089 and b6-1089 were transfected with Galectin-7 plasmid or control plasmid. 
Western blotting shows successful overexpression of Galectin-7 with no expression in 
cells transfected with control vector. Primary myoepithelial cells (Pr) were used as a 
positive control. 
Figure 3-4 Protein expression of Galectin-7 after transfection in N-1089 
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3.2.3 Knockdown of Galectin-7 in Primary myoepithelial cells 
 
Normal primary myoepithelial cells were treated with Galectin-7 siRNA or non-
targeting control siRNA. Substantial knockdown was achieved with the Galectin-
7 siRNA at both 48 and 72 hours post treatment.  (Figure 3-5.) For further 
experiments siRNA treatment for 48 hours was used since successful knockdown 
was achieved and the reduced incubation time increased the chance of 
subsequent treatments being more successful both due to cell viability and cells 
not being over confluent. 
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Figure 3-5 Galectin-7 knockdown in primary myoepithelial cells. 
Western blot shows loss of Galectin-7 at 48 and 72 hours post Galectin-7 siRNA. No 
knockdown was seen with a pooled non targeting control siRNA. The loading control is 
HSC70. 
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3.2.4 Assessment of apoptosis in Primary myoepithelial cells 
 
Galectin-7 has been implicated in modulation of apoptosis, therefore the effect of 
knockdown of Galectin-7 on the apoptosis of primary myoepithelial cells was 
assessed.  Control siRNA or Galectin-7 siRNA primary MECs were exposed to 
TRAIL and expression of cleaved caspase-3, total caspase-3 and cleaved PARP 
was measured using Western blotting. The images are representative of western 
blots performed from 2 experiments passage 3 primary myoepithelial cells were 
used in these experiments. There is an increase in cleaved caspase-3 (figure 3.6) 
and cleaved PARP (figure 3.8) in all TRAIL treated cells. In non TRAIL treated 
cells there are higher levels of total caspase across all 3 patients. There are much 
higher levels of cleaved caspase-3 in the TRAIL treated Galectin-7 knockdown 
cells across all three patients, indicating that in this model, Galectin-7 has an anti-
apoptotic effect. A similar but less marked effect is seen for cleaved PARP. 
Galectin- 7 levels did not have an effect on total caspase levels. 
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There is increased total caspase 3 in the non-TRAIL treated cells.  There is slightly 
increased total caspase 3 in TRAIL treated Galectin-7 knockdown cells. HSC70 was used 
as a loading control.   
Figure 3-6 Effect of TRAIL treatment of Galectin-7 knockdown primary 
myoepithelial cells on Cleaved Caspase-3. 
In Galectin-7 knockdown cells, there is an increase in cleaved caspase-3 (marker 
of apoptosis) following TRAIL treatment, HSC70 was used as a loading control. 
Gal-7 +ve indicates cells were treated with non-targeting control siRNA and Gal-7 
–ve indicates cells were treated with siRNA to Gal-7.  
 
 
 
 
 
 
 
 
 
 
Figure 3-7 Effect on protein expression of Total Caspase-3  following Galectin-7 
knockdown in primary myoepithelial cells treated with TRAIL.  
Gal-7 
TRAIL 
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Cleaved PARP (marker of apoptosis) increases with TRAIL treatment. There is slightly 
increased levels of cleaved PARP in the Galectin-7 knockdown cells versus control cells 
following TRAIL treatment. HSC70 was used as a loading control.  
  
Figure 3-8 Effect on protein expression of cleaved PARP following Galectin-7 knockdown 
in primary myoepithelial cells treated with TRAIL. 
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3.2.5 Galectin-7 overexpression increases apoptosis in N-1089 and b6-1089 
 
Both N-1089 and b6-1089 myoepithelial cell lines lack Galectin-7, therefore the 
cell lines were transfected with Galectin-7 vector or control vector and these cells 
exposed to TRAIL for 4 hours In the established myoepithelial cell lines, TRAIL 
treatment increased cleaved PARP expression in Galectin-7 overexpressing cells 
compared to control vector(figure 3.9 and 3.10), indicating that in these cell line 
models, Galectin-7 is pro-apoptotic. For cleaved PARP this was performed in 
triplicate. Due technical difficulty with the choice of membrane the blots for 
cleaved caspase -3 did not work. 
 
 
 
 
 
 
 
 
                      
 
                      
Western blot shows increased cleaved PARP in N-1089 Galectin-7 overexpressed cells 
treated with TRAIL. (TRAIL + 250ng/ml TRAIL ++ 500ng/ml), indicating overexpressing 
Galectin-7 increases apoptosis in this model. 
Figure 3-9 Effect of protein expression of cleaved PARP in Galectin-7 overexpressed N-
1089 cells following TRAIL treatment 
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PARP 
HSC70 
- + + ++ ++ - 
N-1089 
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n=3 
 147 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
                                                                                                                                 
Figure 3-10 Effect of protein expression of cleaved PARP in Galectin-7 overexpressed 
b6-1089 cells following TRAIL treatment 
Western blot shows increased cleaved PARP in b6-1089 Galectin-7 overexpressed cells 
treated with TRAIL. (TRAIL + 250ng/ml TRAIL ++ 500ng/ml), indicating overexpressing 
Galectin-7 increases apoptosis in this model. 
b6-1089 
TRAIL 
Cleaved
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3.2.6 LDH cytotoxicity assay 
 
An LDH cytotoxicity assay was performed to determine the toxicity of TRAIL on 
N-1089, β6-1089 and primary myoepithelial cells. The impact of Galectin-7 on 
toxicity was also analysed, with Galectin-7 overexpressed in N-1089 and β6-1089 
and knocked down in primary MECs. A ‘maximal lysis’ well was performed for 
each cell type and conditions were all normalised to this with maximal lysis being 
set as 100% cell death. In this assay, the immortalised cell line model exhibits 
increased cell death following TRAIL treatment in cells that have higher levels of 
Galectin-7(Table 3.6 and figure 3.11). In the primary myoepithelial cells there also 
is increased cell death in the cells which have higher levels of Galectin-7 (Table 
3.7 and figure 3.12). 
 
 
3.2.6.1 LDH cytotoxicity N-1089 and β6-1089 
 
Comparison of LDH cytotoxicity in N-1089 and β6-1089 overexpressed with control or 
Galectin-7 vector. In both N-1089 and β6-1089 Galectin-7 overexpressed cells there in 
an increase in cell death following treatment with TRAIL at 250 ng/ml and TRAIL at 500 
ng/ml. Experimental results are from 3 pooled experiments.  
  
 N-1089 
Con 
N-1089 
Gal-7  
p value β6-1089 
Con 
β6--1089 
Gal-7  
p value 
0 24% 14% 2.34E-07 20% 11% 1.72E-07 
Trail 
250ng/ml 
29% 38% 0.045625 26% 32% 0.000887 
Trail 
500ng/ml 
25% 44% 2.91E-05 25% 37% 0.214413 
Table 3-6 LDH cytotoxicity in N-1089 and β6-1089 overexpressed with control or 
Galectin-7 vector following TRAIL treatment. 
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Figure 3-11 LDH cytotoxicity In N-1089 and β6-1089 overexpressed with control or 
Galectin-7 vector following TRAIL treatment. 
In N-1089 and β6-1089 there is increased cell death in Galectin-7 overexpressed cells 
following TRAIL treatment. Error bars represent standard deviation. A t-test was 
performed to assess significance (***<0.001, **<0.01, *<0.05) 
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3.2.6.2 LDH cytotoxicity in primary myoepithelial cells 
 
 
 
 
 
 
 
In primary myoepithelial cells with Galectin-7 knockdown, there was decreased 
cytotoxicity on treatment with TRAIL compared to non-targeting knockdown, 
though this was not significant with a TRAIL dose of 500 ng/ml. Experimental 
results are from 2 pooled experiments demonstrated in table 3.7 and figure 3.12.  
 n=2 
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 siRNA NTC siRNA Gal-7 p value 
0 11.2% 6.9% 9.9115E-05 
Trail 250 ng/ml  31.7% 16.2% 1.04869E-07 
Trail 500 ng/ml 42.0% 36.9% 0.524206538 
Table 3-7 Effect of Galectin-7 knockdown on cytotoxicity measured by LDH assay in 
primary myoepithelial cells following TRAIL treatment 
Figure 3-12 Effect of Galectin-7 knockdown on cytotoxicity measured by LDH assay in 
primary myoepithelial cells following TRAIL treatment 
There is decreased cell death in Galectin-7 Galectin-7 knockdown cells following TRAIL 
treatment. Error bars represent standard deviation. A T test was performed to assess 
significance (***<0.001)  
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3.2.7 Human apoptosis array 
 
A human apoptosis proteome array was used to analyse the impact of knockdown 
of Galectin-7 on a wider range of apoptosis-related proteins.  The difference in 
pixel density was assessed between non-targeting control and Galectin-7 
knockdown treated cells, and TRAIL treated versus vehicle control treated 
primary myoepithelial cells. Passage 3 myoepithelial cells were used. This 
experiment was performed in duplicate, however the knockdown of Galectin-7 
was checked following the array analysis and sufficient knockdown was not 
achieved on one occasion. The data from the population of cells in which the 
knockdown was not achieved was not further analysed.  The knockdown was 
confirmed with western blot as shown in Figure 3-13. 
 
 
 
 
 
 
 
 
 
  
Figure 3-13 Western blot confirming successful Galectin-7 knockdown in the primary 
myoepithelial cell samples used in the human apoptosis array. 
NTC GAL7 NTC GAL7 
- - + + 
Patient	1 
Gal-7 
HSC7
siRNA 
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3.2.7.1 Analysis of human apoptosis array 
 
To analyse the apoptosis array, the Image-J program was used to assess pixel 
density and comparison was made between conditions. For each protein there 
were duplicate spots. The average pixel density for each spot was used. Table 
3-3 shows the coordinates and corresponding apoptotic protein on the array.  
Figure 3.14 illustrates each membrane from the human apoptosis array. The 
average pixel density was then normalised to the siRNA non-targeting control 
exposed to vehicle only treatment. Figure 3.15 shows all apoptotic markers on 
the array on one graph these are then split into smaller graphs and described 
below. 
 
Figure 3.15 illustrates a graph which represents all the apoptotic markers on the 
array, particular apoptotic markers are shown in further detail in the graphs that 
follow. Figure 3.16 shows pro caspase 3 (an inactive form of caspase) is not 
changed by TRAIL treatment, however following TRAIL treatment there Is an 
increase in cleaved caspase-3. There appears to be minimal effect of Galectin-7 
level on apoptotic proteins however this experiment was only performed with on 
one set of primary cells. There is a large increase in catalase in the Galectin-7 
knockdown TRAIL treated cells. Catalase is a key antioxidant enzyme which 
defends against oxidative stress.  
 
Figure 3.17 shows changes in p53 levels, where all 3 p53 subunits decrease 
when cells are treated with TRAIL. There is a larger decrease in the Galectin-7 
knockdown TRAIL treated cells. 
 
 
 
 
 
  
 153 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
1 Bad 11 Fas/ TNFRSF6/CD95 21 Phospho-p53 (s15) 
2 Bax 12 HIF-1a 22 Phospho-p53 (s46) 
3 Bcl-2 13 H0-1/HM0X1/HSP32 23 Phospho-p53 (s392) 
4 Pro Caspase-3 14 H0-2/HM0X2 24 Phospho-Rad17 (s635) 
5 Cleaved Caspase-3 15 HSP27 25 SMAC, Diablo 
6 cIAP-1 16 HSP60 26 survivin 
7 Cytochrome c 17 HTRA2/0mi 27 TNF-R1/TNFRSF1A 
8 TRAIL R1/ DR4 18 PON 2 28 XIAP 
9 TRAIL R2/DR5 19 p21/ CIP1/CDKN1A * Reference spots 
10 FADD 20 P27/ Kip1   
 Figure 3-14 Apoptosis Array 
Control 
Galectin-
7 KD 
 18    19       20    21        22    23        24   25        26    27       
28 
TRAIL 
 1       2         3                4        5                  6                                     7    8       9      10     11        12    13       14    15         16              17 
* 
* * 
The table shows key 
proteins.  Number 5 cleaved 
caspase 3 shows the largest 
difference between control 
and TRAIL treated cells this 
is also shown in the western 
blot in figure 3.13. 
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Figure 3-15 Apoptosis array graph 
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Human apoptosis array normalised to siRNA non targeting control shows changes in p53 
levels: all 3 p53 subunits decrease when cells are treated with TRAIL, there is a greater 
decrease in the Galectin-7 knockdown TRAIL treated cells. 
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Figure 3-16 Human apoptosis array showing changes in caspase 3 and catalase 
Human apoptosis array normalised to si RNA non targeting control shows no change in 
Pro caspase 3 following TRAIL treatement, an increase in cleaved caspase 3 following 
TRAIL treatment and there is minimal effect from Galectin-7 knockdownThere is a large 
increase in catalalse expression compared to control cells in Galectin-7 knockdown 
TRAIL treated cells.   
Figure 3-17 Human Apoptosis array showing changes in p53 
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3.2.8 Adhesion assays- Cell Lines 
 
To establish whether Galectin-7 has an effect on adhesion of myoepithelial cells 
to the extracellular matrix two different models were used; cell lines were 
transfected with Galectin-7 while normal primary myoepithelial cells were treated 
with Galectin-7 siRNA versus non-targeting control, and adhesion to extracellular 
matrix proteins measured. Results were all normalised to BSA controls. 
N-1089 and b6-1089 cell adhesion 
In both N-1089 and b6-1089 cells transfected with Galectin-7 vector, the 
myoepithelial cells showed significantly increased adhesion to Collagen and to 
Fibronectin compared to control vector  (Figure 3.18). A decision was made tp 
used laminin was used in the primary cell model however this was performed after 
the cell line experiment and a decision was made to not repeat the cell line 
experiments. 
 
 
 
 
 
 
 
 
 
                                                                                                             n=3 
N-1089 Galectin-7 transfected cells showed 40% and 43% increased adhesion to 
Fibronectin and Collagen respectively compared to the control cells. b6-1089 Galectin-7 
transfected cells showed 61% and 42% increased adhesion to Fibronectin and Collagen 
respectively compared to the control cells. There is a significant increase in adhesion in 
Galectin-7 transfected cells. The results are from pooled data from 3 experiments, error 
bars represent the standard deviation. (p= T Test ***<0.001) 
 
Figure 3-18 Adhesion assays with N-1089 and b6-1089 cells 
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                                                                                                            n=3 
3.2.9 Adhesion assays - primary myoepithelial cells 
 
In Galectin-7 knockdown primary myoepithelial cells, the cells showed 
significantly decreased adhesion to both Fibronectin and Laminin, with 
significantly greater adhesion to Collagen (figure 3.19). Passage 2 primary 
myoepithelial cells were used. 
 
 n=3 
Figure 3-19  Adhesion assays with primary myoepithelial cells 
There is a 59% decrease in adhesion to Fibronectin in the Galectin-7 knockdown cells 
versus the control cells. Galectin-7 knockdown cells had a 21% increased adhesion 
to collagen compared to the control. In the Galectin-7 knockdown cells there is a 43% 
decrease in adhesion to Laminin compared to the control. The results were from 
pooled data from 3 experiments, error bars represent the standard deviation. (p= T 
Test ***<0.001, ** <0.01) 
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3.2.10 Immunofluorescence for P-Cadherin  
 
The effect of knocking down Galectin-7 in primary myoepithelial cells on P-
Cadherin expression or localisation at the cell-cell junction was investigated using 
immunofluorescence. Myoepithelial cells from three different patients were used 
and experiments were repeated in biological triplicate. Two images were taken 
from each cover slip on the Zeiss LSM 510 confocal microscope.  
Each image was individually assessed, and all P-Cadherin stained junctions were 
counted and divided by the number of nuclei. All the data from the 3 different 
patients and 3 different experiments were pooled into non-targeting control and 
Galectin-7 knockdown. This demonstrated that in myoepithelial cells with 
Galectin-7 knockdown there were significantly fewer P-Cadherin-positive 
junctions compared to myoepithelial cells treated with non-targeting control 
siRNA (Figure 3-20 and 3-21). The standard deviations are large, likely related to 
the use of primary patient samples with their inherent variation but results still 
remain highly significant. 
n=3 
 
 
The ratio of positive P-Cadherin junctions to number of nuclei was assessed. Primary 
myoepithelial cells treated with non-targeting siRNA had a ratio of 0.96 whilst primary 
myoepithelial cells treated with Galectin-7 siRNA had a ratio of 0.12 (p value of 0.0003). 
Data is pooled from 3 experiments. Error bars represent standard deviation. 
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Figure 3-20 Immunofluorescence analysis of P-Cadherin 
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Figure 3-21 P-Cadherin immunofluorescence images 
Immunofluorescence for P-Cadherin in primary myoepithelial cells treated either with 
non-targeting control siRNA (A,C,E,G) or with Galectin-7 siRNA (B,D,F,H). Images A&B 
represent DAPI stain, C-D indicate staining for P-Cadherin, E&F are merged images, and 
G&H are high power images.  Cells treated with Galectin-7 siRNA show less P-Cadherin 
positive cell-cell junctions compared to non-targeting control siRNA cells. 
siRNA NTC siRNA Galectin-7 
P-Cadherin positive cell-cell junctions 
A B 
C D 
E F 
G H 
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3.2.11 P-cadherin Immunohistochemistry  
 
Myoepithelial-associated P-Cadherin expression was assessed in a series of 
DCIS tissue samples, including pure DCIS or DCIS with admixed invasion. In 
normal breast ducts, the myoepithelial cells show strong staining for P-Cadherin 
Figure 3-22. This pattern of staining was maintained in some DCIS ducts but in 
others there was loss of P-Cadherin. Each case was given a global score of 
percentage of DCIS ducts positive for P-Cadherin. This showed that DCIS with 
associated invasion exhibited a greater number of ducts with loss of P-Cadherin 
staining Figure 3.23.  
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 Figure 3-22 P-Cadherin Immunohistochemistry 
P-Cadherin staining. Normal breast duct P-Cadherin positive X10 magnification (A), 
Normal breast duct P-CAD positive X 20 magnification (B), DCIS duct P-Cadherin 
positive X10 magnification (C), DCIS duct P-Cadherin positive X20 magnification (D), 
DCIS duct P-Cadherin negative X10 magnification (E), DCIS duct P-Cadherin negative 
X20 magnification (F). 
A 
C D 
B 
E F 
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Figure 3-23  P- Cadherin Immunohistochemistry analysis 
There is greater loss of P-Cadherin staining in myoepithelial cells in cases where DCIS   
was associated with an invasive component the difference between the pure DCIS and 
DCIS with associated invasion is not significant. 
 
  
0
1
2
3
4
5
6
7
8
neg 1-20%
pos
21-40%
pos
41-60%
pos
61-80%
pos
81-100%
pos
Nu
m
be
r	o
f	c
as
es
P-Cadherin	score
Pure	DCIS
DCIS	with
associated
invasion
 163 
3.2.12 Dual staining immunofluorescence- P-Cadherin with desmoglein-3  
 
As shown previously, normal primary myoepithelial cells treated with Galectin-7 
siRNA demonstrate a reduction in P-Cadherin localisation at cell-cell junctions       
( figure 3.21). Immunofluorescence dual staining has been utilised to analyse cell-
cell junctions further and the effect of Galectin-7 on these cell-cell interactions. P- 
Cadherin has been dual stained with ZO-1 and separately with desmoglein-3. 
Image J was used to quantify P-Cadherin, ZO-1 and desmoglein-3 expression.   
 
Myoepithelial cells from three different patients were used with 3 images analysed 
from each patient. This was quantified using image J assessing the intensity of 
P-Cadherin (green) and desmoglein-3 (red). There is a reduction in desmoglein-
3 expression in all 3 patients when Galectin-7 is knocked down as shown in Figure 
3-24 and Figure 3.25. There is a reduction in ZO-1 in 2 out of 3 patients in the 
Galectin-7 knock down cells (appendix 6.1), however this staining appears non-
specific and the antibody requires further optimisation.  
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Figure 3-24 Immunofluorescence dual staining for P-Cadherin and desmoglein-3 images. 
Immunofluorescence dual staining for P-Cadherin (green) and desmoglein-3 (red). 
These are representative images from 1 patient. A) Non targeting control myoepithelial 
cells and B) Galectin-7 knockdown myoepithelial cells 
A 
B 
n=1 
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Ratio of expression of desmoglein-3 and P-Cadherin non-targeting control versus 
Galectin-7 knockdown myoepithelial cells. This shows that in all 3 patients there is a 
reduction in in DSG-3 expression. In 1492 and 2357 patients there is a reduction in P-
Cadherin in the Galectin-7 knockdown cells. However, in patient 2585 there is an 
increase in P-Cadherin expression in the Galectin-7 knockdown group.  
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Figure 3-25 Dual immunofluorescence analysis P-Cadherin and desmoglein-3 
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3.2.13 Migration assays  
 
To assess if Galectin-7 has an effect on myoepithelial cell migration, the N-1089 
cell line was transfected with Galectin-7 and normal primary myoepithelial were 
transfected with Galectin-7 siRNA with appropriate controls as described 
previously. Subsequently transwell migration assays were performed in triplicate. 
 
After 6 hours incubation the number of migrating cells was determined using the 
Casy counter and this demonstrated a difference in migration of the N-1089 cells 
transfected with Galectin-7 to Collagen and Fibronectin compared to vector 
control, with a mean migration to Collagen of 33.3% and 43.9% for vector control 
cells and Galectin-7 respectively (p=0.0021; Figure 3.26). Similarly, control vector 
cells and Galectin-7 cells had a mean migration of 35.7% and 46.5% to 
fibronectin, respectively (p=0.027; Figure 3-26).  
 
Experiments knocking down Galectin-7 in primary myoepithelial cells indicate that 
Galectin-7 had a similar effect on primary cell migration as it does in the cell lines. 
Non-targeting control siRNA cells and Galectin-7 knockdown cells had a mean 
migration of 38.2% and 27.7% to Collagen respectively. Non-targeting control 
cells and Galectin-7 knockdown cells had a mean migration of 60.4% and 48.2% 
to Fibronectin respectively, and a mean migration of 40.3% and 58.1% to Laminin 
respectively (figure 3.27). Experiments were performed in technical triplicates, 
however biological repeats were not performed due to the high cell number 
required and the finite resource of passage 2 primary myoepithelial cells. While 
these results were not significant (due to the low number of repeats) the observed 
trend is the Galectin-7 knockdown cells are less migratory to Collagen and 
Fibronectin and more migratory to Laminin. This would need to be repeated to 
assess if the results are significant.  
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Cell lines 
 
 n=3 
 
 
Transwell migrations assays. The graphs show the mean migration expressed as 
percentage of total cells migrated over a 6 hour time period. N-1089 cells transfected 
with non-targeting control and Galectin-7 vectors. The migration to collagen increased by 
10.6% in the Galectin-7 transfected cells vs control cells. The migration to fibronectin 
increased by 10.8% in the Galectin-7 transfected cells vs control cells. The data was 
pooled from 3 experiments, error bars show standard deviation. 
  
  
0
10
20
30
40
50
60
BSA Coll FN
%
	of
	to
ta
l	c
ell
s	w
hi
ch
	m
igr
at
ed
Control Galectin-7
Figure 3-26 Migration assay with N-1089 cells 
*** ** 
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Primary cells 
 
 n=1 
 
 
Transwell migrations assays. Passage 2 primary myoepithelial cells with Galectin-7 
knockdown had an 11% reduction in migration to collagen compared to non-targeting 
control and 12% reduction in migration to fibronectin Galectin-7 knockdown cells had an 
18% increased migration to laminin compared to non-targeting control cells. Difference 
were not statistically significant; error bars indicate standard deviation. 
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Figure 3-27 Migration assay with primary myoepithelial cells 
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3.2.14 Effect of Galectin-7 siRNA on myoepithelial cell migration 
 
Scratch assays were used to assess the effect of knocking down Galectin-7 in 
primary myoepithelial cells on cell migration. Passage 2 primary myoepithelial 
cells were used from patient 1989. Pictures were taken at 0,10,12,and 14 hours, 
Image J was used to compare the closure between primary myoepithelial cells 
treated with non-targeting control siRNA or Galectin-7 siRNA. Galectin-7 siRNA 
decreased the rate of myoepithelial cell migration compared to non-targeting 
control siRNA at 16 hours with the percentage closure 46.3% versus 20.7% for 
siRNA non-targeting control and siRNA to Galectin-7 respectively (p=0.03; Figure 
3-28). Closure at 10 and 12 hours showed no significant difference.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 3-28 Scratch Assay images 
Representative images of Scratch assay 
siRNA	NTC siRNA	Galectin-7	 
0	Hours 
10	Hours 
12	Hours 
16	Hours 
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Images at 10 and 12 hours showed a decrease in myoepithelial cell migration in the 
Galectin-7 knockdown cells however this did not reach statistical significance (p=0.27 
and p=0.29 respectively). At 16 hours the difference did reach significance (p=0.03). 
Representative results are from 3 combined experiments (n=3). T Test was used to 
calculate p values, error bars represent standard deviation. 
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3.2.15 Invasion assays 
 
To assess if myoepithelial Galectin-7 has an effect on breast cancer cell invasion, 
conditioned media (CM) from the primary myoepithelial cells transfected with non-
targeting control or Galectin-7 siRNA was added to MDA-MB-231 cells in 
transwell invasion assays. The MDA-MB-231 cells incubated with CM from 
Galectin-7 knockdown cells showed 54% less invasion compared to MDA-MB-
231 cells treated with CM from non-targeting control cells (figure 3.30). The 
results were pooled from 3 experiments.  
 
 
 n=3 
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Figure 3-30 Invasion assay analysis with primary myoepithelial cells. 
Invasion assay shows 54% reduction in invasion of MDA-MB-231 incubated with 
conditioned media from Galectin-7 knockdown primary myoepithelial cells compared to  
MDA-MB-231 incubated with conditioned media from non-targeting control primary 
myoepithelial cells . T Test was used to calculate p values ( <0/001), error bars represent 
standard deviation 
*** 
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3.2.16 Protease array 
 
The protease array as described in 3.1.17 was used to assess the effect of 
myoepithelial cell Galectin-7 on expression of a range of proteases. Conditioned 
media was collected from primary myoepithelial cells treated either with Galectin-
7 siRNA or non-targeting control siRNA from 4 different patients. The conditioned 
media was concentrated as described previously and applied to the protease 
array membrane. The pixel density of each of the protease array spots was 
calculated with Image J. The difference in pixel density was calculated by 
subtracting mean pixel density of Galectin-7 siRNA conditioned media from the 
mean pixel density with the non-targeting control conditioned media. This was 
done for each individual primary myoepithelial cell sample, therefore each patient 
sample (1492,1989,2357 and 2585) are represented by an individual bar  
 
Figure 3-33 represents the changes in concentration of MMP expression on the 
protease array. A positive result indicates higher levels of MMP in the non-
targeting control conditioned media and a negative result indicates higher level of 
MMP in the Galectin-7 knockdown conditioned media. The non-targeting control 
conditioned media had a higher concentration of MMP-1, MMP-3, MMP-9, MMP-
10, MMP-12 AND MMP-13 compared to the Galectin-7 knockdown conditioned 
media across all 4 patients. MMP-7 showed the largest difference of all the MMPs 
in 3 out of the 4 patient samples with higher levels in the non-targeting control 
conditioned media. Indicating in this model when cells have higher levels of 
Galectin-7 there is an increase in MMP-7 in the conditioned media. 
 
Figure 3-34 shows higher levels in Kallikreins in control conditioned media: 
Kallikrein 5 and Kallikrein 10 showed the largest difference with increased 
concentration in control conditioned media versus Galectin-7 knockdown 
conditioned media across all 4 patient samples. 
 
Figure 3-35 shows higher levels of Cathespins in the non-targeting control 
conditioned media compared to Galectin-7 knockdown conditioned media across 
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all 4 patients, with the highest level in cathepsin B, D, V and X/Z/P. Cathespin B 
is involved in matrix degradation and cell invasion, high levels of cathepsin D in 
tumour cells is associated with increased invasion it cleaves fibronectin and 
laminin. Cathespin V has a role in fibronectin degradation. 
 
Figure 3-36 shows levels of uPA/urokinase in control versus Galectin-7 
knockdown cells. In 3 out of 4 patients samples there are higher levels of uPa 
/urokinase in control conditioned media versus the Galectin-7 knockdown 
conditioned media. Urokinase is present in the extracellular matrix, this is a 
plasminogen activator and can subsequently lead to degradation of extracellular 
matrix and tumour cell migration. 
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Figure 3-31 Protease Array picture 
1. Cathepsin A 
2. Cathepsin B 
3. Cathepsin C 
4. Cathepsin D 
5. Cathepsin V 
6. Cathepsin X/Z/P 
7. Kallikrein 3/PSA 
8. Kallikrein 5 
9. Kallikrein 6 
10.Kallikrein 10 
11.MMP 2 
12.MMP 7 
13.MMP 9 
14.Proprotein 
Convertase 9 
15.uPA/Urokinase 
* Reference spots 
1492 
1989 
2357 
2585 
Control Galectin-7 KD 
Individual protease arrays 
from 4 different patient 
samples with control and 
Galectin-7 knockdown. Key 
proteases highlighted and 
listed. 
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A graph to show all proteases, each patient is represented by an individual colour, Bars represent mean pixel density of the control 
conditioned media (CM) minus the mean pixel density of Galectin-7 knockdown conditioned media.
Figure 3-32 Protease array graph of all markers 
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Bars represent mean pixel density of the control conditioned media (CM) minus the mean 
pixel density of Galectin-7 knockdown conditioned media. This, a positive bar represents 
higher levels in the control CM with a negative bar indicating higher levels in the Galectin-
7 knockdown CM. The control conditioned media had higher levels of MMP-1, MMP-3, 
MMP-9, MMP-10, MMP-12 and MMP-13 compared to the Galectin-7 knockdown 
conditioned media. MMP-7 showed the largest difference of all the MMPs in 3 out of the 
4 patient samples with higher levels in the control conditioned media.  
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Figure 3-33 Protease array: MMP levels.  
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Kallikrein 5 and Kallikrein 10 showed the largest difference with increased levels in 
control conditioned media versus Galectin-7 knockdown conditioned media across all 4 
patient samples.  
 
 
 
 
The largest differences were increased levels in the control conditioned media in 
cathepsin B, D, V and X/Z/P compared to Galectin-7 knockdown CM. 
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Figure 3-34 Protease array: Kallikreins levels. 
Figure 3-35 Protease array: Cathepsin levels. 
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uPa /urokinase showed a large difference across 3 patient samples with higher levels in 
control conditioned media versus the Galectin-7 knockdown condition media. 
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Figure 3-36 Protease array: uPa /urokinase levels. 
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3.2.17 Organotypic Co-Culture Assays  
3.2.17.1 Organotypic cultures with primary myoepithelial cells 
 
Organotypic co-culture assays were performed to assess the role of Galectin-7 
further using a 3D model rather than 2D. This was performed with both the primary 
myoepithelial cells and the N-1089 myoepithelial cell line.  Immunofluorescence 
was utilised to assess P-Cadherin in these models as an important cell junction 
marker.  Primary myoepithelial cells are particularly sensitive to changes in 
conditions and this assay was performed many times in an attempt to optimise 
the experiment. Figure 3-37 shows representative images of the primary 
myoepithelial cell organotypic cultures treated either with Galectin-7 siRNA or 
non-targeting control. The cultures containing non-targeting control myoepithelial 
cells had more surviving cells indicated by DAPI and this also showed higher 
levels of P-Cadherin although this may be due to the higher cell number (Figure 
3-37). Figure 3-38 is an image of positive control for P-Cadherin using tonsil 
tissue. 
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                siRNA Control                             siRNA Galectin-7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organotypic cultures with primary myoepithelial cells treated with either non-targeting 
control siRNA or Galectin-7 siRNA and stained with P-Cadherin. This shows increased 
P-Cadherin and number of cells in the control siRNA model. MDA MB 231 breast cancer 
cells were seeded on day 1.  
 
. 
 
 
 
 
Figure 3-37 Primary Cell Organotypic Cultures. 
 
 
 
Figure 3-38 Positive control for P-Cadherin immunofluorescence 
Tonsil tissue was used as positive control for P-Cadherin  
DAPI 
P-Cadherin 
Merg
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3.2.17.2 Organotypic cultures with N 1089 myoepithelial cell line 
 
The myoepithelial cell line N-1089 was transfected with Galectin-7 vector or 
control vector and co-cultured with MDA MB 231 cells. In this model the cultures 
with vector control myoepithelial cells (with lower levels of Galectin-7) exhibit less 
P-Cadherin staining (Figure 3-39).  
                     Control                                    Galectin-7  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There is no evidence of invasion of the MDA-MB-231 cells in either the primary 
myoepithelial cell model or the N-1089 model. 
 
 
Figure 3-39 Organotypic culture assays with N 1089 myoepithelial cells. 
Organotypics with the N-1089 cell transfected with either control plasmid or Galectin-7 
plasmid. Sections were stained with P-Cadherin as an assessment of cell-cell adhesion. 
MDA MB 231 breast cancer cells were seeded on day 1. There appears to be more P-
Cadherin in the  control vector cultures that those over-expressing Galectin-7. 
DAPI 
P-Cadherin 
Merge 
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3.3 Discussion 
 
3.3.1 Myoepithelial cell models 
 
In tissues, normal myoepithelial cells express high levels of Galectin-7 with 
variable loss in DCIS-associated myoepithelial cells. In our laboratory, we have 
generated cell lines that represent normal (N-1089) and DCIS-altered (b6-1089) 
myoepithelial cells. These cell lines, together with primary normal myoepithelial 
cells were used in a series of experiments to explore the functional impact of loss 
of Galectin-7 in DCIS.  
 
It is essential to characterise any cell population that is being used for in-vitro 
experiments. Both the myoepithelial cell lines and the primary myoepithelial cells 
were characterised for expression of a series of myoepithelial and luminal-
associated markers. This demonstrated that primary myoepithelial cells had 
phenotypes consistent with normal myoepithelial cells, however, the cell lines 
show a drift in phenotype with loss of some myoepithelial cell markers. 
 
Established cell lines are either transformed or immortalised, allowing them to be 
grown for prolonged periods in vitro. A major advantage is that cell lines can be 
readily expanded providing ample cells for experiments ,and experimental results 
are more reproducible, since they employ a homogeneous cell population. 
However, this is not necessarily representative of the heterogeneity that is evident 
in patient samples and in clinical practice. It is extremely important to consider 
these factors when interpreting data from experiments both with primary cells and 
cell lines. Cell lines are prone to genotypic and phenotypic drift during their 
continual culture (Burdall, Hanby, Lansdown, & Speirs, 2003). This was 
highlighted by Osborne and colleagues (Osborne, Hobbs, & Trent, 1987), who 
demonstrated many discrepancies in the most commonly used breast cancer cell 
line, namely MCF-7, obtained from different laboratories. Many commonly used 
breast cancer cell lines are derived from metastasis for example pleural effusion 
in MCF-7 rather than breast tumour its self (Burdall et al., 2003). 
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Primary cells are a finite resource and a limited number of passages are possible 
prior to the cells losing their phenotype. The primary myoepithelial cells used in 
this project were often grown up to passage 3. Some experiments were performed 
with passage 2 myoepithelial cells, which are an even more finite recourse. 
Despite these limitations, the primary cells are considered a strength since they 
more accurately reflect the in-vivo situation. 
 
Neither of the myoepithelial cell lines was found to express Galectin-7. However, 
the primary myoepithelial cells retained strong expression. To gain an 
understanding of the biological role of myoepithelial cell Galectin-7, Galectin-7 
was knocked down in the primary cells and was overexpressed in the cell line 
model. 
 
3.3.2 Galectin-7 in apoptosis 
 
Galectin-7 has previously been reported to play a role in apoptosis (Demers et 
al., 2010), therefore the effect of altered expression in myoepithelial cells on 
apoptosis was investigated. Tumour necrosis factor related apoptosis-induced 
ligand (TRAIL) is a pro-apoptotic ligand, which is expressed by peripheral T 
lymphocytes (Salehi et al., 2007) including CD4+ve T cells (Sato et al., 2006). 
DCIS is frequently associated with a periductal immune infiltrate including 
CD4+ve T cells (M. J. Campbell et al., 2017), therefore, it is plausible that DCIS-
associated myoepithelial cells could be physiologically exposed to TRAIL, so 
TRAIL was used as the pro-apoptotic stimulus in this study. The knockdown of 
Galectin-7 in primary myoepithelial cells led to enhanced apoptosis on exposure 
to TRAIL, suggesting that Galectin-7 has an anti-apoptotic role in normal primary 
myoepithelial cells. However, overexpressing Galectin-7 in both N-1089 and b6-
1089 cells led to an increase in apoptosis, as measured by cleaved PARP and 
cleaved caspase 3. These results appear to directly contradict the findings in the 
primary cell model and may reflect limitations of the immortalisation process. In 
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the immortalisation of N-1089 and b6-1089, SV40 large T antigen was used to 
inactivate the tumour suppressor proteins p53 and Rb, both of which must be 
inactivated in order for human cells to circumvent cell cycle arrest/apoptosis 
(Shay, Braester, & Cohen, 1991). Since Galectin-7 is a p53 induced gene, this 
may be why the N-1089 cells do not endogenously express Galectin-7. Therefore, 
the immortalised myoepithelial cell lines, which are available to us, are not an 
ideal model in which to investigate Galectin-7 function. Using cell lines to 
determine the role of Galectin-7 would not be representative of what is happening 
in vivo. The cell lines show increased apoptosis with increased Galectin-7 levels, 
in keeping with Labrie et al, who found overexpression of Galectin-7 sensitised 
DU-145 prostate cancer cells to apoptosis induced by cisplatin (Labrie et al., 
2014). To date, work relating to Galectin-7 in the breast has mainly focused on 
invasive breast carcinoma. Breast cancer cells expressing high levels of Galectin-
7 in the epithelial cells, have an increased ability to metastasise to lungs and 
bone. Examination of normal and malignant human breast tissue indicated 
Galectin-7 is expressed in an aggressive breast carcinoma subtype. High levels 
of Galectin-7 in breast cancer cells render them more resistant to apoptosis, and 
they metastasise earlier (Demers et al., 2010). It is very possible that Galectin-7 
will behave differently in non-malignant cells and given previous discussion it is 
likely that the primary myoepithelial cells used in these experiments are more 
representative of the in-vivo situation and should be a gold standard for future 
work investigating the role of apoptosis in myoepithelial cell loss. 
 
These results suggest that primary myoepithelial cells that have higher levels of 
Galectin-7 are more resistant to apoptosis. Man et al., have hypothesised that in 
DCIS progression myoepithelial cells are lost through apoptosis (Man et al, 2007). 
This data supports the theory that Galectin-7 positivity is a good prognostic sign 
in DCIS, potentially retaining the myoepithelial cells by preventing their loss 
through apoptosis.  
 
To assess more global effects of Galectin-7, an apoptosis marker proteome 
profiler was used to analyse myoepithelial cells with and without TRAIL treatment. 
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Primary myoepithelial cells from 1 patient were treated either non targeting control 
siRNA or Galectin-7 siRNA and treated with TRAIL or vehicle only after 48 hours. 
While using a single sample  this might be acceptable with a cell line, given the 
heterogeneity of primary cells, performing this with samples of more than one 
patient would have been beneficial, however a decision had already been made 
to investigate other areas of Galectin-7 function and myoepithelial cells were 
limited. There was an increase in cleaved caspase-3 in myoepithelial cells 
following TRAIL treatment, though the effect of change in Galcetin-7 expression 
was minimal with both control and knockdown myoepithelial cells exhibiting 
similar effects. However, there was a large increase in catalase levels in the 
Galectin-7 knockdown TRAIL treated cells.  
 
Catalase is a key antioxidant enzyme which defends against oxidative stress. 
When cells are exposed to hypoxia there is an increase in reactive oxidative 
species (ROS). Superoxide dismutases (SODs) are important antioxidant 
enzymes against reactive oxidant species. The extracellular superoxide 
dismutase (EC-SOD) is present in the extracellular matrix. Lee et all investigated 
the role of EC-SOD in the skin using mouse models assessing proteins that were 
differentially expressed between EC-SOD transgenic mouse and an EC-SOD wild 
type mouse; Galectin-7 was one of these proteins (J. S. Lee et al., 2012). This 
study showed the EC-SOD transgenic mouse model had a thinner epidermis than 
the wild type mouse model. This was due to increased apoptosis in the transgenic 
model; the transgenic model had higher levels of Galectin-7 (J. S. Lee et al., 
2012). Increases in catalase in the TRAIL treated Galectin-7 knockdown cells 
could potentially indicate that the loss of Galectin-7 increases oxidative stress, 
resulting in an increase in catalase.  
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This diagram hypothesises from the findings of apoptosis array, in myoepithelial cells that have 
Galectin-7 knocked down there is an increase in oxidative stress and production of reactive 
oxidative species (ROS)following TRAIL treatment as a result of this there may either be cell 
damage or extracellular superoxide dismutase (EC SOD) acts as an important antioxidant defence 
mechanism with free oxygen radicals being transformed into hydrogen peroxide which in itself can 
be damaging to cells. Catalase is a second antioxidant enzyme that is recruited to convert 
hydrogen peroxide to water and oxygen. 
 
To further investigate the role of myoepithelial Galectin-7 in apoptosis, utilising a 
3D primary cell model system would be beneficial, to include other components 
of the microenvironment such as fibroblasts and extracellular matrix. 
 
 
 
 
 
Figure 3-40 Schematic diagram showing the actions and mechanisms of catalase and 
EC SOD. 
Decrease in Galectin-7 
Increase in oxidative stress 
(ROS) 
TRAIL treatment 
H2O2 
H2O + O2 
EC SOD 
Catalase 
Cell damage 
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3.3.3 Adhesion and migration 
 
A major role of myoepithelial cell function is to form the interface with the stromal 
compartment, where they form stable adhesion with each other and with the 
basement membrane. It is hypothesised that destabilisation of the myoepithelial-
basement membrane interface would involve changes in the adhesive and 
migratory capacity of myoepithelial cells, and these changes may influence 
tumour cell invasion. In N-1089 and b6-1089 cell lines, overexpression of 
Galectin-7 resulted in increased adhesion to fibronectin and collagen I. In primary 
myoepithelial cells, knockdown of Galectin-7 resulted in decreased adhesion to 
fibronectin and laminin but increased adhesion to collagen I. Again, the results 
between the cell lines and primary cells are contradictory, but the primary cells 
are likely to be more representative. The basement membrane is rich in laminin, 
whilst collagen I is the major component of the interstitial matrix. The change in 
adhesion exhibited by Galectin-7 knockdown cells could indicate that Galectin-7 
negative myoepithelial cells have preferential binding to the interstitial matrix. Not 
only would this destabilise the myoepithelial-basement membrane junction, it 
could also suggest that myoepithelial cells form a leading invasive ‘channel’ for 
tumour cells to invade the surrounding stroma. In keeping with this hypothesis, 
Erik Sahai et al., have shown the importance of the role that stromal cells play in 
invasion. Cancer associated fibroblasts support cancer invasion creating tracks 
through which cancer cells migrate (Labernadie et al., 2017). Real time imaging 
has been used with co-cultures of carcinoma cells and stromal fibroblasts, 
demonstrating fibroblasts are always the leading cells of invasion in this model. 
Carcinoma cells move within tracks in the extracellular matrix behind the 
fibroblasts. Real time imaging would be useful in a DCIS model to investigate the 
interaction between the myoepithelial cells and fibroblasts (Gaggioli et al., 2007).  
These adhesion assays suggest that Galectin-7 promotes a more stable to 
basement membrane related proteins, and thus contributes to the integrity of the 
myoepithelial- basement membrane barrier.  
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The immunohistochemical assessment of P-Cadherin in the DCIS tissue samples 
supports this theory; for DCIS with associated invasion there is associated loss 
of myoepithelial cell P-Cadherin, in association with loss of Galectin-7. 
Furthermore, knockdown of Galectin-7 in primary myoepithelial cells leads to 
reduced cell-cell localisation of P-Cadherin, supporting a relationship between 
Galectin-7 and cell-cell adhesion, and the integrity of the myoepithelial interface. 
Paredes et al., showed that P Cadherin was associated with high nuclear grade 
and ER negativity (Paredes, Milanezi, Viegas, Amendoeira, & Schmitt, 2002). The 
loss of P-Cadherin in DCIS progression has not previously been published.  
 
Scratch assays were undertaken to assess the effect of Galectin-7 on primary 
myoepithelial cell migration. Cancer cell migration shows many similarities to the 
migration seen in wound healing. The role of Galectin-7 in wound healing has 
been investigated using mouse models. Coa et al., demonstrated upregulation of 
Galectin-7 in response to corneal injury (Cao et al., 2003). Another study by 
Gendronneau et al. using Galectin-7 +/+ and -/- mouse models, investigated 
healing from superficial scratches made on the tails. They showed that wound 
healing was less efficient in the Galectin-7 -/- mouse (Gendronneau et al., 2008). 
In the current study, the migration assays show that primary myoepithelial cells 
with Galectin-7 knockdown migrate less on collagen and fibronectin but show 
increased migration on laminin. This is consistent with the adhesion assay results. 
Myoepithelial cells normally exhibit strong adhesion to laminin through a6b4 in 
hemidesmosomes. However, in would healing models using keratinocytes, it has 
been shown that a6b4 translocates from hemidesmosomes to focal contacts and 
mediates migration on laminin (Ozawa et al., 2010). Loss of hemidesmosomes 
has previously been reported in DCIS (Bergerstrasser et al). Further studies are 
warranted to establish whether hemidesmosome integrity is modulated by 
Galectin-7. 
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3.3.4 Protease arrays 
 
One of the ways in which myoepithelial cells can modulate its microenvironment 
is through the release of proteolytic enzymes. Up-regulation of avb6 in 
myoepithelial cells leads to TGF-b-dependent up-regulation of MMP-9. To 
determine whether Galectin-7 influences the proteolytic activity of myoepithelial 
cells, conditioned media from primary myoepithelial cells with or without 
knockdown of Galectin-7 was placed onto protease arrays. This demonstrates 
that knockdown of Galectin-7 in primary myoepithelial cells appears to lead to 
down-regulation of a series of proteolytic enzymes, including key MMPs, uPa, and 
cathepsins. This would appear to suggest that Galectin-7 negative myoepithelial 
cells exhibit an anti-proteolytic phenotype, which seems counterintuitive for a 
phenotype associated with more progression to invasion. Validation of these 
results using different approaches, for example qPCR or zymographgy would be 
important.  
 
Previous work in the lab has indicated that DCIS-associated myoepithelial cells 
both in-vitro and in tissue studies exhibit elevated levels of MMP-9, and this is 
critical to their pro-tumourigenic properties. The myoepithelial cells in the studies 
performed in this thesis were avb6-negative. It may be that both acquisition of 
avb6 and loss of Galectin-7 are required for the full pro-tumorigenic phenotype. 
This would support the notion that the development of a risk stratification DCIS 
tool would involve a number of markers. 
 
3.3.5 Organotypic co-culture assays 
 
Organotypic cultures represent an alternative method of investigating the role of 
myoepithelial Galectin-7 and has the advantage of including other important 
components of the tumour microenvironment. In the primary cell organotypic 
culture there are less cells in the Galectin-7 knockdown group compared to the 
non-targeting control, and also lower levels of P-Cadherin expression, though this 
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was not formally quantified. There may be less cells as myoepithelial cells with 
lower levels of Galectin-7 are less adherent and could therefore be lost in the 
assay, however this is speculative and further work is needed to assess if this is 
significant. Primary myoepithelial cells are extremely sensitive to culture 
conditions, therefore less cells survive than in the cell line model. For this reason, 
due to the 14 days required to culture the model, this may have affected the 
primary myoepithelial cell survival. Invasion of MDA-MB-231 cells was not seen 
which is unusual in this model system and suggests that the cultures were not 
fully optimised. Unfortunately, lack of time precluded any further work on these 
systems. For future work, the use of primary fibroblasts should be considered, 
particularly from the same patient as the primary myoepithelial cell population, as 
appropriate cross-talk between the cells may be required to achieve tumour cell 
invasion. 
 
In conclusion, this series of functional studies has indicated that primary 
myoepithelial cells are a more physiologically relevant model than the 
myoepithelial cell lines. These show enhanced apoptosis, increased catalase 
expression and reduced adhesion to laminin with increased adhesion to collagen 
I when Galectin-7 is knocked down. In Galectin-7 positive DCIS the myoepithelial 
cells may be protected from loss by the anti-apoptotic role of Galectin-7 and the 
increased adhesion to laminin. 
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4 Global Analysis of Effect of Galectin-7 on 
Myoepithelial Cells using RNA sequencing 
 
4.1 Materials and methods 
4.1.1 Patient Selection 
 
Normal primary myoepithelial cells isolated from reduction mammoplasty were 
used from four different patients.  The sample IDs were 127, 1492, 2858, and 
2357.  The cells were seeded on collagen-coated 6 well plates in HuMec Medium 
(see section 3.1.5). When they reached 60% confluency, siRNA treatments for 
non-targeting control and Galectin-7 was added as per method 3.1.7. After 48 
hours cells were typsinised and centrifuged at 1200rpm for 3 minutes. 
 
4.1.2 RNA extraction 
 
RNA was extracted from the cell pellets using the RNeasy Plus Mini kit (QIAGEN, 
74136) using a slight modification of the manufacturer’s protocol. The pelleted 
cells were re-suspended and lysed using 600 µl buffer RLT Plus plus 10 µl β-
mercaptoethanol per 1ml buffer, followed by vigorous vortexing. The lysate was 
transferred to a gDNA Eliminator spin column, placed in a 2ml collection tube, 
and centrifuged for 60 seconds at 10,000 rpm (8000g). 1 volume (600 µl) of 70 % 
ETOH was added to the column eluate, mixed thoroughly by pipetting and 
transferred to an RNeasy spin column, placed in a 2 ml collection tube and 
centrifuged for 15 seconds at 10,000 rpm. The column was transferred to a new 
2ml collection tube and 700 µl Buffer RW1 was added to the RNeasy column 
(which was gently inverted a couple of times to ensure thorough mixing) and 
centrifuged as above to wash the column. This procedure was repeated using 
500 µl buffer RPE, the column was placed in a fresh 2ml collection tube and 
centrifuged at 10000 rpm. The spin column was transferred to a new 2 ml 
collection tube and, with the lid open, centrifuged at full speed for 2 minutes. The 
spin column was placed in a new 1.5 ml collection tube. 35µl of warmed RNase -
free water was then added directly to the centre of the silica gel membrane in the 
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spin column. The samples were left to sit at room temperature for 5 minutes and 
then centrifuged at 10000 rpm for 60 seconds to recover the RNA. Eluted RNA 
was placed immediately on wet ice to allow for aliquots to be taken for QC. Stock 
RNA was then stored at -80C. RNA concentration was quantified using the Qubit 
® Fluorometer in conjunction with the Qubit ® RNA HS (High Sensitivity) Assay 
Kit. Sample purity was measured by A260 spectrophotometry using the 
Nanodrop. RNA integrity was ascertained using the Agilent 2100 Bioanalyser 
(Agilent Technologies) in coordination with RNA 6000 Pico Kit (Agilent 
Technologies)  
 
4.1.3 Bioinformatics Analysis 
 
Bioinformatics analysis was performed by Dr E Gadaleta, Dr A Nagano and 
Professor C Chelala, Bioinformatics Group, Centre for Molecular Oncology, Barts 
Cancer Institute, London, UK. Raw data reads were aligned uniquely on the hg38 
gene feature. The percentage of reads used for gene quantification was ~60%. 
The samples were sent in 2 separate batches and common differential gene 
expression was analysed across both batches. 
 
4.1.4 Validation of RNA sequencing 
 
In order to validate the results from the RNA sequencing data a combination of 
immunohistochemistry and qPCR was performed. The most relevant genes and 
those having the most translational promise with regards to the role of the 
myoepithelial cells in DCIS progression were selected. 
 
The immunohistochemistry analysis of LOX was undertaken on the DCIS patient 
cohort.  The LOX antibody was optimised and then used in patient samples, each 
patient sample was stained twice with the same antibody. This is not discussed 
in the main body of the thesis as the results have wide variance in the same case 
therefore it was decided these data could not be reliably interpreted . LOX is an 
important protein to investigate further and this work will be continued. 
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The technique of qPCR was used to validate 3 genes that were upregulated and 
3 genes that were downregulated in Galectin-7 knockdown myoepithelial cells. 
The same 4 patients were used. 
 
4.1.5 qPCR-Isolation of RNA 
 
Residual RNA from the same samples that were submitted for RNA sequencing 
were used for validation and extracted as previously described (4.2).  
 
4.1.6 qPCR- Synthesis of cDNA 
 
cDNA was obtained by reverse transcription (RT). To initiate RT, 1μL of 50ng/μL 
hexanucleotide primers (Sigma, H0268) and 1μL of 10 mM deoxynucleotide 
(dNTPs, Sigma, GE28-4065-57) are added to 1μL of 50ng mRNA with 7μL of 
nuclease-free dH2O (HyClone, SH30538.02) to give a total volume of 10μL per 
reaction. The reaction was performed with the following conditions: 70oC for 10 
minutes, followed by 4oC for 5 minutes in a Mastercycler Polymerase Chain 
Reaction (PCR) system (Eppendorf). To synthesise cDNA from the RNA-DNA 
hybrid by polymerisation, 1μL of Moloney-murine leukaemia virus (M-MLV) 
reverse transcriptase enzyme and 2μL of M-MLV buffer (Sigma, M1302) was 
added to the initial reaction mix with 7μL of nuclease-free deionized water to give 
a final volume of 20μL per reaction. The reaction was performed with the following 
conditions: 22oC for 10 minutes, 37oC for 50 minutes and 90oC for 10 min. cDNA 
was kept at 4oC until required. 
 
4.1.7 qPCR 
 
Taqman primers were used for 6 genes to validate the RNA sequencing work. 
The primers used were from Thermo Fisher and the selected genes were: NT5E 
(ref Hs00159686_m1), CDH11 (ref Hs00901473_g1), LOX (ref 
Hs00942480_m1), GPER1 (ref Hs01922715_s1), PDGFD (refHs00228671_m1), 
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MAP3K12 (ref Hs00951240_m1). For housekeeping 18S Primers were used (ref 
Hs03003631_g1). A typical reaction was as follows; 10 ul of TaqMan Master Mix 
20x (4331182), 1ul Taqman Primer/Probe (FAM), 1ul Housekeeping 
Primer/Probe (VIC), 7ul dH2O, 1ul cDNA. Each reaction was performed in 
triplicate. The mixture with the relevant taqman probe and cDNA for control and 
Galectin -7 knockdown from 4 different patients were added to a 96 well plate. A 
‘no template’ control was also set up to check for contamination.   
 
The change in gene expression was then calculated by the change in cycle 
threshold (dCT), determined by subtracting the average CT for the reference gene 
(18S) from the average CT of the target gene. The change in dCT of control 
samples was then subtracted from the change in dCT of the Galectin-7 
knockdown samples (ddCT), this value was then introduced to the formula 2-ddCt 
to give the relative expression, where a value of 1 is no change, higher than 1 is 
up-regulation and less than 1 is down-regulation of a gene. 
 
 
 
4.1.8 Immunohistochemistry validation of GPER and NT5E  
 
For validation of the RNA sequencing results immunohistochemistry was also 
used, with tonsil tissue used for optimisation. The method used was the same as 
the method described in section 2.1. Sections were heated at 60°C for 10 
minutes, and incubated serially in xylene (Fisher Scientific, X5-1) for 2 x 5 minutes 
then in decreasing alcohol dilutions and dH2O after which endogenous peroxidase 
was blocked with a 10-minute incubation in 100% methanol/0.9% hydrogen 
peroxide. Antigen retrieval was performed using boiling citrate buffer at pH 6.0 for 
8 minutes. Sections were blocked with appropriate serum (depending on the 
secondary antibody used) and 3% BSA/PBS, for 15 minutes, then GPER 
(Cambridge bioscience HPA027052) or NT5E (Cambridge bioscience 
HPA02705217357) primary antibodies were applied. The incubation for all 
primary antibodies was 4oC overnight as this gave optimal results.  
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Following incubation, sections were then washed with PBS in triplicate followed 
by incubation with the rabbit secondary antibody at room temperature for 40 
minutes. The sections were then washed again in triplicate followed by incubation 
with an avidin-biotin peroxidase complex (ABC) reagent (Vectastatin ABC Kit, 
Vecor Laboratories PK Rabbit 6101,) for 30 minutes at room temperature. 
Sections were washed again in triplicate with PBS before developing using a DAB 
kit (Vectastain, Vector Laboratories SK 4100) and then counterstained with 
Haematoxylin for 2 minutes (Sigma, MHS16). The sections were washed with tap 
water and dehydrated through graded alcohols and xylene, and mounted with 
DPX (Sigma, 06522) and glass cover slips. 
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4.2 Results 
4.2.1 Analysis of gene expression 
 
14401 genes were filtered to show differential expression analysis. A principle 
component analysis (PCA) plot was constructed to visualise the difference in 
gene expression between patients, and between control and knockdown of 
Galectin-7. 
 
 
 
 
PCA plot shows the overall gene expression of the four patient samples with control 
(orange) and Galectin-7 knock down (green) treatment. The plot shows heterogeneity in 
baseline gene expression between patients. Each circle contains samples from individual 
patients.  
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Figure 4-1 PCA plot 
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The RNA sequencing was sent in 2 batches therefore 2 heat maps were 
constructed (figure 4.2 and 4.3) The left 2 columns (orange) represent non-
targeting control and the right 2 columns (blue) represent Galectin-7 knockdown 
(blue).  
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Figure 4-2 Batch 1 heat map 
Batch 1 heat map showing differential expression in 417 genes,  184 genes were 
upregulated in  Gal7 knockdown cells; 233  genes were upregulated in  Ctrl cell. LGALS7 
(Galactin-7) is confirmed as down-regulated in Gal7 samples. Orange represents non-
targeting control and blue represents Galectin-7 knockdown.  
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Figure 4-3 Batch 2 heat map 
Batch 2 heat map showing differential expression in 109 genes,  35 genes were 
upregulated in  Gal7 knockdown cells; 74  genes were upregulated in  Ctrl cells. 
LGALS7 (Galactin-7) is confirmed as down-regulated in Gal7 samples.  Orange 
represents non-targeting control and blue represents Galectin-7 knockdown. 
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A Venn diagram (figure 4.4) was used to demonstrate the cross-over between 
patients of the top 500 differentially expressed genes seen with knockdown of 
Galectin-7. Each patient P1, P2, P3 and P4 is identifiable by a colour. There ware 
16 genes that show consistent changes in all 4 patients. Given the intrinsic 
variation between patients when using primary cells it is important to acknowledge 
that there may also be relevant changes in fewer than all patients that still merit 
further investigation. 
 
 
 
 
Figure 4-4 Venn chart show the overlap of the top 500 genes 
Venn chart illustrates the number and percentage of genes which have an overlap of 
differential gene expression between patients. There 16 genes which have a common 
differential gene expression across all 4 patient samples when comparing control to 
Galectin-7 knockdown. 
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A multidimensional scaling plot is used to visualise the common genes that are 
most upregulated and down regulated in the Galectin-7 knockdown samples 
versus the control samples across all 4 patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This plot shows the most down regulated and upregulated genes which were 
common across all 4 patients. 
Figure 4-5 Multidimensional scaling plot of global gene expression     
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4.2.2 qPCR  
 
A heat map was used to demonstrate the qPCR data. The Galectin-7 knockdown 
cells were compared to non-targeting control cells to assess if there was an 
increase or decrease in the genes selected as a validation set. Each of the 4 
patients has been represented in the table separately. Across the experiment the 
patient sample 2585 showed large variation in results, possibly due to 
degradation of RNA quality, as this variation was also seen in the 18S 
(housekeeping gene). The table is colour coded, with green representing a 
decrease, red an increase, and grey where there were not enough data points for 
robust interpretation (Table 4.1). The qPCR data has shown in 2 of 4 patients that 
CDH11 was upregulated in the Galectin-7 knockdown samples compared to the 
control samples, 1 of 4 was down regulated, and 1 was not interpretable. In 2 of 
4 patients LOX was upregulated in the Galectin-7 knockdown samples and 2 of 4 
was down regulated. In 3 of 4 patients NT5E was upregulated in the Galectin-7 
knockdown samples and 1 of 4 was down regulated. In 2 of 4 patients GPER was 
upregulated in the Galectin-7 knockdown samples and 2 of 4 was down regulated. 
In 3 of 4 patients PDGFD was downregulated in the Galectin-7 knockdown 
samples and 1 out of 4 was upregulated. In 2 of 4 patients MAP3K12 was 
downregulated in the Galectin-7 knockdown samples  and 1 of 4 was upregulated, 
and 1 was not interpretable. 
RNA sequencing 
results UP UP UP Down Down Down 
Gene CDH11 LOX NT5E GPER1 PDGFD MAP3K12 
Patient  
127 1.160692 0.087635 2.126501 10.88208 0.038022 31.25364 
1492 0.104127 0.025317 6.483296 0.57805 0.11715 0.602531 
2357 2.4069 2.745192 4.264556 1207.52 59.99287 0.505454 
2585 0.160909 239.7238 0.310618 0.004079 0.231797 - 
 
 
Demonstrates qPCR validation of RNA sequencing. The red represents an up-regulation 
in Galectin-7 knockdown RNA compared to the non-targeting control RNA and green 
represents down-regulation in Galectin-7 knockdown RNA compared to the non-targeting 
control RNA. Each patient sample is analysed individually, in technical triplicate and the 
experiment was performed twice.  
 
Table 4-1 qPCR results  
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4.2.3 Immunohistochemistry validation of GPER and NT5E 
 
For immunohistochemical validation of the RNA sequencing tonsil tissue was 
used to optimise the antibodies as shown in figure 4.6. Sections were chosen 
from the DCIS cohort dependent on their Galectin-7 status.  Table 4.2 shows 
patients from the DCIS cohort, which were either Galectin-7 positive or Galectin-
7 negative. 
Despite optimisation, the staining for the NT5E was not interpretable on the DCIS 
sections and time limitations meant this could not be repeated.  
Interpretation of GPER staining also was not straightforward and as analysed 
there does not appear to be a correlation between Galectin-7 positivity and GPER 
status. Some sections did not show DCIS as these were from deeper within the 
block and had evidently ‘cut through’. 
 
 
 
Tonsil staining using GPER1 at 1:1000 and 1:2000 and NT5E at 1:250 and 1:500, 
images were taken at magnification x20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6 GPER and NT5E immunohistochemistry images  
GPER1 1:1000 x20 GPER1 1:2000 x20 
 
NT5E 1:250 x20 NT5E 1:500 x20 
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Patient Galectin-7 
score 
GPER1 
score 
Patient Galectin-7 
score 
GPER1 
1990 100% Pos DCIS Neg 250 90% Neg 
10% Het 
100% Pos 
1916 100% Pos DCIS Neg  93 80% Neg 
20% Het 
DCIS Neg 
862 100% Pos HET Pos 
MECs 
1062 95% Neg 
5% Het 
DCIS Neg 
1098 100% Pos DCIS Neg 1156 100% Neg MECs Neg 
1115 95% Pos DCIS Neg 1161 80% neg No DCIS 
229 100% Pos DCIS Neg 2296 100% Neg No DCIS 
 
 
This table demonstrates the GPER scoring selected patients from the DCIS cohort. In 
this small set of patents there does not appear to be a correlation between Galectin-7 
status and GPER status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4-2 GPER1 immunohistochemistry scoring 
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4.3 Down regulated genes in Galectin-7 knockdown cells 
 
A short synopsis of selected genes showing differential expression on knockdown 
of Galectin-7 is given below, with particular focus on those where previous studies 
suggest a role in breast biology. 
 
 
4.3.1 GPER1 (G-protein-coupled estrogen receptor-1) 
 
This gene encodes a multi-pass membrane protein that localises to the 
endoplasmic reticulum and is a member of the G-protein coupled receptor 1 
family. This receptor binds to oestrogen and activates multiple downstream 
signalling pathways, leading to stimulation of adenylate cyclase and an increase 
in cyclic AMP levels, while also promoting intracellular calcium mobilisation and 
synthesis of phosphatidylinositol 3,4,5-trisphosphate in the nucleus. This protein 
therefore plays a role in the rapid nongenomic signalling events widely observed 
following stimulation of cells and tissues with oestrogen 
("https://www.ncbi.nlm.nih.gov/gene/2852,").  
 
GPER signalling can activate tyrosine kinase Src, inducing the release of heparin-
bound epidermal growth factor (HB-EGF) and subsequent transactivation of the 
epidermal growth factor receptor (EGFR), activating downstream signalling 
pathways such as PI3K/Akt and ERK/MAPK. With regards to previous 
investigations in to the role of Galectin-7 in apoptosis, GPER1 triggers 
mitochondrial apoptosis during pachytene spermatocyte differentiation, 
stimulates uterine epithelial cell proliferation, contributes to thymic atrophy by 
inducing apoptosis. GPER-1 is also involved in regulation of cancer progression 
as it stimulates proliferation of cancer-associated fibroblast (CAF) by a rapid 
genomic response through the EGFR/ERK transduction pathway. This is 
associated with EGFR and may act as a transcription factor activating growth 
regulatory genes (c-fos, cyclin D1), which promotes integrin alpha-5/beta-1 and 
fibronectin (FN) matrix assembly in breast cancer cells. 
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Recently, GPER has been evaluated as a candidate biomarker for growth 
regulation of triple negative breast cancers (TNBC). In particular, the knockdown 
of GPER expression was shown to prevent the proliferation of TNBC cells as well 
as the EGFR activation and c-fos expression induced by E2 (Girgert, Emons, & 
Gründker, 2012). A potential role elicited by GPER in TNBCs was suggested by 
a retrospective analysis demonstrating that GPER is prevalent in TNBCs, 
associated with young age and possible malignant recurrence (Steiman, Peralta, 
Louis, & Kamel, 2013).  Taken together, this data suggests that the inhibition of 
GPER might be an appropriate targeted therapy in TNBC. GPER also plays a role 
in breast cancer progression and tamoxifen resistance (Lappano, Pisano, & 
Maggiolini, 2014). 
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4.3.2 MAP3K12 (Mitogen-Activated Protein Kinase Kinase Kinase 12) 
 
MAP3K12 (Mitogen-Activated Protein Kinase Kinase Kinase 12), the mitogen-
activated protein kinase (MAPK) pathways respond to diverse extracellular 
stimuli to regulate cellular processes including proliferation, differentiation, 
migration, survival and apoptosis(Johnson & Lapadat, 2002). 
 
Mixed-lineage kinase 3 (MLK3) is recognised as a player in oncogenic signalling. 
MLK3 is a mitogen-activated protein kinase kinase kinase (MAP3K) that mediates 
signals from several cell surface receptors including receptor tyrosine kinases 
(RTKs), chemokine receptors, and cytokine receptors. Once activated, MLK3 
transduces signals to multiple downstream pathways, primarily to c-Jun terminal 
kinase (JNK) MAPK, as well as to extracellular-signal-regulated kinase (ERK) 
MAPK, P38 MAPK, and NF-κB, resulting in both transcriptional and post-
translational regulation of multiple effector proteins. In several types of cancer, 
MLK3 signalling is implicated in promoting cell proliferation, as well as driving cell 
migration, invasion and metastasis (Rattanasinchai & Gallo, 2016). 
 
Chen et al., used a 3D DCIS model and induced the expression of active MLK3. 
Multiple features of DCIS were observed, including bypass of growth arrest and 
re-initiation of luminal filling. The increase in the proliferation marker Ki-67 and 
suppression of the proapoptotic BimEL upon MLK3 induction reveals both 
proliferative and novel antiapoptotic roles for MLK3 in the context of breast 
cancer (Chen, Miller, & Gallo, 2010).   
 
4.3.3 PDGFD (platelet-derived growth factor D) 
  
The protein encoded by this gene is a member of the platelet-derived growth 
factor family This is a growth factor that plays an essential role in the regulation 
of embryonic development, cell proliferation, cell migration, survival and 
chemotaxis. It also plays an important role in wound healing. - it induces 
macrophage recruitment, increased interstitial pressure, and blood vessel 
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maturation during angiogenesis. It can initiate events that lead to a mesangial 
proliferative glomerulonephritis, including influx of monocytes and macrophages 
and production of extracellular matrix. 
 
Dysregulation of paracrine PDGF signalling can cause extracellular matrix 
remodelling in a tumour-promoting way to facilitate migration, invasion and 
angiogenesis (Ehnman & Östman, 2014),(Andrae, Gallini, & Betsholtz, 2008).  
 
PDGF also plays a major role in initiating the desmoplastic response of breast 
cancers (Walker, 2001) (Shao, Nguyen, & Barsky, 2000). Patients with recurrent 
disease have elevated circulating PDGF levels, suggesting that it may serve as a 
recurrence marker (Pasanisi et al., 2008).  
 
At the stage of in situ carcinoma, growth factors secreted by the malignant 
epithelial cells, either PDGF (Shao et al., 2000) or TGF-β1 (Walker & Dearing, 
1992) or both, with or without other factors, stimulate myofibroblasts within the 
adjacent stroma. These synthesise a variety of stromal proteins (such as 
fibronectin, tenascin and collagens 1 and 3), metalloproteinases (Rønnov-
Jessen, Petersen, & Bissell, 1996),(Jones, Glynn, & Walker, 1999) and growth 
factors with angiogenic effects (de Jong, van Diest, van der Valk, & Baak, 1998) 
which aid invasion, aid the subsequent growth of cancer cells and promote 
metastasis.  
 
4.3.4 CA11 
 
Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that 
catalyse the reversible hydration of carbon dioxide. They participate in a variety 
of biological processes, including respiration, calcification and acid-base balance. 
They show extensive diversity in tissue distribution and in their subcellular 
localisation (Dodgson, Tashian, Gross, & Carter, 1991).  
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Shiozaki et al., investigated the role of CA11 in gastric carcinogenesis. Northern 
blot analysis showed that expression of CA11 gene in cancer tissue was down-
regulated compared with normal tissue, semi-quantitative RT-PCR also 
demonstrated that CA11 gene expression was decreased in 41 out of 50 (82%) 
of gastric cancer tissues, when compared with normal stomach tissues. These 
findings suggest that the loss of CA11 expression in gastric tissues may play an 
important role in gastric carcinogenesis (Shiozaki et al., 2001). There are no 
reported studies for a role in DCIS or breast cancer biology. 
 
4.3.5 CERK  
 
CERK converts ceramide to ceramide-1-phosphate (C1P), a sphingolipid 
metabolite. Both CERK and C-1-P is involved in various cellular processes, 
including proliferation, apoptosis, phagocytosis, and inflammation (T. J. Kim, 
Mitsutake, & Igarashi, 2006). C-1-P also prevents apoptosis by inhibiting 
the caspase-9/caspase-3 pathway. This is thought to occur via C-1-P interacting 
with and blocking functionality of acid sphingomyelinase. This results in 
diminished ceramide production, which precludes apoptosis. Phosphorylation of 
ceramide via CERK has been shown to stimulate myoblast proliferation. CERK 
has demonstrated an ability to activate phosphatidylinositol 3-
kinase/Akt (PI3K/Akt), ERK1/2, and mTOR (Gangoiti et al., 2012). CERKs ability 
to activate signalling molecules that facilitate the cell proliferation as well as its 
interaction with PI3K/Akt, and mTOR indicate that dysregulated CERK expression 
may contribute to cancer progression. 
 
Elevated CERK expression is associated with an increased risk of recurrence in 
women with breast cancer. It is suggested that CERK inhibition might be a 
potential target for tumour recurrence (Pastukhov et al., 2014). In addition, 
although CERK expression is associated with aggressive subtypes of breast 
cancer, including those that are oestrogen receptor-negative, HER2(+), basal-
like, or high grade, its association with poor clinical outcome is independent of 
these clinicopathologic variables (A. W. Payne, Pant, Pan, & Chodosh, 2014).   
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4.3.6 SYT16 (Synaptotagmin 16) 
 
SYT16 (Synaptotagmin 16) is a Protein Coding gene. Gene Ontology (GO) 
annotations related to this gene include calcium ion binding and protein 
heterodimerization activity, which may be involved in the trafficking and 
exocytosis of secretory vesicles in non-neuronal tissues. There have been no 
previous roles identified in breast pathology. 
 
4.3.7 SYT11 (Synaptotagmin 11) 
 
This gene is a member of the synaptotagmin gene family and encodes a protein 
similar to other family members that are known calcium sensors and mediate 
calcium-dependent regulation of membrane trafficking in synaptic transmission 
("https://www.ncbi.nlm.nih.gov/gene/23208 
 "). The protein expression of SYT11 is mainly cytoplasmic in the central nervous 
system and peripheral nervous system. SYT11 has an association with 
Parkinsons disease. There are low levels of protein expression in breast tissue. 
 
4.3.8 LGR5 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 
5) 
 
LGR5 encoded protein is a receptor involved in the Wnt signalling pathway. This 
protein plays a role in the formation and maintenance of adult intestinal stem cells 
during postembryonic development (Hou, Chen, & Chu, 2018). LGR5 Is involved 
not only in early events, but also in late events in colorectal tumorigenesis.  Zheng 
et al demonstrated that LGR5 expression in colorectal cancer is higher at the 
invasive front than at the tumour centre. Colorectal cancer cells expressing LGR5 
are reported to have a higher potential for invasion and metastasis (Zheng et al., 
2018). 
 
The cancer stem cell hypothesis suggests that a subset of cancer cells retain 
stem cell properties. LGR5 is a marker of adult stem cells. Yang et al showed 
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LGR5 overexpression was detected in breast cancer and significantly associated 
with breast cancer recurrence and poor outcome. LGR5 promoted cell motility, 
tumour formation, and epithelial-mesenchymal transition in breast cancer cells by 
activating Wnt/β-catenin signalling (L. Yang et al., 2015).   
 
4.3.9 RASGRP1 
 
This gene is from a family of genes characterized by the presence of a Ras 
superfamily guanine nucleotide exchange factor (GEF) domain. It functions as a 
diacylglycerol (DAG)-regulated nucleotide exchange factor specifically activating 
Ras through the exchange of bound GDP for GTP. It activates the Erk/MAP 
kinase cascade and regulates T-cell and B-cell development, homeostasis and 
differentiation 
("https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&T
ermToSearch=10125," 2008). Wang et al have evaluated gene expression in 
total RNA isolated from formalin-fixed paraffin-embedded tumour samples using 
the NanoString Counter assay for 469 triple negative breast cancer cases from 
the Shanghai Breast Cancer Survival Study. A twofold higher expression 
of RASGRP1 (HR 0.89, 95% CI 0.82–0.97), was associated with better overall 
survival and was also associated with better disease-free survival (Wang et al., 
2018). 
 
Overexpression of RasGRP1 had a profound effect on keratinocyte morphology 
and cell biology as it increases apoptosis (Rambaratsingh, Stone, Blumberg, & 
Lorenzo, 2003). The reason that RasGRP1's differential effect on JNK-1 and -2 
is interesting is that phospho-JNK2 has been reported to have pro-tumorigenic 
effects in mouse keratinocytes, whereas pJNK1 has the opposite effect raising 
the possibility that dysregulated levels of RasGRP1 could have oncogenic 
properties through specific activation of JNK2 (Sharma, Luke, Dower, Stone, & 
Lorenzo, 2010). 
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4.3.10 CHN1 Chimerin 1  
 
This gene encodes GTPase-activating protein for ras-related p21-rac and a 
phorbol ester receptor. It is predominantly expressed in neurons and plays an 
important role in neuronal signal-transduction mechanisms. Mutations in this 
gene are associated with Duane's retraction syndrome 2 (DURS2) 
("https://www.ncbi.nlm.nih.gov/gene/1123 
 ").  
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4.4 Up-regulated genes in Galectin-7 knockdown cells 
4.4.1 LOX  
LOXL2 is highly expressed in the basal/myoepithelial mammary cell lines this was 
shown in a study by Erler et al., which studied 3 main breast cancer cell lines 
(Barker et al., 2011) like many other genes that are up-regulated in basal-like 
breast cancers. LOXL2 catalyses the cross-linking of collagens and elastin 
(Csiszar, 2001), (Y. M. Kim, Kim, & Kim, 2011). 
 
Weaver et al have shown how modulating the activity of LOX can directly modify 
tumour progression by regulating collagen crosslinking and stiffness. The results 
are consistent with data indicating that LOX enzymes are elevated in many 
cancers (Erler & Weaver, 2009) and that LOX is induced by hypoxia inducible 
factor (HIF-1) and TGFβ; two key regulators of tumour behaviour (Postovit et al., 
2008). Indeed, cellular LOX promotes breast cell migration and invasion and 
enhances tumour proliferation and survival (Kirschmann et al., 2002). 
 
There are also contradictory reports that LOX may act as a tumour suppressor 
(S. L. Payne, Hendrix, & Kirschmann, 2007) possibly by directly inhibiting ECM 
adhesions and integrin signaling (Zhao et al., 2009). LOX-mediated ECM 
stiffening could also impede cell invasion in the absence of MMP activity (Zaman 
et al., 2006) reminiscent of highly crosslinked, stiff fibrotic tissues and scars that 
often never progress to malignancy.  
 
4.4.2 NT5E (also known as CD73) 
 
High CD73 expression has been significantly associated with lymph node 
metastases in different types of cancers (Jiang et al., 2018). Targeting CD73 
results in favourable antitumor effects in preclinical studies and combination of 
CD73 blockade with other immune checkpoint inhibitors, such as anti-cytotoxic T-
lymphocyte antigen (CTLA)-4 antibody or anti-programmed cell death protein 
(PD)-1/PD-1 ligand (PDL1) antibody, is particularly promising (Antonioli, 
Yegutkin, Pacher, Blandizzi, & Haskó, 2016)) . Increasing evidence suggests that 
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CD73 is highly expressed in a wide range of cancer types, including breast 
cancer, colorectal cancer, glioblastoma, melanoma, prostate cancer, ovarian 
cancer, and non-small-cell lung cancer (NSCLC). High CD73 expression is 
frequently reported to be  associated with poor prognosis in different cancer types, 
however, several studies found high CD73 expression was not correlated with the 
prognosis of patients with breast cancer (Supernat et al., 2012). It has been 
shown recently that CD73 expression negatively correlates with oestrogen 
receptor (ER) signalling and is associated with poor prognosis and 
chemoresistance in the triple-negative breast cancer (Loi et al., 2013) 
 
4.4.3 Cadherin 11 (CDH11)  
 
Cadherins are calcium-dependent cell adhesion proteins, which play an essential 
role in tissue morphogenesis and homeostasis. The cadherin 11 gene encodes a 
type II classical cadherin from the cadherin superfamily. Mature cadherin proteins 
are composed of a large N-terminal extracellular domain, a single membrane-
spanning domain, and a small, highly conserved C-terminal cytoplasmic domain. 
Type II (atypical) cadherins are defined based on their lack of a HAV cell adhesion 
recognition sequence specific to type I cadherins.  Cadherins are thought to play 
an important role in development and maintenance of tissues through selective 
cell-cell adhesion activity and may be involved also in the invasion and metastasis 
of malignant tumours (Tanihara, Sano, Heimark, St John, & Suzuki, 1994).  
 
CDH11 is overexpressed in 15% of breast cancers.  CDH11 expressing basal-
like breast carcinomas and other CDH11 expressing malignancies exhibit poor 
prognosis. CDH11 is increased in early breast cancer and ductal carcinoma in 
situ (Assefnia et al., 2014). The overexpression in a subset of DCIS suggests it is 
an early event in breast cancer development. Not all DCIS lesions are CDH11 
positive and high expression occurs when comedo necrosis is present: this type 
DCIS is a subtype thought to have a greater invasive potential (Burstein et al., 
2004) 
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4.4.4 TMCO1 (Transmembrane and Coiled-Coil Domains 1) 
 
This locus encodes a transmembrane protein. TMCO1 transcript was 
downregulated in the progression of urinary bladder urothelial carcinoma (UBUC). 
Shiue et al investigated this further showing that TMCO1 dysregulates cell cycle 
progression via suppression of the AKT pathway and S60 of the TMCO1 protein 
is crucial for its tumour suppressor roles. Stable overexpression of the TMCO1 
gene suppressed tumour growth in xenograft mice (C. F. Li et al., 2017). 
 
4.4.5 TNFSF18 
 
The protein encoded by this gene is a cytokine that belongs to the tumour necrosis 
factor (TNF) ligand family. This cytokine is a ligand for receptor 
TNFRSF18/AITR/GITR. It has been shown to modulate T lymphocyte survival in 
peripheral tissues. This cytokine is also found to be expressed in endothelial cells 
and is thought to be important for interaction between T lymphocytes and 
endothelial cells ("https://www.ncbi.nlm.nih.gov/gene/8995,").  
 
 
4.4.6 CDC42EP5- Cell division control protein 42 Effector Protein 5 
 
Cell division control protein 42 (CDC42), a small Rho GTPase, regulates the 
formation of F-actin-containing structures through its interaction with the 
downstream effector proteins. The protein encoded by this gene is a member of 
the Borg (binder of Rho GTPases) family of CDC42 effector proteins. Borg family 
proteins contain a CRIB (Cdc42/Rac interactive-binding) domain. They bind to 
CDC42 and regulate its function negatively. The encoded protein may inhibit c-
Jun N-terminal kinase (JNK) independently of CDC42 binding. The protein may 
also play a role in septin organization and inducing pseudopodia formation in 
fibroblasts ("https://www.ncbi.nlm.nih.gov/gene/148170,").  
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In most human cancers CDC42 is abnormally expressed and promoting 
neoplastic growth and metastasis. Regarding possible new treatments for 
cancer, miRNA and small molecules targeting CDC42 and related pathways 
have been recently found to be effective on cancer (Xiao et al., 2018). 
 
The gene expression of CDC42 is different in several types of cancer (Xiao et 
al., 2018), as is the case with Galectin-7. Research has shown CdcC42 induces 
invasiveness and metastatic activity by breast cancer cells (S. Lee, Craig, 
Romain, Qiao, & Chung, 2014). 
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4.5 Discussion 
 
The hypothesis was that loss of myoepithelial cell Galectin-7 in DCIS alters 
myoepithelial cell function and contributes to disease progression. RNA 
sequencing comparing myoepithelial cells treated with non-targeting control 
siRNA and Galectin-7 siRNA knockdown was performed to assess the global 
effect of Galectin-7 knockdown on myoepithelial cell function, to better understand 
the biology of Galectin-7 and how this might contribute to the development of a 
DCIS risk stratification tool. 
 
RNA sequencing was performed to identify potential direction for future work. The 
sequencing data has identified a number of interesting genes of potential 
relevance. Genes which had particular relevance to breast pathology these were 
further studied; genes down regulated in the Galectin-7 knockdown cells were 
GPER1, PDGFR, MAP3K12 and genes which were upregulated in the Galectin-
7 knockdown cells were LOX, CDH11 and NT5E. 
 
Following the bioinformatics sequence analysis, validation for selected genes was 
performed using qPCR and immunohistochemistry.  Empirically, three  genes that 
were up-regulated  and three genes that were down-regulated in the in the 
Galectin-7 knockdown that appeared relevant to breast cell biology were selected. 
Ideally all the genes would have been validated however it was not possible due 
time limitations.  qPCR is an established technique for validating RNA sequencing 
data("https://www.phalanxbiotech.com/validating-rna-seq-results-with-qpcr/," 
2017). Samples from the same 4 patients used in RNA sequencing were used. In 
one of the patients, labelled as 2585, there was a lot of variation in the results 
including for the housekeeping genes, possibly as a result of RNA degradation, 
and therefore these results were excluded. Ideally, more samples would have 
been used for validation, but time restraints precluded this. 
 
There was variation in the qPCR results, however, NTSE showed consistent up-
regulation, concordant with the RNA sequencing results. There was increased 
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expression of CDH11 in 2 of the 3 samples on qPCR, but apparent reduced 
expression of LOX in 2 of 3 samples.  For the genes found to be down-regulated 
on RNA sequencing, two of the three genes showed reduced expression on 
qPCR in 2 of 3 samples. It is clear that further validation is required. In our 
experience qPCR generates considerable variation in results (Dr M Allen, 
personal communication). Orthogonal testing, using Western blotting and 
immunohistochemistry, would be important. 
 
Where antibodies were available, further validation was attempted using 
immunohistochemistry. LOX is of particular interest causing cross-linking of 
collagen leading to increased stiffness and promoting tumorigenesis of pre-
malignant cells (Levental et al., 2009). A study has shown up regulation of LOX 
in the periductal stroma in DCIS with associated invasion when compared to pure 
DCIS (Castro et al., 2008). 
 
The DCIS cohort that has been used throughout the thesis was stained for LOX. 
Disappointingly the results were inconclusive: the first batch of staining showed a 
lot of background and was hard to interpret therefore the staining was repeated 
and this showed very different staining patterns, making it difficult to be confident 
about these results. Increased ECM stiffness can promote cancer cell invasion 
(Levental et al., 2009) there was up regulation of LOX when Galectin-7 was 
knocked down in the myoepithelial cells. This is an exciting and interesting finding, 
the hypothesis that lower levels of myoepithelial Galectin-7 promotes the 
transition of DCIS to invasive cancer would fit with this hypothesis that increased 
levels of LOX would promote a more fibrotic stroma. Further work is needed to 
further validate the up regulation of LOX following Galectin-7 knockdown. 
Because of the potential relevance to DCIS progression, this should be pursued. 
An alternative technique, such as RNA scope may be more appropriate, or 
sourcing alternative antibodies. 
 
Knockdown of Galectin-7 showed a down-regulation of GPER1 in the RNA 
sequencing. GPER may be included among the factors facilitating oestrogen-
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activated cross-talk within the tumour microenvironment contributing towards 
breast tumour progression. GPER triggers the expression of various genes 
involved in the growth and migration of diverse oestrogen-responsive tumours 
(De Francesco et al., 2014; Lappano, Rosano, et al., 2012; Lappano, Santolla, et 
al., 2012; D. P. Pandey et al., 2009). Tamoxifen is an agonist of the G protein-
coupled oestrogen receptor (GPER). Cortes et al., have investigated the role of 
tamoxifen in modulating the stroma of  pancreatic adenocarcinoma and shown 
that tamoxifen can inhibit myofibroblastic differentiation of pancreatic stellate cells 
(PSCs) in the tumour microenvironment of pancreatic cancer in a GPER-
dependent manner (Cortes et al., 2019).  This again implicates myoepithelial cell 
control of the periductal stromal microenvironment. Unfortunately, the quality of 
immunohistochemical staining for GPER again made interpretation difficult and 
further work is needed to verify the RNA sequencing results. 
 
In conclusion, RNA sequencing of primary myoepithelial cells has indicated as 
series of genes up- or down-regulated by altered Galectin-7 expression. Further 
validation is needed, but there are a number of genes of potential relevance to 
DCIS progression that should be pursued. 
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5 Final discussion and future work 
 
This study aimed to investigate the hypothesis that changes in MEC in DCIS 
contribute to progression to invasion by altering the tumour microenvironment. 
Specifically, the study focussed on altered Galectin-7 in MEC, its effect on MEC 
function and its relationship with another DCIS marker avb6. 
 
 
 
  
 
This schematic illustrates a normal breast duct with luminal cells organised and polarised 
with myoepithelial cells strongly positive for Galectin-7 and negative for avb6. There is 
then transition to DCIS with neoplastic proliferation of epithelial cells within the ductal-
lobular structures of the breast that does not penetrate the myoepithelial basement 
membrane interface. The myoepithelial cells have an altered phenotype with loss of 
Galectin-7 and up-regulation of avb6.  In the DCIS ducts that progress to invasive 
disease there is loss of the myoepithelial basement membrane interface, possibly 
through TRAIL-induced apoptosis. 
 
 
Up-regulation of avb6 by MEC in DCIS has previously been reported and shown 
to  be associated with disease progression  Expression of avb6 is almost 
universal (95%) in DCIS with an established invasive component. This study 
Figure 5-1 Hypothetical DCIS  progression 
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identified loss of Galectin-7 in DCIS-MEC in a subset of cases, with significantly 
less Galectin-7 positive ducts in DCIS with associated invasion compared to pure 
DCIS. Any DCIS risk score will be improved by the integration of multiple markers, 
thus each duct was assigned a avb6- Galectin-7 score.  These indicated that 
scores of Galectin-7 positive/ avb6 heterogeneous, Galectin-7 positive/avb6 
negative, Galectin-7 heterogeneous/ avb6 negative were significantly more 
frequent in DCIS ducts in the pure DCIS cohort compared to the DCIS with 
associated invasion cohort. Conversely, the combinations of Galectin-7 
heterogeneous /avb6 positive, Galectin-7 negative /avb6 positive and Galectin-7 
negative /avb6 heterogeneous were seen in a significantly higher number of DCIS 
ducts in the DCIS with associated invasion cohort. These findings suggest an 
inverse relationship between Galectin-7 and avb6 integrin in DCIS-myoepithelial 
cells. 
 
These results tentatively support the hypothesis in figure 5.1 where combined 
loss of Galectin-7 and upregulation of avb6 represents ‘late stage’ DCIS, with an 
increased likelihood to progress to invasion. To further validate this, it would be 
useful to test the predictive power of avb6 and Galectin-7 in a series of pure DCIS 
with long term follow up, where a subset of patients will have developed ipsilateral 
invasive recurrence.  
 
It could be argued that to develop a robust and clinically useful progression tool, 
it is important to establish the functional relevance of individual markers. This 
study therefore sought to establish the functional impact of loss of Galectin-7 in 
MECs. Experiments were performed with a combination of established cell lines 
and primary cells. There are advantages and disadvantages to the use of cell 
lines versus primary cells. Cell lines do not have the heterogeneity that is evident 
in patient samples and in clinical practice, and do not always fully replicate the in-
vivo situation. In contrast, primary cells are likely to be more physiologically 
relevant, but they are a finite resource and more challenging to work with. It is 
extremely important to consider these factors when interpreting data from 
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experiments both with primary cells and cell lines. Cell lines are prone to 
genotypic and phenotypic drift during their continual culture. In the current study, 
marked differences were seen between the cell lines and the primary MECs, and 
the results seen with the primary cells are considered more relevant, since the 
primary MECs exhibited a phenotype more representative of MECs in vivo. 
 
Galectin-7 is implicated in apoptosis, and therefore the impact of loss of Galectin-
7 on MEC apoptosis was investigated. This demonstrated that knockdown of 
Galectin-7 in primary MECs there was an increase in apoptosis, with or without 
exposure to TRAIL. This could feasibly contribute to the pathognomonic loss of 
MECs seen as DCIS progresses, and be one mechanism y which loss of Galectin-
7 contributes to DCIS progression. Another important role of MEC is to maintain 
the myoepithelial-basement membrane (BM) barrier, with strong adhesion to BM, 
to adjacent MECs and to luminal cells. This study has shown decreased adhesion 
to BM associated laminin, increased adhesion to collagen I, decreased migration 
to collagen I, and increased migration to laminin in Galectin-7 knockdown primary 
MECs. This suggests Galectin-7 negative MECs are less adhesive to BM 
extracellular matrix proteins and more adhesive to interstitial collagen, which may 
reflect the altered interactions in DCIS progression to invasion. 
 
Another key element of tumour invasion is the release of proteolytic enzymes that 
can breakdown BM and modify interstitial matrix. (Kessenbrock, Plaks, & Werb, 
2010) Conditioned media from primary MEC treated either with Galectin-7 siRNA 
or non-targeting control siRNA was applied to protease proteome profiles. This 
demonstrated down-regulation of a range of proteolytic enzymes when Galectin-
7 was knocked down. This seems counterintuitive since loss of Galectin-7 
appears to be associated with more advanced disease. Interestingly, in invasion 
assays with MDA MD 231 breast cancer cells, conditioned media from Galectin-
7 knockdown MEC resulted in reduced invasion compared to conditioned media 
from non-targeting control cells, which would be consistent with down-regulation 
of proteolytic enzymes. We previously have shown that MEC up-regulate avb6 
and this leads to up-regulation of MMP-9, which promotes tumour invasion. It is 
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feasible that both loss of Galectin-7 and gain of avb6 is required to develop the 
full pro-tumourigenic effect of MEC. 
 
Galectins are complex and implicated in multiple functions therefore RNA 
sequencing of primary MEC with Galectin-7 knockdown versus non-target control 
cells was carried out to gain a global view of its role in MEC. A number of genes 
showed altered expression but of particular interest were LOX and GPER1. Both 
LOX and GPER1 have been shown to have influence changes in the tumour 
microenvironment (Levental et al., 2009), (Cortes et al., 2019) and would be 
predicted to contribute to a pro-invasive environment. qPCR and 
immunohistochemistry was carried out with the aim of validating the RNA seq, 
however, results were not conclusive and further work is required. 
 
In conclusion, loss of Galectin-7 in DCIS-associated MEC is more frequent in 
more advanced disease and is inversely related to up-regulation of avb6. 
Functional assays suggest that loss of Galectin-7 alters DCIS behaviour and 
could contribute to the destabilisation of the MEC-BM interface thus promoting 
progression of DCIS to invasive disease. RNA seq analysis has identified a series 
of genes modulated by Galectin-7 which also could contribute to disease 
progression, though this requires further validation. Given loss of Galectin-7 is 
such a consistent change and of functional relevance in DCIS, it could be 
incorporated into a risk algorithm to help stratify management of patients with 
DCIS and so reduce issues of overtreatment in this disease. 
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5.1 Future work 
The immunohistochemistry analysis of the 2 DCIS cohorts used in this study has 
shown very promising results, however further validation is required. Ideally this 
validation set of tissues would have long term follow up data, this could potentially 
assess if Galectin-7 expression is able to predict recurrence. The SLOANE study 
would potentially offer an ideal validation set.  
 
In DCIS progression the myoepithelial maybe lost through apoptosis, data in this 
study shows that Galectin-7 in primary myoepithelial cells has anti apoptotic role. 
A wider range of primary myoepithelial cells and apoptotic markers could be used 
to further validate this.  
 
Organotypic models were used as an alternative model further optimisation of the 
organotypic model is required potentially using primary fibroblasts , ideally the 
primary fibroblasts and the primary myoepithelial would be from the same patient. 
 
RNA sequencing provided interesting results however this requires much more 
extensive validation. In particular validation of the changes in LOX expression is 
important, an alternative LOX antibodies would be beneficial to assess if the 
results were more consistent. RNA scope is an alternative method that could 
potentially be used to assess LOX expression in the DCIS cohorts used in this 
study. 
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6 Supplementary 
6.1 A comparison of heterogeneity between pure DCIS and DCIS with 
associated invasion using ER, PR and HER-2 
immunohistochemical markers  
 
Another method to compare the pure DCIS and DCIS with associated invasion 
cohorts was to compare diversification of the scores between the 2 groups for 
ER, PR and HER 2. These markers were scored at strongly (3) positive, 
moderately (2) positive and weakly (1) positive, strongly (3) heterogeneous, 
moderately( 2) heterogeneous and weakly (1) heterogeneous and negative. 
Having seven categories enabled further assessment of the diversification of 
results. Heterogeneity is a challenge in DCIS diagnostics. This has shown there 
is a slight increased diversification in the pure DCIS  (41.1%)  compared to 37.4% 
in the DCIS with associated invasion in the ER staining. There is decreased 
diversification for PR  in the pure DCIS  (36.6%)  compared to 47.7% in the DCIS 
with associated invasion. There is increased diversification for HER-2  in the pure 
DCIS  (47.4%)  compared to 34.5% in the DCIS with associated invasion 
 
ER Pure DCIS 
Diversification 
              
 Positive 
3 
Positive 
2 
Positive 
1 
Hetero 
3 
Hetero 
2 
Hetero 
1 
Negative 
Sum^2 36864 3721 729 25 324 1600 126736 
sum(x^2) 488601           
sum(x)^2 169999           
Diversification 41.1%           
 
 
Represents the diversification of 41.1% for ER in pure DCIS.  
 
 
 
 
 
 
Table 6-1 ER diversification for Pure DCIS 
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ER DCIS with 
associated 
invasion 
Diversification 
              
 Positive 
3 
Positive 
2 
Positive 
1 
Hetero 
3 
Hetero 
2 
Hetero 
1 
Negative 
Sum^2 39204 1024 100 0 64 729 70225 
sum(x^2) 291600           
sum(x)^2 111346           
Diversification 37.4%           
 
 
Represents the diversification of 37.4% for ER in DCIS with associated invasion. 
 
 
PR Pure DCIS 
Diversification 
      
  
      
 Positive 
3 
Positive 
2 
Positive 
1 
Hetero 
3 
Hetero 
2 
Hetero 
1 
Negative 
Sum^2 529 1849 8649 4 1156 8281 176400 
sum(x^2) 498436           
sum(x)^2 196868           
Diversification 36.2%           
 
 
 
Represents the diversification of 36.2% for PR in pure DCIS.  
 
 
PR DCIS with 
associated 
invasion 
Diversification 
              
 Positive 
3 
Positive 
2 
Positive 
1 
Hetero 
3 
Hetero 
2 
Hetero 
1 
Negative 
Sum^2 15876 1681 4356 9 256 1296 64516 
sum(x^2) 293764           
sum(x)^2 87990           
Diversification 47.7%           
 
 
Represents the diversification of 47.7% of PR in DCIS with associated invasion. 
 
 
 
 
Table 6-2 ER diversification for DCIS with associated invasion 
Table 6-3 PR diversification in Pure DCIS 
Table 6-4 PR diversification in DCIS with associated invasion 
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HER 2 Pure DCIS 
Diversification 
             
 Positive 
3 
Positive 
2 
Positive 
1 
Hetero 
3 
Hetero 
2 
Hetero 
1 
Negative 
Sum^2 89401 2025 2209 225 1444 1296 72900 
sum(x^2) 562500           
sum(x)^2 169500           
Diversification 47.4%           
 
 
Represents the diversification of 47.4% of HER-2 in pure DCIS.  
 
 
HER-2 DCIS with 
associated 
invasion 
Diversification 
              
 Positive 
3 
Positive 
2 
Positive 
1 
Hetero 
3 
Hetero 
2 
Hetero 
1 
Negative 
Sum^2 7921 4900 289 25 576 49 105625 
sum(x^2) 288369           
sum(x)^2 119385           
Diversification 34.5%           
 
 
Represents the diversification of 34.5% for HER-2 in DCIS with associated invasion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6-5 HER-2 diversification in Pure DCIS 
Table 6-6 HER-2 diversification in DCIS with associated invasion 
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6.2 Immunofluorescence- Dual staining P-Cadherin and ZO-1 
 
 
 
 
 
 
 
 
 
 
 
 
 n=1 
 
 
 
 
 
 
B 
A 
Figure 6-1 Immunofluorescence duel staining P-Cadherin and zo-1 
P-Cadherin (green) and zo-1 (red) A) control myoepithelial cells and B) Galectin-7 
knockdown myoepithelial cells (staining is non specific) 
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Figure 6-2 Dual immunofluorescence analysis P-Cadherin and ZO-1 
Ratio of expression of zo-1 and PCAD control versus Galectin-7 knock down 
myoepithelial cells. This shows that 2 patients have a reduction in in zo-1 expression. 
2585 has a slight increase in zo-1 expression in the control cell versus Galectin-7 
knockdown cells however staining is non specific. 
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6.3 Differential gene expression across patient groups 
Patient 1  
Patient 4 
Patient 1-Patient 
3 
Patient 1, Patient 
2, Patient 4 
Patient 2-Patient 
4 
LGALS7B ANKRD1 GNRHR MMP13 
LGALS7 LUCAT1 EXTL1 NOV 
DNAH10OS MPZL3 PDE4B PDGFD 
CNNM1 SHISA9 ASB13 ANGPTL7 
LOX SPRR1A SOSTDC1 COMP 
CERK IFIT3 SLC7A8 DIO2 
SCG5 CCDC188 PEG10 NT5E 
TMCO1 MRGPRX3 CXCL5 NEGR1 
LGR5 FGF1 FREM2 STON1 
LIMS2 LHFPL6 ENOX1 TCHH 
MICB RSAD2 IGFBP7 CA11 
GPER1 MAP3K12 LINC00702 P2RX5 
SYT11 UHRF1BP1 DIRAS3 LINC01704 
CDH11 NACAD 
 
STRADB 
RASGRP1 SLCO2A1 
 
SYT16 
LINC01564 
  
MEX3A 
   
TAS1R3 
   
WNT10A 
   
CHN1 
   
PRR9 
   
CSF3 
   
MST1 
   
CSGALNACT1 
   
CDC42EP5 
   
GAB3 
   
FZD4 
   
LINC02407 
   
LINC01291 
   
LINC02154 
   
ACADSB 
   
MALL 
   SERPINB4 
   
NREP 
Table 6-7 Differential gene expression across patient groups between control and 
Galectin-7 knock down 
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